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ABSTRACT
Background
Somatoform disorders are characterised by chronic, medically unexplained physical symptoms (MUPS). Although different medications
are part of treatment routines for people with somatoform disorders in clinics and private practices, there exists no systematic review or
meta-analysis on the efficacy and tolerability of these medications. We aimed to synthesise to improve optimal treatment decisions.
Objectives
To assess the effects of pharmacological interventions for somatoform disorders (specifically somatisation disorder, undifferentiated
somatoform disorder, somatoform autonomic dysfunction, and pain disorder) in adults.
Search methods
We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR) (to 17 January 2014). This
register includes relevant randomised controlled trials (RCTs) from The Cochrane Library (all years), MEDLINE (1950 to date), EMBASE (1974
to date), and PsycINFO (1967 to date). To identify ongoing trials, we searched ClinicalTrials.gov, Current Controlled Trials metaRegister,
the World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry. For grey literature,
we searched ProQuest Dissertation & Theses Database, OpenGrey, and BIOSIS Previews. We handsearched conference proceedings and
reference lists of potentially relevant papers and systematic reviews and contacted experts in the field.
Selection criteria
We selected RCTs or cluster RCTs of pharmacological interventions versus placebo, treatment as usual, another medication, or a
combination of different medications for somatoform disorders in adults. We included people fulfilling standardised diagnostic criteria for
somatisation disorder, undifferentiated somatoform disorder, somatoform autonomic dysfunction, or somatoform pain disorder.
Data collection and analysis
One review author and one research assistant independently extracted data and assessed risk of bias. Primary outcomes included the
severity of MUPS on a continuous measure, and acceptability of treatment.
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Main results
We included 26 RCTs (33 reports), with 2159 participants, in the review. They examined the efficacy of different types of antidepressants,
the combination of an antidepressant and an antipsychotic, antipsychotics alone, or natural products (NPs). The duration of the studies
ranged between two and 12 weeks.
One meta-analysis of placebo-controlled studies showed no clear evidence of a significant difference between tricyclic antidepressants
(TCAs) and placebo for the outcome severity of MUPS (SMD -0.13; 95% CI -0.39 to 0.13; 2 studies, 239 participants; I2 = 2%; low-quality
evidence). For new-generation antidepressants (NGAs), there was very low-quality evidence showing they were effective in reducing the
severity of MUPS (SMD -0.91; 95% CI -1.36 to -0.46; 3 studies, 243 participants; I2 = 63%). For NPs there was low-quality evidence that they
were effective in reducing the severity of MUPS (SMD -0.74; 95% CI -0.97 to -0.51; 2 studies, 322 participants; I2 = 0%).
One meta-analysis showed no clear evidence of a difference between TCAs and NGAs for severity of MUPS (SMD -0.16; 95% CI -0.55 to 0.23;
3 studies, 177 participants; I2 = 42%; low-quality evidence). There was also no difference between NGAs and other NGAs for severity of
MUPS (SMD -0.16; 95% CI -0.45 to 0.14; 4 studies, 182 participants; I2 = 0%).
Finally, one meta-analysis comparing selective serotonin reuptake inhibitors (SSRIs) with a combination of SSRIs and antipsychotics
showed low-quality evidence in favour of combined treatment for severity of MUPS (SMD 0.77; 95% CI 0.32 to 1.22; 2 studies, 107
participants; I2 = 23%).
Differences regarding the acceptability of the treatment (rate of all-cause drop-outs) were neither found between NGAs and placebo (RR
1.01, 95% CI 0.64 to 1.61; 2 studies, 163 participants; I2 = 0%; low-quality evidence) or NPs and placebo (RR 0.85, 95% CI 0.40 to 1.78; 3
studies, 506 participants; I2 = 0%; low-quality evidence); nor between TCAs and other medication (RR 1.48, 95% CI 0.59 to 3.72; 8 studies, 556
participants; I2 =14%; low-quality evidence); nor between antidepressants and the combination of an antidepressant and an antipsychotic
(RR 0.80, 95% CI 0.25 to 2.52; 2 studies, 118 participants; I2 = 0%; low-quality evidence). Percental attrition rates due to adverse effects were
high in all antidepressant treatments (0% to 32%), but low for NPs (0% to 1.7%).
The risk of bias was high in many domains across studies. Seventeen trials (65.4%) gave no information about random sequence generation
and only two (7.7%) provided information about allocation concealment. Eighteen studies (69.2%) revealed a high or unclear risk in
blinding participants and study personnel; 23 studies had high risk of bias relating to blinding assessors. For the comparison NGA versus
placebo, there was relatively high imprecision and heterogeneity due to one outlier study. Although we identified 26 studies, each
comparison only contained a few studies and small numbers of participants so the results were imprecise.
Authors' conclusions
The current review found very low-quality evidence for NGAs and low-quality evidence for NPs being effective in treating somatoform
symptoms in adults when compared with placebo. There was some evidence that different classes of antidepressants did not differ in
efficacy; however, this was limited and of low to very low quality. These results had serious shortcomings such as the high risk of bias, strong
heterogeneity in the data, and small sample sizes. Furthermore, the significant effects of antidepressant treatment have to be balanced
against the relatively high rates of adverse effects. Adverse effects produced by medication can have amplifying effects on symptom
perceptions, particularly in people focusing on somatic symptoms without medical causes. We can only draw conclusions about short-term
efficacy of the pharmacological interventions because no trial included follow-up assessments. For each of the comparisons where there
were available data on acceptability rates (NGAs versus placebo, NPs versus placebo, TCAs versus other medication, and antidepressants
versus a combination of an antidepressant and an antipsychotic), no clear differences between the intervention and comparator were
found.
Future high-quality research should be carried out to determine the effectiveness of medications other than antidepressants, to compare
antidepressants more thoroughly, and to follow-up participants over longer periods (the longest follow up was just 12 weeks). Another
idea for future research would be to include other outcomes such as functional impairment or dysfunctional behaviours and cognitions as
well as the classical outcomes such as symptom severity, depression, or anxiety.

PLAIN LANGUAGE SUMMARY
Medication as a treatment for long-term medically unexplained physical symptoms (somatoform disorders): a review of the
evidence
Who may be interested in this review?
- People with long-term unexplained physical symptoms (somatoform disorders) and their family and friends.
- Professionals working with people with somatoform disorders.
- Professionals working in chronic pain services.
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- General practitioners.
Why is this review important?
Around 6 in 100 people are affected by long-term physical symptoms that have no clear medical cause (somatoform disorders). Symptoms
can include pain, digestive problems, sexual or menstrual problems, breathing problems, and symptoms that mimic brain or nerve damage
such as memory loss or sensory problems. Somatoform disorders often cause considerable distress and mean that people spend a lot of
time consulting doctors and health professionals to try to find the cause of their symptoms and the correct treatment.
Guidelines for the treatment of somatoform disorders recommend that people receive talking therapies alongside medication. In current
practice many people are treated 'off label' with medications that are intended for the treatment of anxiety, depression, and other mental
health problems. However, it is unclear why medications such as antidepressants help to reduce the severity of medically unexplained
physical symptoms.
What questions does this review aim to answer?
- What is the quality of current research on medication as a treatment for somatoform disorders?
- Is medication an effective treatment for physical symptoms in somatoform disorders compared with placebo (dummy pill)?
- Which types of medication are most effective?
- Are natural products such as St. John's wort an effective treatment for somatoform disorders compared with placebo?
- How well do people with somatoform disorders tolerate medication or natural products?
Which studies did we include in the review?
We searched databases to find all studies of medication for somatoform disorders published until January 2014. To be included in the
review, studies had to compare medication with either placebo, usual treatment, another medication, or a combination of medication and
include adults with a clear diagnosis of somatoform disorders. We included 26 studies in the review with 2159 participants aged between
18 and 77 years.
What does the evidence from the review tell us?
Although we identified 26 studies, each comparison only contained a few studies and a relatively small number of participants and so the
findings must be interpreted with caution. We rated the quality of current research as low or very low and the risks of bias were high in
many of the studies.
There was not sufficient evidence in order to make a statement about the efficacy of tricyclic antidepressants for the treatment of
somatoform disorders.
New-generation antidepressants were moderately effective treatments for physical symptoms, anxiety, and depression in somatoform
disorders.
There was no difference found between the effectiveness of tricyclic antidepressants and new-generation antidepressants for the
treatment of physical symptoms. There was some evidence that a combination of antidepressants and antipsychotics was more effective
than antidepressants alone.
Natural products, such as St. John's wort, significantly reduced the severity of physical symptoms compared with placebo.
High numbers of people dropped out of treatment due to side effects or lack of effects with antidepressant medication, and low numbers
dropped out with natural products.
What should happen next?
The review authors suggest that future high-quality research should be carried out to look at the effectiveness of medications other than
antidepressants, to compare antidepressants more thoroughly and to follow up participants over longer periods (the longest follow-up
was just 12 weeks). The review authors also suggest that future research should measure changes in people's quality of life and daily
functioning as well as physical symptoms and depression/anxiety symptoms.
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Tricyclic antidepressants versus placebo for somatoform disorders in adults
Patient or population: somatoform disorders in adults
Settings: outpatient setting
Intervention: tricyclic antidepressants versus placebo
Outcomes

Illustrative comparative risks* (95% CI)
Corresponding risk

Control

Tricyclic antidepressants versus placebo

Severity/intensity of MUPS (post-treatment score on self report
scales)
Different self report scales (SCL-90-R Somatisation Subscore, VAS)1
Follow-up: 6-12 weeks

-

The mean severity/intensity of
MUPS (post-treatment score on
self report scales) in the intervention groups was
0.13 standard deviations lower
(0.39 lower to 0.13 higher)

Acceptability (all-cause drop-outs)

No data available

Anxiety (post-treatment score on self report and clinician-rated
scales)

No data available

Depression (post-treatment score on self report and clinician-rated
scales)

No data available

Adverse effects (drop-outs due to adverse effects)

No data available

Treatment response (post-treatment score on self report and clinician-rated scales)

No data available

Functional disability and quality of life (post-treatment score on self
report and clinician-rated scales)

No data available

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

-

239
(2 studies)

⊕⊕⊝⊝
low 2,3

SMD
-0.13
(95% CI
-0.39 to
0.13)

4

Cochrane Database of Systematic Reviews

Assumed
risk

Relative
effect
(95%
CI)
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2 We considered the results to have a serious risk of bias and so we downgraded the quality of evidence by 1 point because none of the following criteria was met: a low risk of

bias for sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data, and selective outcome reporting.
3 We considered the results to be imprecise because the total population size was fewer than 400 and so we downgraded the quality of evidence by 1 point.
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1 SCL-90-R and VAS: high scale scores correspond to a negative outcome.
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High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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Library

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MUPS: medically unexplained physical symptoms; SCL: Symptom Checklist; SMD: standardised mean difference; VAS: visual analogue scale.

Summary of findings 2. New-generation antidepressants versus placebo for somatoform disorders in adults
New-generation antidepressants versus placebo for somatoform disorders in adults
Patient or population: somatoform disorders in adults
Settings: outpatient setting
Intervention: new-generation antidepressants (SSRI, SNRI) versus placebo
Outcomes

Illustrative comparative risks* (95% CI)
Corresponding risk

Control

New-generation antidepressants versus placebo

Severity/intensity of MUPS (post-treatment score on
self report scales)
Different self report scales (PHQ-15, MOSPM)1
Follow-up: 8-12 weeks

-

The mean severity/intensity of MUPS in the intervention groups was
0.91 standard deviations lower
(1.36 to 0.46 lower)

Acceptability (all-cause drop-outs)5

Study population

Follow-up: mean 12 weeks

265 per
1000

268 per 1000
(170 to 427)

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

-

243
(3 studies)

⊕⊝⊝⊝
very
low 2,3,4

SMD
-0.91
(95% CI
-1.36 to
-0.46)

RR 1.01
(0.64 to
1.61)

163
(2 studies)

⊕⊕⊝⊝
low 2,6

-

5
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Assumed
risk

Relative
effect
(95%
CI)

Anxiety (post-treatment score on self report and clinician-rated scales)
Clinician-rated scales (HARS)7
Follow-up: mean 12 weeks

-

The mean anxiety score in the intervention groups
was
0.88 standard deviations lower
(1.81 lower to 0.05 higher)

-

163
(2 studies)

⊕⊝⊝⊝
very
low 2,3,4

SMD
-0.88
(95% CI
-1.81 to
0.05)

Depression (post-treatment score on self report and
clinician-rated scales)
Different clinician-rated scales (HDRS, MADRS)8
Follow-up: mean 12 weeks

-

The mean depression score in the intervention
groups was
0.56 standard deviations lower
(0.88 to 0.25 lower)

-

163
(2 studies)

⊕⊝⊝⊝
very
low 2,3,4

SMD
-0.56
(95% CI
-0.88 to
-0.25)

Adverse effects (drop-outs due to adverse effects) 5
Follow-up: mean 12 weeks

Study population

RR 2.26
(0.52 to
9.81)

163
(2 studies)

⊕⊕⊝⊝
low 2,6

-

RR 2
(0.9 to
4.43)

163
(2 studies)

⊕⊝⊝⊝
very
low 2,3,6

-

-

163
(2 studies)

⊕⊝⊝⊝
very
low 2,3,4

SMD
-0.52
(95%
CI -1 to
-0.04)

24 per
1000

54 per 1000
(13 to 236)
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195 per 1000
(124 to 311)

Trusted evidence.
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1000
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Moderate

Moderate
18 per
1000
Treatment response (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (PHQ-15,
CGI - Improvement Scale)
Follow-up: mean 12 weeks

41 per 1000
(9 to 177)

Study population
337 per
1000

675 per 1000
(304 to 1000)

Functional disability and quality of life (post-treatment score on self report scales)
Different self report scales (SF-36, SDS)9
Follow-up: mean 12 weeks

319 per
1000

638 per 1000
(287 to 1000)

-

The mean functional disability score/quality of life
score in the intervention groups was
0.52 standard deviations lower/higher
(1 to 0.04 lower/higher)

6

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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Moderate

2 We considered the results to have a serious risk of bias and so we downgraded the quality of evidence by 1 point because none of the following criteria was met: a low risk of

bias for sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data, and selective outcome reporting.
3 We assumed that in 1 study, the SE instead of SD were reported (Muller 2008). Therefore, we re-calculated the values of variance before we entered them into the meta-analysis.
The effect size of this study was still quite high in comparison to the other studies and could be considered as an outlier. A sensitivity analysis where we excluded this study did
not change the pooled effect size significantly. Therefore, we considered the results to be inconsistent and so we downgraded the quality of evidence by 1 point.
4 We considered the results to be imprecise because the total population size was fewer than 400 and so we downgraded the quality of evidence by 1 point.
5 We calculated this rate as a proportion of the total number of randomised participants.
6 We considered the results to be imprecise because the total number of events was fewer than 300 and so we downgraded the quality of evidence by 1 point.
7 HARS: high scale scores correspond to a negative outcome.
8 HDRS and MADRS: high scale scores correspond to a negative outcome.
9 SF-36: high scale scores correspond to a positive outcome and had to be re-coded; SDS: high scale scores correspond to a negative outcome.
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CGI: Clinical Global Impression Scale; CI: confidence interval; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; MADRS: Montgomery-Åsberg
Depression Rating Scale; MOSPM: Medical Outcomes Study Pain Measures; MUPS: medically unexplained physical symptoms; PHQ: Patient Health Questionnaire; RR: risk
ratio; SDS: Sheehan Disability Scale; SF-36: 36-item Short Form; SMD: standardised mean difference; SNRI: serotonin norepinephrine reuptake inhibitor; SSRI: selective
serotonin reuptake inhibitor.

Summary of findings 3. Natural products versus placebo for somatoform disorders in adults
Natural products versus placebo for somatoform disorders in adults
Patient or population: somatoform disorders in adults
Settings: outpatient setting
Intervention: natural products versus placebo

Severity/intensity of MUPS (post-treatment score on self report scales)

Illustrative comparative risks* (95% CI)
Assumed
risk

Corresponding risk

Control

Natural products versus placebo

-

The mean severity/intensity of MUPS in
the intervention groups was
0.74 standard deviations lower

Relative
effect
(95%
CI)

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

-

322
(2 studies)

⊕⊕⊝⊝
low 2,3

SMD
-0.74
(95% CI
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Outcomes

Study population
58 per
1000

50 per 1000
(23 to 104)

-0.97 to
-0.51)

RR 0.85
(0.4 to
1.78)

506
(3 studies)

⊕⊕⊝⊝
low 2,5

-

68 per
1000

58 per 1000
(27 to 121)

Anxiety (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (HARS, VAS)6
Follow-up: 2-6 weeks

-

The mean anxiety score in the intervention groups was
0.83 standard deviations lower
(1.13 to 0.52 lower)

-

321
(2 studies)

⊕⊕⊝⊝
low 2,3

SMD
-0.83
(95% CI
-1.13 to
-0.52)

Depression (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (HDRS, BDI)7
Follow-up: 2-6 weeks

-

The mean depression score in the intervention groups was
0.64 standard deviations lower
(0.87 to 0.41 lower)

-

321
(2 studies)

⊕⊕⊝⊝
low 2,3

SMD
-0.64
(95% CI
-0.87 to
-0.41)

Adverse effects (drop-outs due to adverse effects4)
Follow-up: 2-6 weeks

Study population

RR 0.54
(0.08 to
3.5)

506
(3 studies)

⊕⊕⊝⊝
low 2,5

-

RR 1.77
(1.34 to
2.34)

324
(2 studies)

⊕⊝⊝⊝
very
low 2,5,8

-

13 per
1000

7 per 1000
(1 to 47)

Trusted evidence.
Informed decisions.
Better health.

Moderate

Cochrane

Acceptability (all-cause drop-outs4)
Follow-up: 2-6 weeks

(0.97 to 0.51 lower)
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Different self report scales (SOMS-7, SCL-90-R Somatisation Subscore)1
Follow-up: mean 6 weeks

Moderate

Treatment response (post-treatment score on self report and
clinician-rated scales)
Different self report and clinician-rated scales (PHQ-15, CGI - Improvement Scale)
Follow-up: mean 12 weeks

9 per 1000
(1 to 56)

Study population
340 per
1000
Moderate

601 per 1000
(455 to 794)

8

Cochrane Database of Systematic Reviews

16 per
1000

No data available

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Trusted evidence.
Informed decisions.
Better health.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BDI: Beck Depression Inventory; CGI: Clinical Global Impression Scale; CI: confidence interval; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating
Scale; MUPS: medically unexplained physical symptoms; PHQ: Patient Health Questionnaire; RR: risk ratio; SCL: Symptom Checklist; SMD: standardised mean difference;
SOMS: Screening for Somatoform Symptoms; VAS: visual analogue scale.
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Functional disability and quality of life (post-treatment score
on self report scales)

623 per 1000
(472 to 824)
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352 per
1000

1 SOMS-7 and SCL-90-R: high scale scores correspond to a negative outcome.
2 We considered the results to have a serious risk of bias and so we downgraded the quality of evidence by 1 point because none of the following criteria was met: a low risk of

bias for sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data, and selective outcome reporting.
3 We considered the results to be imprecise because the total population size was fewer than 400 and so we downgraded the quality of evidence by 1 point.
4 We calculated this rate as a proportion of the total number of randomised participants.
5 We considered the results to be imprecise because the total number of events was fewer than 300 and so we downgraded the quality of evidence by 1 point.
6 HARS and VAS: high scale scores correspond to a negative outcome.
7 HDRS and BDI: high scale scores correspond to a negative outcome.
8 We assumed that in 1 study, the SE instead of SD were reported (Muller 2008). Therefore, we re-calculated the values of variance in SE before we entered them in the metaanalysis. The effect size of this study was still quite high in comparison to the other studies and could be considered as an outlier. A sensitivity analysis where we excluded this
study did not change the pooled effect size significantly. Therefore, we considered the results to be inconsistent and so we downgraded the quality of evidence by 1 point.

Tricyclic antidepressants versus another medication for somatoform disorders in adults
Patient or population: somatoform disorders in adults
Settings: outpatient and inpatient setting
Intervention: tricyclic antidepressants versus another medication
Outcomes

Illustrative comparative risks* (95% CI)

Relative
effect
(95%
CI)

9

No of
participants
(studies)

Quality of
the evidence
(GRADE)

Comments

Cochrane Database of Systematic Reviews

Summary of findings 4. Tricyclic antidepressants versus another medication for somatoform disorders in adults

Tricyclic antidepressants versus another
medication

Severity/intensity of MUPS (post-treatment score on self
report scales)
Different self report scales (VAS-Pain, SCL-90-R Somatisation
Subscore)1
Follow-up: 6-8 weeks

-

The mean severity/intensity of MUPS in the
intervention groups was
0.16 standard deviations lower
(0.55 lower to 0.23 higher)

Acceptability (all-cause drop-outs4)
Follow-up: 4-8 weeks

Study population
28 per
1000

41 per 1000
(16 to 103)

-

177
(3 studies)

⊕⊕⊝⊝
low 2,3

SMD
-0.16
(95% CI
-0.55 to
0.23)

RR 1.48
(0.59 to
3.72)

556
(8 studies)

⊕⊕⊝⊝
low 2,5

-

Cochrane

Control

Trusted evidence.
Informed decisions.
Better health.

Corresponding risk
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Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Assumed
risk

Moderate
0 per 1000
(0 to 0)

Anxiety (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (HARS, SCL-90
Anxiety Subscore)6
Follow-up: 6-8 weeks

-

The mean anxiety score in the intervention
groups was
0.37 standard deviations higher
(0.21 lower to 0.95 higher)

-

255
(4 studies)

⊕⊝⊝⊝
very
low 2,3,7

SMD 0.37
(95% CI
-0.21 to
0.95)

Depression (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (VAS Sadness,
HDRS, SCL-90 Depression Subscore, ZDS)8
Follow-up: 6-8 weeks

-

The mean depression score in the intervention groups was
0.17 standard deviations higher
(0.07 lower to 0.4 higher)

-

395
(6 studies)

⊕⊕⊝⊝
low 2,3

SMD 0.17
(95% CI
-0.07 to
0.4)

Adverse effects (drop-outs due to adverse effects4)
Follow-up: 4-8 weeks

Study population

RR 2.37
(0.39 to
14.28)

556
(8 studies)

⊕⊕⊝⊝
low 2,5

-

10 per
1000

25 per 1000
(4 to 148)

Moderate
0 per
1000

0 per 1000
(0 to 0)
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0 per
1000

Study population
630 per 1000
(494 to 806)

130
(2 studies)

⊕⊕⊝⊝
low 2,9

-

Moderate

Functional disability and quality of life

633 per 1000
(497 to 810)

No data available

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CGI: Clinical Global Impression Scale; CI: confidence interval; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; MUPS: medically unexplained physical symptoms; RR: risk ratio; SCL: Symptom Checklist; SMD: standardised mean difference; VAS: Visual Analogue Scale; ZDS: Zung Depression Scale.

Trusted evidence.
Informed decisions.
Better health.

681 per
1000

Cochrane

677 per
1000

RR 0.93
(0.73 to
1.19)
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Treatment response (post-treatment score on self report
and clinician-rated scales)
CGI - Improvement Scale
Follow-up: mean 8 weeks

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 VAS - Pain and SCL-90-R: high scale scores correspond to a negative outcome.
2 We considered the results to have a serious risk of bias and so we downgraded the quality of evidence by 1 point because none of the following criteria was met: a low risk of

Summary of findings 5. Antidepressants versus a combination of medications for somatoform disorders in adults
Antidepressants versus a combination of medications for somatoform disorders in adults
Patient or population: somatoform disorders in adults
Settings: outpatient setting
Intervention: antidepressants versus a combination of antidepressant and antipsychotic
11
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bias for sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data, and selective outcome reporting.
3 We considered the results to be imprecise because the total population size was fewer than 400 and so we downgraded the quality of evidence by 1 point.
4 We calculated this rate as a proportion of the total number of randomised participants.
5 We considered the results to be imprecise because the 95% CI around the pooled effect included both 1. no effect and 2. appreciable benefit or appreciable harm. Therefore,
we downgraded the quality of evidence by 1 point.
6 HARS: high scale scores correspond to a negative outcome.
7 We considered the results to be inconsistent because the I2 value was large. Therefore, we downgraded the quality of evidence by 1 point.
8 VAS Sadness, HDRS, SCL-90, and ZDS: high scale scores correspond to a negative outcome.
9 We considered the results to be imprecise because the total number of events was fewer than 300 and so we downgraded the quality of evidence by 1 point.

Illustrative comparative risks* (95% CI)

Control

Pharmacotherapy versus a combination
of medications

Severity/intensity of MUPS (post-treatment score on self report scales)
Different self report and clinician-rated scales (SOMS-7, SCL-90
Somatisation Score)1
Follow-up: 6-8 weeks

-

The mean severity/intensity of MUPS in the
intervention groups was
0.77 standard deviations higher
(0.32 to 1.22 higher)

Acceptability (all-cause drop-outs4)
Follow-up: 6-8 weeks

Study population
190 per
1000

152 per 1000
(47 to 478)

Quality of
the evidence
(GRADE)

Comments

-

107
(2 studies)

⊕⊕⊝⊝
low 2,3

SMD 0.77
(95% CI
0.32 to
1.22)

RR 0.8
(0.25 to
2.52)

118
(2 studies)

⊕⊕⊝⊝
low 2,5

-

Cochrane

Corresponding risk

No of
participants
(studies)

Trusted evidence.
Informed decisions.
Better health.

Assumed
risk

Relative
effect
(95%
CI)

Library
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Outcomes

Moderate
149 per 1000
(47 to 469)

Anxiety (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (HARS, SCL-90
Anxiety Subscore)6
Follow-up: 6-8 weeks

-

The mean anxiety in the intervention
groups was
0.95 standard deviations higher
(0.91 lower to 2.82 higher)

-

107
(2 studies)

⊕⊝⊝⊝
very
low 2,3,7

SMD 0.95
(95% CI
-0.91 to
2.82)

Depression (post-treatment score on self report and clinician-rated scales)
Different self report and clinician-rated scales (HDRS, SCL-90
depression subscore)8
Follow-up: 6-8 weeks

-

The mean depression in the intervention
groups was
0.58 standard deviations higher
(0.33 lower to 1.48 higher)

-

107
(2 studies)

⊕⊝⊝⊝
very
low 2,3,7

SMD 0.58
(95% CI
-0.33 to
1.48)

Adverse effects (drop-outs due to adverse effects)

No data available

Treatment response (post-treatment score on self report
and clinician-rated scales)

No data available

Functional disability and quality of life

No data available
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186 per
1000

2 We considered the results to have a serious risk of bias and so we downgraded the quality of evidence by 1 point because none of the following criteria was met: a low risk of

bias for sequence generation, allocation concealment, blinding of participants and assessors, incomplete outcome data, and selective outcome reporting.
3 We considered the results to be imprecise because the total population size was fewer than 400 and so we downgraded the quality of evidence by 1 point.
4 We calculated this rate as a proportion of the total number of randomised participants.
5 We considered the results imprecise because the total number of events was fewer than 300 and so we downgraded the quality of evidence by 1 point.
6 HARS and SCL-90: high scale scores correspond to a negative outcome.
7 We considered the results to be inconsistent because the I2 value was large. Therefore, we downgraded the quality of evidence by 1 point.
8 HDRS and SCL-90 Depression Subscore: high scale scores correspond to a negative outcome.

Cochrane

1 SOMS-7 and SCL-90 Somatisation Score: high scale scores correspond to a negative outcome.

Trusted evidence.
Informed decisions.
Better health.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; MUPS: medically unexplained physical symptoms; RR: risk ratio;
SCL: Symptom Checklist; SMD: standardised mean difference; SOMS: Screening for Somatoform Symptoms.

Cochrane Database of Systematic Reviews

13

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

BACKGROUND
Description of the condition
Medically unexplained physical symptoms (MUPS) are somatic
symptoms that cannot or have not been sufficiently explained
by organic causes after a thorough physical examination (Sharpe
1995). The key feature of conditions known as 'somatoform
disorders' is the presence of such MUPS with a chronic
manifestation. Corresponding to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV; APA 1994), and the
International Classification of Diseases (ICD-10; WHO 1992), there
are four somatoform diagnostic categories that include MUPS as
their main indication:
•
•
•
•

somatisation disorder;
undifferentiated somatoform disorder;
somatoform autonomic dysfunction; and
pain disorder.

The current review is confined to these four categories. We did
not consider other somatoform diagnoses because they either do
not primarily focus on MUPS (hypochondriasis, body dysmorphic
disorder), or the duration and chronic manifestation criteria are not
specifically required (other somatoform disorders or somatoform
disorders unspecified), or it is required that the physical symptoms
are associated with a distressing event (conversion disorder).
Somatisation disorder depicts an extreme and chronic form
of MUPS. To be diagnosed with this disorder, DSM-IV (APA
1994) requires an overall number of eight unexplained physical
symptoms, with a chronic manifestation relating to at least
four different organ systems: pain, gastrointestinal, sexual, and
pseudoneurological symptoms. Physical symptoms should begin
before the age of 30 years and must lead to healthcare utilisation
or significant impairment in important areas of functioning.
Diagnostic criteria for somatisation according to the ICD-10 are
similar to those of DSM-IV. The only differences are that ICD-10
requires the duration of symptoms to be at least two years
(independent of age at onset), that the lists of physical symptoms
are structured in different ways, and that the person persistently
refuses to accept that his or her symptoms are unexplained by a
medical condition.
A less stringent form of somatisation disorder is undifferentiated
somatoform disorder, where MUPS must have persisted for at
least six months. The diagnostic category 'somatoform autonomic
dysfunction' is only registered in the ICD-10 and requires chronic
symptoms especially related to the autonomic system. Finally,
pain disorder involves the persistence of medically unexplained
pain symptoms. In DSM-5 (ww2.dsm-5.org/) - the new revision of
the DSM (APA 2013) - the diagnostic category 'somatic symptom
disorder' has been proposed. Although this category includes
a somewhat lesser emphasis on the "medically unexplained"
criterion and requires three "positive" psychological criteria such
as disproportionate or excessive thoughts, feelings, or behaviour,
it covers the four mentioned somatoform diagnoses focusing on
MUPS of DSM-IV or ICD-10.
Apart from the categories defined in DSM-IV and ICD-10, over the
years further 'abridged' diagnostic labels have been developed
because the classic criteria of the international classification
systems are difficult to use for research purposes. Whereas for
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somatisation disorder the criteria are considered too stringent,
for undifferentiated somatoform disorder the threshold level
is considered too low. Therefore, diagnostic labels such as
abridged somatisation disorder or the Somatic Symptom Index
(SSI-4,6; Escobar 1987), multisomatoform disorder (Kroenke 1997),
polysymptomatic somatoform disorder (Rief 1999), or bodily
distress syndrome (Fink 2010), were developed. All of these
constructs have received varying amounts of attention in research
on somatoform disorders.
One European study based on general populations and using a
stepwise multi-method approach, found the 12-month prevalence
for somatoform disorders in general (including somatisation
disorder, undifferentiated somatoform disorder, pain disorder,
and hypochondrias) to be approximately 6.3% (range 1.1% to
11%; Wittchen 2005; Wittchen 2011). Prevalence rates for the
separate forms of somatoform disorders vary considerably. The 12month prevalence rate for people fulfilling the stringent criteria of
somatisation disorder was found to be low (range 1.1% to 2.1%)
among the European (Wittchen 2005), and American (Robins 1991),
general populations. However, in contrast, the lifetime prevalence
rates for the less stringent categories of somatoform disorders such
as undifferentiated somatoform disorder, somatoform autonomic
dysfunction, or pain disorder were much higher, ranging between
12% and 19% (Creed 2011; Fröhlich 2006; Grabe 2003; Jacobi 2004;
Martin 2006; Meyer 2001; Robins 1991; Wittchen 1992).
Whereas female gender (e.g. Nimnuan 2001; Verhaak 2006), and
low socioeconomic status (e.g. Jacobi 2004), seem to be clear risk
factors for developing chronic MUPS, associations between MUPS
and age seem to be more complex. MUPS appear in the general
population more frequently in older than in younger people.
However, studies on the epidemiology of somatoform diagnoses
are different. For example, Leiknes 2007 showed that a peak of
the prevalence of the multisomatoform disorder lies between
18 and 34 years. The highest co-morbidity rates were found for
anxiety disorders, affective disorders, and substance abuse (e.g. De
Waal 2004; Fröhlich 2006; Kroenke 1997). Somatoform disorders
in general are associated with excessive treatment and healthcare
costs (Barsky 2005).
Aetiological theories of somatoform disorders and MUPS in general
are varied (Rief 2007; Witthöft 2010). One of the most important
concepts is that of somatosensory amplification (Barsky 1990). The
authors assume that people with a tendency to experience somatic
sensations as intense, noxious, and disturbing amplify benign
somatic sensations by mis-attributing them to serious illnesses and
by focusing attention on them. Kirmayer and colleagues expanded
this perceptional-cognitive model by integrating social aspects (e.g.
communication of distress with others, help-seeking behaviour)
(Kirmayer 1997). Another important model, focusing more on
the perceptual process itself and its psychobiological correlates,
is a signal-filtering model of MUPS (Rief 2005). It emphasises
the interaction of biological and psychological processes in the
perception of MUPS. Finally, Ursin 1997 and Yunus 2007 have
postulated mechanisms of central sensitisation for explaining
MUPS. Central sensitisation describes a plastic response of an
increased efficacy in synapses in specific brain areas - especially in
limbic structures - as a consequence of repeated use (Ursin 1997).
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Description of the intervention

How the intervention might work

In addition to psychological therapy approaches (Kleinstäuber
2011), pharmacological agents are also used to treat somatoform
disorders. However, in contrast to psychological therapies,
the mechanisms of action of pharmacotherapy in somatoform
disorders are still partly unclear.

Antidepressants

Based on the findings of research on chronic pain syndromes
such as neuropathic pain (Saarto 2007), and fibromyalgia (Häuser
2009; O'Malley 2000), or other syndromes of MUPS such as irritable
bowel syndrome (IBS) (Ford 2009; Jackson 2000; Jackson 2006a), or
chronic fatigue syndrome (Pae 2009), antidepressants in particular
have been used. Furthermore, findings from studies examining
the effects of antidepressants on psychiatric co-morbid conditions
that are common in people with somatoform symptoms (e.g.
depression or anxiety disorders), also support the administration of
antidepressant drugs in people with somatoform disorders (Verdu
2008; Whitehead 2002).
Two groups of antidepressants are particularly relevant:
tricyclic antidepressants (TCAs; e.g. amitriptyline, desipramine,
trimipramine, doxepin, opipramol), and new-generation
antidepressants (NGAs). Typical NGAs that are used for
treating somatoform symptoms are selective serotonin reuptake
inhibitors (SSRIs; e.g. citalopram, escitalopram, sertraline,
paroxetine, fluvoxamine, fluoxetine), serotonin and noradrenaline
(norepinephrine) reuptake inhibitors (SNRIs; e.g. venlafaxine,
duloxetine), or serotonin antagonist and reuptake inhibitors (SARI;
e.g. trazodone) that operate as a serotonin receptor antagonist
and by inhibiting the serotonin reuptake. Antiepileptic drugs are
another group of pharmacological agents used for the treatment of
somatoform disorders. Here there are also parallels to the research
on chronic pain, where efficacy in pain relief of antiepileptics
such as pregabalin (Moore 2009), or gabapentin (Moore 2011), has
been demonstrated. For primarily pain-dominated somatoform
symptoms such as headache, the efficacy of antipsychotics (APs;
e.g. olanzapine) has already been shown (Silberstein 2002). Finally,
natural products (NPs) such as St. John's wort are also used in the
treatment of MUPS.
In Germany, a guideline for the treatment of non-specific functional
or somatoform symptoms has been developed (AWMF 2012).
The guideline recommends the use of different classes of
antidepressants, particularly for severe syndromes dominated
by pain symptoms and with or without co-morbid depressive
symptoms. For severe syndromes not determined by pain,
the guideline recommends antidepressants only if there is comorbid depression. Furthermore, the guideline discourages the
use of anxiolytic drugs (e.g. benzodiazepines), tranquillisers, or
hypnotics, and APs when there is no co-morbid symptomatology
that justifies the prescription of such agents. The TCA opipramol
has been officially approved in Germany for the medical treatment
of somatoform disorders (www.rote-liste.de). It should be taken
into consideration that current guidelines in general do not
recommend treating somatoform disorders with pharmacotherapy
alone, but rather in combination with psychosocial interventions
(e.g. AWMF 2012).

The mechanisms of action of antidepressants on somatoform
symptoms remain unclear. Once more, parallels to syndromes
such as IBS or fibromyalgia can be drawn. In these syndromes,
people have demonstrated increased prefrontal cortex activity with
noxious stimulation. These are areas responsible for increased
attention to a stimulus (Bonaz 2002; Drossman 2003). Furthermore,
abnormal activity in brain areas involved with serotonin (5-HT) and
noradrenaline (norepinephrine; NE) have been observed in people
with somatoform symptoms. In addition, 5-HT and NE produce
analgesic effects via inhibitory descending pain pathways (Jones
1991; Richardson 1990; Stahl 2002). Therefore, serotonin and NE
could be involved in suppression of somatic symptoms at the
level of the spinal cord. This could explain why people with IBS
experience gastric and colonic distention as more painful than
people without the syndrome (Naliboff 1997). The same can be
observed in people with fibromyalgia: these people have lower
thresholds when they experience pain from noxious stimulation
(Montoya 2005; Petzke 2005). Therefore, antidepressant action
may involve processing pain on a central as well as peripheral
level. In addition, antidepressants may alter pathophysiological
mechanisms involved in somatoform symptoms and could have
direct effects on different organ systems. For example, TCAs may
slow gastrointestinal transit due to anticholinergic effects. This
can improve diarrhoea-predominant IBS in particular (Gorard
1994). Additionally, especially in the treatment of fatigue with
antidepressants, it is speculated that immunoregulatory effects
could play an important role. Studies have demonstrated that an
increased production of pro-inflammatory cytokines may play a
role in somatic symptoms such as anergy, sleeping disturbances,
or psychomotor retardation (Maes 1999; Yirmiya 1996). Different
studies demonstrated that the effects of antidepressants on such
symptoms could be related to their negative immunoregulatory
effects (Kubera 2001; Maes 2001). Finally, a mechanism of action
could be that antidepressants reduce co-morbid psychiatric
conditions such as depressive disorders, anxiety disorders, and
post-traumatic stress (De Waal 2004). This can then influence
symptom severity and functional impairment. For example, it
could be demonstrated that anxiety and depression are associated
with distinctive cognitive-affective biases related to attention or
encoding and recall processes. In turn, they can be critical for the
cognitive processing of somatic changes. Suls 2012 reflected in
their review that anxiety seems to be associated with an elevated
report of momentary symptoms, whereas depression is related to
an exaggerated recall of past symptoms.
Antiepileptic drugs
The mechanisms of action of antiepileptic drugs on MUPS are
also unclear. In neuropathic pain, there is evidence that two
antiepileptic drugs - gabapentin and pregabalin - bind calcium
channels and modulate calcium influx (Urban 2005). Furthermore,
they influence GABAergic neurotransmission (Gu 2002). Apart
from antiepileptic effects, this mode of action can also produce
analgesic, anxiolytic, and sedative effects. Pregabalin is more
potent than gabapentin and is, therefore, administered at lower
doses.
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Antipsychotics
The use of APs in somatoform disorders is based on their analgesic
effects (Nix 1998). The method by which APs reduce pain is still
unclear. It is possible that the modes of action vary between
different agents. The analgesic effect could be mediated by opioid
mechanisms, serotonin antagonism (Schreiber 1999), or activity at
alpha2-adrenoreceptors (Silberstein 2002).
Natural products
Mechanisms of action are also unclear for NPs such as St. John's
wort. Its administration in somatoform disorders is primarily
based on diagnostic overlaps between depressive or anxiety
and somatoform disorders (Linde 2009). Several studies on the
efficacy of St. John's wort for mild depression demonstrated
an additional positive effect on somatoform symptoms such as
headache or gastrointestinal complaints (e.g. Sommer 1993; Woelk
2000). The effect of Hypericum extracts, and especially hyperforin
and adhyperforin, may be mediated by their function as potent but
non-specific inhibitors of the synaptosomal reuptake of serotonin,
noradrenaline, and dopamine (Butterweck 2003).

Why it is important to do this review
In addition to psychotherapeutic approaches, pharmacological
agents are also often used in the treatment of somatoform
disorders. Previously, the efficacy of these agents has been
mainly researched in people with chronic pain where the use
of specific medications has been judged critically. For example,
the authors of another Cochrane review critically considered the
application of APs for chronic painful conditions (Seidel 2008). They
emphasised that the particularly strong extrapyramidal adverse
effects and sedating effects have to be considered before they are
prescribed. With few exceptions, there are no official indications
(e.g. the TCA opipramol for treating somatoform disorders) of
medication such as antidepressants, antiepileptic drugs, or APs
for treating somatoform disorders. This 'off-label' use of different
pharmacological agents, that are in fact indicated for example for
depressive or anxiety symptoms but not for somatic symptoms, is
part of treatment routines for people with somatoform disorders
or pain syndromes in clinics and private practices. One study
demonstrated in a sample of people with headaches that 47% of
the prescriptions met the criteria for off-label use (Loder 2004).
Although this 'off-label' use is common practice (Di Franco 2010;
Stone 2003), there exists no systematic review or meta-analysis on
the efficacy and tolerability of these medications.
Therefore, the intention of this meta-analysis is to give an
overview of: 1. the current status of research on the efficacy
of pharmacological treatments for somatoform disorders, and
2. the acceptability of using medication to treat people with
somatoform disorders. It will assist patients as well as providers in
making optimal treatment decisions. Furthermore, it will highlight
the shortcomings of previous research in pharmacotherapy for
somatoform disorders and help to stimulate further research in
this area. In this way, the current review adds to a portfolio of five
Cochrane reviews covering somatoform disorders (the other four
being Hoedeman 2010; Ipser 2009; Ruddy 2005; Thomson 2007).

OBJECTIVES
To assess the effects of pharmacological interventions
for somatoform disorders (specifically somatisation disorder,
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undifferentiated somatoform disorder, somatoform autonomic
dysfunction, and pain disorder) in adults.

METHODS
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and clusterrandomised controlled trials (CRCTs). We also included cross-over
trials, but used only data from the first randomisation period in
the review. We excluded quasi-randomised trials (e.g. allocation to
the study group by day of the week). In the case that treatment
outcome data were absent, we excluded the trial from metaanalysis but included it as part of the narrative literature review.
Types of participants
Participant characteristics
Participants aged 18 to 65 years (where a trial has defined adults to
include those older than 65 years but most participants were under
65 years of age we included the trial; however, we excluded any trial
that focused on older adults or where the mean age of participants
was greater than 65 years). We applied no restrictions on gender or
culture.
Diagnosis
Participants had to meet the requirements for diagnosis of a
somatoform disorder, based on chronic, multiple, MUPS, according
to DSM-III (APA 1980), DSM-IV-TR (APA 2000), ICD-9 (WHO 1975),
ICD-10 (WHO 1992), the Chinese Classification of Mental Disorders
(CCMD)-III (Chinese Society of Psychiatry 2001), or the criteria of
a somatic symptom disorder according to DSM-5 (APA 2013). See
Table 1 for an overview of all diagnostic categories of somatoform
disorders and a clear indication of whether or not they were eligible
for this review. A medical assessment of the physical symptoms was
required to rule out the possibility that the physical symptoms and
their intensity can be explained sufficiently by a medical condition.
Co-morbidities
We included people with certain co-morbidities, but the
somatoform disorder had to be the primary diagnosis. We included
studies that included participants with co-morbid psychiatric
disorders, with the exception of studies in which participants had a
co-morbid psychosis or dementia, which we excluded. We excluded
studies that examined the efficacy of a pharmacotherapy in a
group of participants diagnosed with only one specific functional
syndrome (e.g. IBS, chronic fatigue syndrome, fibromyalgia).
Setting
We placed no restrictions on setting.
Types of interventions
Experimental interventions
Eligible studies included one or more of the following experimental
interventions:
• TCAs (e.g. amitriptyline);
• NGAs, such as SSRIs (e.g. fluoxetine), SNRIs (e.g. venlafaxine),
noradrenaline reuptake inhibitors (NRIs; e.g. reboxetine),
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tetracyclic antidepressants (TeCAs; e.g. maprotiline),
noradrenergic and specific serotonergic antidepressants
(NaSSAs; e.g. mirtazapine), SARIs (e.g. trazodone), and
reversible inhibitors of monoamine oxidase type A (RIMAs; e.g.
moclobemide)
any other antidepressants such as irreversible monoamine
oxidase inhibitors (MAOIs; e.g. bupropion);
antiepileptics (e.g. pregabalin, gabapentin);
NPs (e.g. St. John's wort);
APs (e.g. paliperidone);
other pharmacological agents (e.g., benzodiazepines).

Comparator interventions
The following comparator interventions were accepted:
•
•
•
•

placebo;
treatment as usual;
another medication;
combination of medication.

Types of outcome measures
Primary outcomes
1. Severity/intensity of MUPS. If a validated self report scale
was used, we considered this the primary outcome. Validated
scales for the assessment of MUPS considered for this review
were: Screening for Somatoform Symptoms (SOMS; Rief 2008),
and Bradford Somatic Inventory (Mumford 1991). If no validated
scales were available, we also accepted component subscales
of validated standardised instruments for the assessment of
general psychopathology or general health status, for example,
the subscale 'Somatisation' of the Patient Health Questionnaire-15
(PHQ-15; Kroenke 2002), the subscale 'Somatisation' of the
Symptom Checklist-90-R (SCL-90-R; Derogatis 1983), or the
subscale 'Somatisation' of the Brief Symptom Inventory (BSI;
Derogatis 1992). Where unvalidated or visual analogue self report
scales (VAS) were used, we decided which scale most closely
approximated MUPS. One of the review authors (WH) who is an
expert in somatoform disorders and clinical diagnostics, but who
was not directly involved in the process of study selection or data
extraction and management, decided this, so that he could be
blinded to the results. We examined clinician-rated severity of
MUPS separately and did not aggregate it with self report outcomes
into one effect size index.
2. Acceptability. We considered the proportion of people who
dropped out during the experimental as well as the comparator
intervention. We calculated this rate as a proportion of the total
number of randomised participants. In addition, we presented the
acceptability rate as a risk ratio (RR) calculated from the total
number of all randomised participants.
Secondary outcomes
3. Anxiety: using a. validated self report instruments (e.g. Beck
Anxiety Inventory (BAI); Beck 1990), b. clinician-rated instruments
(e.g. Hamilton Anxiety Rating Scale (HARS); Hamilton 1959), or
c. component subscales of validated standardised instruments
for the assessment of general psychopathology or general health
status (e.g. the subscale 'Anxiety' of the SCL-90-R; Derogatis 1983).
Where unvalidated or self report VAS were used, we decided
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which scale most closely approximates anxiety. One of the review
authors (WH) who is an expert in somatoform disorders and clinical
diagnostics, but who was not directly involved in the process of
study selection or data extraction and management, decided this,
so that he could be blinded to the results.
4. Depression: using a. validated self report instruments (e.g.
Beck Depression Inventory (BDI); Beck 1961), b. clinician-rated
instruments (e.g. Hamilton Depression Rating Scale (HDRS);
Hamilton 1960), or c. component subscales of validated
standardised instruments for the assessment of general
psychopathology or general health (e.g. the subscale 'Depression'
of the SCL-90-R; Derogatis 1983). Where unvalidated or self report
VAS were used, we decided which scale most closely approximates
depression. One of the review authors (WH) who is an expert in
somatoform disorders and clinical diagnostics, but who was not
directly involved in the process of study selection or data extraction
and management, decided this, so that he could be blinded to the
results.
5. Dysfunctional cognitions, emotions, or behaviours/participantrated: validated self report scales (e.g. the Whiteley Index (WI);
Pilowsky 1967); Illness Attitude Scales (IAS); Kellner 1986); Scale for
the Assessment of Illness Behavior (SAIB); Rief 2003); Cognitions
About Body and Health Questionnaire (CABAH); Rief 1998)).
6. Adverse effects: when possible, we described the most common
drug-related adverse effects (defined as effects that occurred in
at least 10% of people receiving medication) as well as significant
differences in the rate of occurrence of drug-related adverse
events between medication and control groups, as part of the
narrative literature review. We calculated the rate of participants
who dropped out due to adverse effects during the experimental
as well as the comparator intervention as a proportion of the total
number of randomised participants. In addition, we presented the
adverse effect-related drop-out rate as an RR calculated out of
the total number of all randomised participants. As a limitation to
interpreting these adverse effects, we noted that the inclusion of
RCT or CRCT studies was not sufficient to gain information about
the more rare or long-term adverse outcomes.
7. Treatment response (responder versus non-responder;
with regard to the primary outcome 'severity/intensity of
MUPS'); clinician-rated Clinical Global Impression Scale (CGI) Improvement Scale (Guy 1976); we defined responders on this
scale as those with a score of "1 = very much improved" or "2
= much improved". Alternatively, the number of participants who
responded to the treatment according to the author's definition. We
calculated response rates out of the total number of all randomised
participants.
8. Functional disability and quality of life: a. validated clinicianrated scales (e.g. Global Assessment of Functioning (GAF); APA
1994) or b. validated self report instruments (e.g. Sheehan Disability
Scale (SDS); Sheehan 1983; 36-item Short Form Questionnaire
(SF-36); Ware 1992).
Timing of outcome assessment

In the protocol, we had planned that the primary and secondary
outcomes were classified as assessed: 1. post treatment, 2. within
12 months' post treatment, or 3. more than 12 months' post
treatment. However, in all included studies data were only available
for post treatment.
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Search methods for identification of studies

Searching other resources

The Cochrane Depression, Anxiety and Neurosis Review
Group's Specialised Register (CCDANCTR)

Grey literature

The Cochrane Depression, Anxiety and Neurosis Group
(CCDAN) maintain two clinical trials registers at their
editorial base in Bristol, UK: a References Register and a
Studies Register (ccdan.cochrane.org/specialised-register). The
CCDANCTR-References Register contains over 36,000 reports of
RCTs in depression, anxiety, and neurosis. Approximately 60% of
these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers using unique
Study ID tags. Coding of trials is based on the EU-Psi coding
manual, using a controlled vocabulary; please contact the CCDAN
Trials Search Coordinator for further details. Reports of trials
for inclusion in the Group's registers are collated from routine
(weekly), generic searches of MEDLINE (1950 to date), EMBASE
(1974 to date) and PsycINFO (1967 to date); quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL) and
review-specific searches of additional databases. Reports of trials
are also sourced from international trials registers via the World
Health Organization's (WHO) trials portal (the International Clinical
Trials Registry Platform (ICTRP)), pharmaceutical companies, the
handsearching of key journals, conference proceedings, and other
(non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN's generic search strategies (used to identify RCTs)
can be found on the Group's website.
Electronic searches
1. We searched the CCDANCTR-Studies Register (to 17 January
2014) using the following terms:
Condition = "Somatization Disorder"
We screened records manually for pharmacological interventions.
2. We searched the CCDANCTR-References Register for additional
untagged references (to 17 January 2014), using a more sensitive
set of free-text terms:
("somatoform disorder*" or (somatoform and "autonomic
dysfunction") or "somatic symptom disorder*" or somatization
or somatisation or hysteri* or briquet or "pain disorder*" or
polysymptom* or multisomatoform or somatizer* or (multiple and
(MUPS or "medically unexplained" or "unexplained symptoms" or
"physical symptoms" or "symptom diagnos*")))
We screened records manually for pharmacological interventions.
3. To ensure that we had missed no studies, we conducted
complementary searches on the following bibliographic databases,
using relevant subject headings (controlled vocabularies) and
search syntax, appropriate to each resource: CENTRAL (all years,
see Appendix 1), PsycINFO (all years, Appendix 2), and PSYNDEX
(from 1977 onwards, see Appendix 3).
4. To identify ongoing trials, we searched the ClinicalTrials.gov
register (clinicaltrials.gov/), the Current Controlled Trials
metaRegister of Controlled Trials-active registers (mRCT;
www.controlled-trials.com/mrct/), the WHO International Clinical
Trials Registry Platform Search Portal (www.who.int/trialsearch),
and the Chinese Clinical Trials Registry (www.chichtr.org/).
We applied no date or language restrictions to the searches.

We searched the ProQuest Dissertation & Theses Database,
OpenGrey (System for Information on Grey Literature in Europe
launched by the Institute for Scientific and Technical Information
INIST), and BIOSIS Previews for trials published in dissertations or
theses, or other sources of grey literature.
Handsearching
We handsearched the proceedings of the following conferences
since 2008 if available:
American Psychiatric Association (APA) Annual Meeting;
World
Congress
of
The
International
College
of
Neuro-Psychopharmacology (CINP); European College of
Neuropsychopharmacology (ECNP) Congress; International
Congress of Behavioral Medicine (ICBM); European Conference
on Psychosomatic Research (ECPR); Annual Meeting of the
European Association for Consultation-Liaison Psychiatry and
Psychosomatics (EACLPP); and Congress of the German
Association for Psychiatry, Psychotherapy, and Neurology
(DGPPN).
Reference lists
We screened reference lists of all potentially relevant papers
and of systematic reviews or meta-analyses for further relevant
studies. We identified systematic reviews or meta-analyses using
appropriate search filters in the above-mentioned electronic
databases (see Electronic searches).
Correspondence
We asked experts in the field of somatoform disorders, as well as
authors who have published studies on pharmacotherapy or other
therapies for MUPS, if they knew of any published or unpublished
or ongoing trials meeting the criteria of the current review.

Data collection and analysis
Selection of studies
In a first step, two review authors (MK, MW) independently screened
titles and abstracts of reports that were identified from the
literature search. We discarded those studies that obviously did not
fulfil the inclusion criteria at this stage of the screening process.
We retrieved potentially relevant articles for full-text assessment. In
the next step, two review authors (MK, MW) independently assessed
the main text of these retrieved trials for eligibility. We resolved
disagreements by consensus, if necessary with the involvement
of a third review author (WH). We had planned that studies for
which additional information was required in order to determine
their suitability for inclusion in the review would be listed in
the 'Studies awaiting assessment' table in the Review Manager
5 software (RevMan 2012). One review author (MK) checked the
reference lists of articles that were retrieved after the second stage
of the selection process. The review authors were not blinded to the
name(s) of the study author(s). We reported reasons for exclusion
in the 'Characteristics of excluded studies' table.
We recorded all decisions that were made throughout the review
process, along with the number of references and studies found and
presented them in a PRISMA flow diagram (Moher 2009; Figure 1).
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Figure 1. PRISMA study flow diagram.
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Figure 1. (Continued)

Data extraction and management

Assessment of risk of bias in included studies

One review author (MK) and one research assistant independently
conducted data extraction. We had previously prepared a data
extraction form a priori and piloted it before use. The research
assistant had training in completing the data extraction form.
We assessed characteristics regarding the trial, participants,
methods, intervention and outcome details, summary statistics,
and associated commentaries. If necessary, we contacted authors
of reports for clarification or additional information. We organised
data using the most recent version of Review Manager 5 software
(RevMan 2012). We resolved disagreements by consultation with
another review author (MW or WH). We extracted the following
information.

The first review author (MK) and a research assistant independently
assessed the risk of bias within each included study. The
assessment of risk of bias was based on a tool in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a),
which included six categories. The following judgements had to
be passed with consensus of the review author and the research
assistant for each of these categories.

1. Characteristics of the trial: primary researcher, publication year,
status of publication, language of publication, source of funding,
study design, length of follow-up.
2. Characteristics of participants: source of sample, sample
size, gender, age, number of drop-outs, nationality, applied
diagnostic criteria, somatoform diagnosis, co-morbidity, comorbid diagnoses, screening procedure (e.g. interview),
screening instruments, inclusion and exclusion criteria, mean
length of time since diagnosis of a somatoform disorder,
previous treatments.
3. Characteristics of intervention: category of medication,
medication, treatment setting, dose of medication, frequency
of intake, mode of administration of medication, period over
which the medication was administered, number of participants
that dropped out due to adverse effects or inefficacy of
treatment, most common drug-related adverse effects, details
of concurrent treatments (e.g. psychotherapy).
4. Details of methodology: number of centres involved; number
of participants that were not included in the analyses
(lost to follow-up); whether blinding occurred for assessors,
participants, or people who administered medication.
5. Outcome measures: primary and secondary outcome measures,
summary statistics of continuous data (mean, standard
deviation (SD)) and dichotomous data (number of responders),
timing of outcome assessments, intention-to-treat (ITT) analysis
(with last observation carried forward (LOCF)) or observed
cases/completer analysis, other methods of estimating the
outcome for participants who dropped out (e.g. mixed effect
analyses).
As medication classes can all have different effects, where data
allowed, we stratified the comparisons by medication class (see
Types of interventions). Therefore, the following main comparisons
were planned for each class of medication.
1.
2.
3.
4.

Pharmacotherapy versus placebo.
Pharmacotherapy versus usual treatment.
Pharmacotherapy versus another medication.
Pharmacotherapy versus a combination of medications.

1. Random sequence generation. Was the method to generate
the sequence of randomised allocation adequate to produce
comparable groups?
2. Allocation concealment. Was the allocation concealed
adequately so that intervention allocations could not have been
foreseen in advance of or during enrolment?
3. Blinding. Was knowledge of the allocation of treatment of the
participant and study personnel adequately prevented during
the study? Was knowledge of the allocation of treatment of the
outcome assessor(s) adequately prevented during the study?
Were any measures applied to blind participants, personnel,
and outcome assessors described. The assessment was made
separately for each outcome domain.
4. Incomplete outcome data. Were incomplete outcome data
adequately addressed? Was the completeness of outcome data
described, including attrition and exclusions from analyses? If
there were attritions and exclusions in the treatment and control
group, were they reported, along with the reasons? If the review
authors conducted any re-inclusions in their analyses, we also
reported this. We made the assessment separately for each
outcome domain.
5. Selective reporting. Were reports of the study free of suggestion
of selective outcome reporting?
6. Other sources of bias. Was the study apparently free of other
sources that could produce risk of bias?
In order to assess risk of bias in the following specific types of study
design, we passed the following additional judgements.
• Multiple-intervention studies. Were data presented for each of
the groups to which participants were randomised?
• Cross-over trials. Was it clear that the order of receiving a
treatment was randomised? Were unbiased data from the first
treatment-period available?
• CRCTs. Were individuals recruited to the trial after the clusters
had been randomised? Were methods of stratified or pairmatched randomisations of clusters used? Were adequate
statistical analyses (taking clustering into account) used?
We used the following scale to rate each of the categories:
'high' (high risk of bias), 'low' (low risk of bias), and
'unclear' (uncertain risk of bias).
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We resolved disagreements regarding the ratings by consultation
with a further review author (MW or WH). If necessary, we contacted
study authors for further information.
Measures of treatment effect
Dichotomous data
For computing treatment effects based on dichotomous data,
we used the pooled RR with 95% confidence interval (CI) for
each comparison. We calculated the number needed to treat
for an additional beneficial outcome (NNTB) for every class of
pharmacological agent for which we found a statistically significant
treatment effect. We interpreted the NNTB as the number of
participants that needed to be treated for one to benefit compared
with a control in a clinical trial. Therefore, we used the RR estimate
and the control risk from the placebo group.
Continuous data
We collected the mean score, SD, and the number of participants
at endpoint. Unfortunately, none of the included studies provided
data for follow-ups. We pooled these values for the single trials as
follows: assuming that at least two studies using the same scale
are available, we calculated the mean difference (MD) with a 95%
CI between experimental and comparator intervention at endpoint
and follow-up. In case measures of an outcome domain varied
across studies, we used the standardised mean difference (SMD)
with 95% CI. We paid specific attention to the secondary outcome
'functional disability and quality of life' because the direction of
corresponding scales can differ. Whereas an increase of scales of
functional disability usually indicates deterioration, an increase
of scales of quality of life often indicates improvement. The SMD
method does not correct for such differences in the direction of
the scale. In this case, we multiplied the mean values from one set
of studies by -1 to ensure that all the scales pointed in the same
direction.
Unit of analysis issues
Cluster-randomised controlled trials
In order to avoid unit-of-analysis errors for trials in which incorrect
statistical analyses were conducted, we performed approximate
analyses based on inflating standard errors (SE). Before data were
entered into Review Manager 5 for meta-analytic calculations
(RevMan 2012), we multiplied the SE of the effect estimate (from
an analysis not taking into to account the clustering) by the
square root of the so-called design effect. The design effect is 1
+ (M - 1) ICC, where M is the mean cluster size and ICC is the
intracluster correlation coefficient. We assumed a common design
effect across intervention groups. If the ICC was not available in
the published report, we used an external estimate obtained from
similar studies or another external resource. It was planned that
the meta-analysis using the inflated variances would be performed
using Review Manager 5 (RevMan 2012), and the generic inversevariance method.
Studies with multiple treatment groups
In trials comparing the efficacy of more than one medication for
somatoform disorders, we considered three aspects.
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control group. For continuous data, we pooled means and SDs
across all of the treatment arms as a function of the number
of participants in each arm. For dichotomous outcomes, we
summed both the sample sizes and the numbers of people with
events across groups.
2. If the different medications were of different classes of chemical
agents (e.g. SSRIs versus TCAs), we included each pair-wise
comparison separately, but divided the 'shared group' into
two or more groups (according to the number of intervention
groups) with smaller sample size. For dichotomous outcomes,
we divided up both the number of events and the total number
of participants. For continuous outcomes, we divided up only
the total number of participants and left the means and SDs
unchanged. Although this method only partially overcomes the
unit-of-analysis error, an advantage of this approach is that
investigations of heterogeneity across intervention arms are
possible.
3. In the case of data from trials employing multiple fixed doses of
medication, we summarised the different experimental groups
into one group corresponding to the pooling procedure of the
aspect 2 above. We restricted the pooling of outcome data to
those treatment arms that employed at least the minimum
dose recommended by clinical guidelines or experts, in order
to reduce the influence of data from arms that employ doses
unlikely to have a clinical effect.
Cross-over trials
We only included cross-over trials in meta-analytical calculations if
it was possible to extract relevant data of the treatment and control
group from the first treatment period.
Dealing with missing data
In the case of a missing continuous data summary, we preferred
statistics based on mixed-effects models, followed by statistics
based on ITT analysis with LOCF and on observed cases. This is in
accordance with the finding that mixed-effects methods are more
robust to bias than LOCF (Verbeke 2000). If SDs were not available
directly, we attempted to calculate them from t, F, P, or CI values
(Higgins 2011b), or SEs (Altman 1996).
In the case of missing dichotomous data, we applied ITT analysis,
in which it was assumed that participants who dropped out after
randomisation had a negative outcome. According to Gamble
and Hollis, sensitivity analyses for dichotomous data were also
conducted (Gamble 2005): we calculated best-case/worst-case
scenarios for the clinical response outcome, in which it was
assumed that drop-outs in the active treatment group had positive
outcomes and drop-outs in the control group had negative
outcomes (best-case scenario), and that drop-outs in the active
treatment group had negative outcomes and drop-outs in the
control group had positive outcomes (worst-case scenario).
If data were not in a suitable format or if relevant data were
not available, we tried to contact trial authors to obtain further
information. We reported reasons for missing data where they were
provided in the published trials. Where we could not include data,
we reported a qualitative summary of the results in the text of the
review.

1. If the different medications were of the same class of chemical
agent (e.g. TCAs), we summarised the different experimental
conditions into a single group that were compared with the
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Assessment of heterogeneity
We first assessed statistical heterogeneity visually by inspecting
forest plots of standardised mean effect sizes and of RR.
Furthermore, we applied a Chi2 test to assess heterogeneity. The
test has low power in general but especially when the sample size
of the included studies is low or there are only a few included
studies. Therefore, we used a P value of 0.10 to determine statistical
significance in a conservative way. Another problem of the Chi2
statistic is that it indicates only significance or non-significance but
does not give any information about the level of heterogeneity.
For this reason, we used the I2 statistic. The I2 statistic describes
the percentage of variability in effect estimates that is due to
heterogeneity rather than sampling error. We used conventions of
interpretation that were defined by Higgins (Higgins 2011a). In the
case of substantial levels (I2 = 50% to 90%) and considerable levels
(I2 = 75% to 100%) of heterogeneity, we examined data by subgroup
and sensitivity analyses (see Subgroup analysis and investigation of
heterogeneity; Sensitivity analysis) for different aspects of clinical
and methodological heterogeneity.
For the assessment and examination of clinical heterogeneity,
we planned subgroup analyses (see Subgroup analysis and
investigation of heterogeneity) for the following pre-specified
characteristics: class of medication, co-morbidity, gender, source of
funding for the trial, and source of outcome rating.
Assessment of reporting biases
In order to prevent publication bias, we made every attempt to
include unpublished trials (e.g. by searching online trial registries
or registries of unpublished doctoral theses). In order to assess for
a publication bias, we implemented funnel plots (effect versus SE
of the effect size) when a sufficient number of trials was available
(according to recommendations of the Cochrane Handbook for
Systematic Reviews of Interventions there should be at least 10
studies; Sterne 2011). For the analysis and the interpretation of the
funnel plots, other reasons for asymmetry besides publication bias
have to be considered (e.g. differences in methodological quality,
true heterogeneity in intervention effects).
Data synthesis
In the case that two or more studies that were eligible for inclusion
were found per comparison category (see Data extraction and
management), and that these studies measured the same outcome
construct, we performed a meta-analysis of the results. One review
author (MK) entered data into Review Manager 5 software (RevMan
2012). We obtained dichotomous and continuous treatment effects
using a random-effects model. However, we specified the fixedeffect model as a sensitivity analysis in order to compare the results
informally. Where heterogeneity analysis indicated significant
heterogeneity, we performed subgroup analysis. We based the
calculation of the mean effect size for each (sub)group as well
as the 95% CI on the inverse-variance method. This was reported
for the post-treatment assessment. If data were available, we
also reported the summarised statistic for follow-up assessment
(less than 12 months post treatment or 12 months or more post
treatment).
Subgroup analysis and investigation of heterogeneity
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performed a priori defined analyses in order to explore whether
methodological and clinical differences between the trials had
systematically influenced the differences that were observed in
the treatment outcomes. If sufficient data were available, we
planned the following subgroup analyses for the main comparison
'pharmacotherapy versus placebo' (primary outcomes only).
1. Co-morbidity. As known from other mental disorders, co-morbid
psychological problems can moderate the efficacy of a medication.
Therefore, we planned to compare the effects of pharmacotherapy
for people with somatoform disorders, with or without co-morbid
mental disorders.
2. Gender. Sex differences have been found in the absorption,
metabolism, and excretion of many medications (Clayton 2005).
Therefore, we planned to examine gender differences in the efficacy
of pharmacotherapy for somatoform disorders.
3. Source of funding. Industrial funding of pharmacological trials
can be associated with conflicts of interest for the trial conductors
(e.g. when a new medication shall be placed on the market). Studies
sponsored by pharmaceutical companies might be more likely
to have outcomes favouring the sponsor than studies funded by
other bodies (Heres 2006; Lexchin 2003). Therefore, we planned
subgroup analyses in order to examine differences in the efficacy of
medications between trials funded versus not funded by industry.
4. Source of outcome rating. Previous studies (e.g. Rief 2009), have
demonstrated that results based on participant-rated measures,
or on clinician-ratings, can differ considerably from each other.
Therefore, we plan subgroup analyses relating to different sources
of outcome rating.
Due to a lack of studies, we could only perform the subgroup
analyses for co-morbidity, gender, and source of outcome rating.
Sensitivity analysis
We conducted sensitivity analyses in order to determine whether
conclusions were robust to decisions made during the review
process (e.g. the inclusion or exclusion of specific studies or choice
of the method of analysis). It should be verified that the results of
the review do not depend on specific decisions that were made
during the review process. As part of a sensitivity analysis, we
compared effect sizes based on random-effects and fixed-effect
analyses. If sufficient data were available (i.e. at least 10 studies),
we planned to examine the following aspects in further sensitivity
analyses for the primary outcomes.
1. Exclusion of studies with unclear allocation concealment.
2. Exclusion of studies with unclear methods of blinding of
outcome assessors.
3. Exclusion of studies with unclear methods of sequence
generation.
4. Exclusion of Chinese studies (because we did not run a
comprehensive, up-to-date search of the Chinese biomedical
literature and so the studies analysed in this review may be an
incomplete list of relevant research from China and other Asian
countries).
5. For continuous outcomes only: exclusion of results based on
complete-case analyses.

Although subgroup analyses have to be treated with caution, as
they are rather hypothesis-forming than hypothesis-testing, we
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6. For dichotomous outcome of treatment response only: bestcase and worse-case analyses (see also Dealing with missing
data).
7. Exclusion of studies with a drop-out higher than 20%.
With the exception of the best-case and worst-case analyses as
well as the sensitivity analyses for the comparison of fixed-effect
and random-effects models, we were unable to conduct any of the
planned sensitivity analyses because there were not enough data
available.
'Summary of findings' tables
In order to summarise the main findings of the review in a simple
tabular format, we prepared 'Summary of findings' tables. The
tables include a list of seven of the outcomes specified under Types
of outcome measures (i.e. all outcomes apart from dysfunctional
cognitions, emotions, or behaviours). The tables summarise effects
based on a population of participants fulfilling inclusion criteria for
this review (see Types of participants). For dichotomous outcomes
(treatment response), we reported an assumed and corresponding
absolute risk with 95% CI as well as an RR with 95% CI obtained
from the meta-analysis. For continuous outcomes (level of severity/
intensity of MUPS, dysfunctional cognitions/emotions/behaviours,
anxiety and depression, functional disability/quality of life), in the
column of assumed and corresponding risk we present a difference
in means or SMD with 95% CI. We use footnotes in order to specify
the source or rationale for each assumed and corresponding risk. In
order to assess the quality of body of evidence for each outcome,
we used the GRADE approach (GRADEpro software; Schünemann
2011), providing a transparent procedure to classify the quality of
evidence as 'high', 'moderate', 'low', and 'very low'. Judgements
other than of 'high' quality are made transparent using footnotes
or the Comments column in the 'Summary of findings' tables.

RESULTS
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The full literature search identified 26 RCTs (33 reports) (with
25 studies included in the final quantitative analysis). Figure 1
summarises each stage of the search process in the PRISMA study
flow diagram.
Electronic search
The search of CCDANCTR-Studies Register and CCDANCTRReference Register (both searched 17 January 2014) yielded 157
references of potentially eligible studies. After de-duplication, 149
references remained. Based on the screening of the title and
abstracts, we excluded 94 references. Thus, we retrieved 55 full-text
papers for full inspection. Of these full-text papers, we excluded 23
from further analyses. The subtotal of studies from the CCDANCTR
was 25 studies included in the qualitative analyses and 24 studies
in the quantitative analyses. Complementary searches in CENTRAL
(10 April 2014), PSYNDEX (23 March 2014), and PsycINFO (10 April
2014) revealed 672 references of potentially eligible studies. After
de-duplication, 599 references remained. Based on the screening of
title and abstract, we excluded 596 references. We retrieved three
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full-text papers for full inspection. Of these full-text references, we
excluded two from further analyses and included one reference
(Volz 2003), which was an erratum for one study (Volz 2002) that had
already been identified with the search in the CCDANCTR-Studies
Register and CCDANCTR-Reference Register.
It is important to note that the CCDANCTR retrieved many Chinese
studies. While several of these were identified through routine
searches of MEDLINE, EMBASE, and PsycINFO (used to inform the
register), the provenance of some of the other Chinese studies in
the CCDANCTR was less clear and probably dates back to an ad
hoc search of Wang Fang Data (c/o The British Library) in 2007.
While we ensured searches were run on sources other than the
CCDANCTR, we did not run a comprehensive, up-to-date search of
the Chinese biomedical literature and so the studies analysed in
this review may be an incomplete list of relevant research from
China and other Asian countries. However, an up-to-date search
of the WHO ICTRP (see Electronic searches) retrieved no ongoing
or unpublished studies from the Chinese Clinical Trial Registry
(ChiCTR) for somatoform disorders or somatisation.
Handsearching of conference proceedings
Handsearch of proceedings of seven conferences (see Searching
other resources) since 2008 revealed 10 references of potentially
eligible studies. After de-duplication, nine references remained.
After the screening of titles and abstracts, we excluded eight
references. The reference of one potentially eligible study remained
(Agger 2014). We contacted the authors of this study in order to gain
more information. The authors replied that the trial is still ongoing
and will be finished in December 2014. For this reason, we included
the study in the current review as an ongoing study after checking
inclusion and exclusion criteria.
International trial registers
The search of international trial registers such as the
ClinicalTrials.gov register (12 June 2014), the Current Controlled
Trials metaRegister of Controlled Trials-active registers (26 March
2014), the WHO ICTRP (26 March 2014), and the ChiCTR (15 August
2014) revealed protocols of 274 potentially eligible citations. After
de-duplication, 271 references remained. Screening titles and
abstracts revealed five potentially relevant citations of which we
excluded two after the screening of the full study protocol because
they did not fulfil the intervention- or participant-related criteria
of the current review (Farnbach 2013; Liu 2011). Finally, three
references remained (Fink 2011; Fink 2012a; Fink 2012b). These
references are triplicate, international trial registration protocols
for the ongoing study, which we identified from the handsearching
of conference proceedings (Agger 2014).
Grey literature
The search of grey literature in web portals such as ProQuest
Dissertation & Theses Database, OpenGrey, and BIOSIS Previews
(all 26 March 2014) yielded 193 reference of potentially eligible
studies and 113 after de-duplication. However, after the screening
of the titles and abstracts, we excluded all references for different
reasons (see Figure 1).
Reference lists
The search of reference lists of 24 reviews or meta-analyses
(Allen 2002; Atkinson 1985; Decoutere 2011; Escobar 1996; Fallon
2004; Fishbain 1998; Gildenberg 1984; Grothe 2004; Jackson 2000;

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Jackson 2006a; Jackson 2006b; Kroenke 2007; Lynch 2001; Magni
1991; Marks 2009; McQuay 1995; O'Malley 1999; Price 2000; Prior
2013; Raine 2002; Satterthwaite 1990; Sharma 2013; Somashekar
2013; Sumathipala 2007) revealed six references of potentially
eligible studies. After de-duplication, five citations remained for
titles and abstracts screening. Four references were entered in the
full-text inspection, which resulted in one additional eligible study
(Eberhard 1988), after the exclusion of the other three references.
In addition to reviews and meta-analyses, we also screened the
reference lists of all potentially relevant trial reports. This search
yielded 11 references of potentially relevant articles; this was
reduced to eight citations after de-duplication. However, after
screening the titles and abstracts, none of these references fulfilled
the inclusion criteria of the current review.
Correspondence and personal communication
We contacted 26 international experts in the field of
somatoform disorders and 11 replied (response rate 42.3%). The
correspondence with experts yielded one study that had already
been identified with the handsearch of conference proceedings and
was already included as an ongoing study in the current review
(Agger 2014).
Included studies
We included 26 studies (2159 participants) in this review (see
Characteristics of included studies).
Design
Of the 26 included RCTs, eight had a placebo-controlled design
where the medication was compared with placebo. Eighteen
studies used a parallel-group design. Most of these trials had
two arms where the medication was compared with another
medication. In one of these studies, there were three study arms
(paroxetine versus "open paroxetine" versus amitriptyline; Kong
2004). One study used a combined placebo-controlled, parallelgroup design (Melzer 2009). One study was a cross-over trial
(Zitman 1991). We included no CRCTs. In four of the 26 included
studies, a placebo run-in phase took place before the treatment
started (Altamura 1991; Müller 2004; Volz 2000; Volz 2002). After this
run-in phase, placebo responders were excluded from the further
trial.
Three studies included a one- or two-week wash-out phase
before the study treatment started in order to discontinue other
medications (Aragona 2005; Ouyang 2006; Zitman 1991). Of the
included 26 studies, 15 were stated to be double-blind.
One study included four study arms: amitriptyline plus
psychotherapy, amitriptyline plus support, placebo plus
psychotherapy, and placebo plus support (Pilowsky 1990). We only
extracted data from the amitriptyline plus support and the placebo
plus support groups. In fact, we originally defined in our inclusion
criteria that no studies were included where pharmacotherapy
was combined with a psychosocial intervention. However, in
this study, the supportive interventions in comparison to the
psychotherapeutic intervention was described by the trial authors
as follows: "The 'support' included briefer and less frequent
sessions, interaction with the clinician comprised a predominant
focus on the physical symptoms themselves, and on the effects and
side effects of medication prescribed during the treatment period.
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No attempt was made to broaden, or achieve, a re-direction of the
definition of the participant's problems, from the somatic to the
interpersonal and intrapsychic domains. On those occasions where
spontaneous disclosure of interpersonal and subjective personal
problems were nonetheless revealed, there was sympathetic
attention, encouragement and support, but not interpretation at
a dynamic level. In particular, no attempt was made to link such
personal experiences with the pain symptoms" (Pilowsky 1990, p.
6). We assumed that this type of support was comparable to a usual
physician-patient contact in the context of a study visit. For this
reason, we did not exclude the study from the current review.
Twelve studies were trials with only one study centre (Aragona
2005; Huang 2012; Ju 2003; Luo 2009; Muller 2008; Ouyang 2006;
Pilowsky 1990; Sanada 2010; Wang 2003; Yang 2006; Zhao 2006;
Zitman 1991), three studies were multicentre trials (Eberhard 1988:
six centres; Kroenke 2006: 19 centres; Melzer 2009: two centres),
and for 12 studies no information was provided how many study
centres were involved (Altamura 1991; Han 2008a; Han 2008b; Jiang
2005; Kong 2004; Li 2006; Müller 2004; Volz 2000; Volz 2002; Xu 2004;
Ye 2006).
Sample sizes
The number of participants randomised to the relevant arms in
the 26 trials ranged between 21 and 208 (median 69). For one
of the 26 included studies, only the number of participants who
complied with the study protocol was reported (Pilowsky 1990).
The total sample size of included participants was 2159. The
placebo-controlled studies comprised 1031 participants and the
parallel-group trials comprised 1128 participants.
Setting
The included trials were conducted in numerous countries (China:
12, Germany: four, Italy: two, South Korea: two, Australia: one,
Japan: one, the Netherlands: one, South Africa: one, Sweden:
one, USA: one). There was a remarkably high number of Chinese
studies (46.2%). Study participants were recruited in inpatient
departments of general hospitals in eight studies (Huang 2012;
Jiang 2005; Ju 2003; Ouyang 2006; Sanada 2010; Wang 2003; Yang
2006; Zhao 2006). It should be noted that all of these eight trials
were conducted either in China (Huang 2012; Jiang 2005; Ju 2003;
Ouyang 2006; Wang 2003; Yang 2006; Zhao 2006), or in Japan
(Sanada 2010). In all remaining studies, either no information
about the methods of recruitment were given (Han 2008a; Han
2008b; Kong 2004; Li 2006; Volz 2000; Xu 2004; Ye 2006), or
participants were recruited in mixed settings such as outpatient
centres (e.g. pain-specialised centres or psychiatric consultation
services); in departments of general, neurological, or psychiatric
clinics; in general practitioner practices; or by other specialists in
the community and other primary healthcare facilities (Altamura
1991; Aragona 2005; Eberhard 1988; Kroenke 2006; Luo 2009; Melzer
2009; Müller 2004; Muller 2008; Pilowsky 1990; Volz 2002; Zitman
1991). Six trials were conducted in an inpatient setting (Jiang 2005;
Ju 2003; Ouyang 2006; Wang 2003; Yang 2006; Zhao 2006). They
were all Chinese. The remaining studies took place in an outpatient
setting or no information about the setting was provided.
Participants
Age

Most studies were limited to adults aged 18 to 65 years. In
some studies, this age limit was slightly exceeded (Aragona 2005;
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Eberhard 1988; Kong 2004; Melzer 2009; Volz 2000; Wang 2003; Xu
2004; Yang 2006). The mean age of the included studies ranged
between 37.04 and 53.64 years. The lower age limit was between
18 and 26 years whereas the higher age limit was between 51 and
77 years. For 17 studies, there was no information on the age range
(see also Characteristics of included studies).
Proportion of men and women

In six studies, there were similar proportions of men and women.
The proportion of women ranged between 43.3% and 58.8%,
and the proportion of men ranged between 41.3% and 56.7%.
Furthermore, there were 17 studies where the proportion of women
was considerably higher than the proportion of men ranging
between 60.0% and 90.2% for women and 9.8% and 40.0% for men.
There was only one study with considerably more men (92.3%) than
women (9.8%) (Sanada 2010). In almost all studies, the proportion
of women and men was balanced between the trial conditions (Chi2
0.00 to 3.80; P value 0.116 to 1.000). Only in one study was there
a statistically significant difference between the trial arms for the
distribution of the gender (Müller 2004). In the treatment group,
only slightly more women than men were included, whereas in the
placebo group, considerably more women than men were included
(Chi2 = 4.24; P value = 0.039).
Diagnosis and screening procedures

All included studies comprised participants diagnosed with a
somatoform disorder according to explicit diagnostic criteria.
Nine studies included people with somatoform/psychogenic
pain disorder only (Aragona 2005; Eberhard 1988; Luo 2009;
Ouyang 2006; Pilowsky 1990; Sanada 2010; Wang 2003; Xu 2004;
Zitman 1991). Four studies included people with somatisation
disorder, undifferentiated somatoform disorder, with somatoform
autonomic dysfunction, or somatoform/psychogenic pain disorder
(Jiang 2005; Kong 2004; Li 2006; Yang 2006). Three studies included
people with somatisation disorder, undifferentiated somatoform
disorder, or somatoform autonomic dysfunction (Huang 2012;
Müller 2004; Volz 2000; Volz 2002). Three studies included people
with a somatisation disorder only (Ju 2003; Ye 2006; Zhao 2006).
Two studies included people with an undifferentiated somatoform
disorder only (Han 2008a; Han 2008b). Two studies included people
with a somatisation disorder or an undifferentiated somatoform
disorder only (Altamura 1991; Melzer 2009). Two studies included
people diagnosed with a multisomatoform disorder (Kroenke 2006;
Muller 2008).
Nine studies applied diagnostic criteria of CCMD-III (Jiang 2005; Ju
2003; Kong 2004; Li 2006; Ouyang 2006; Yang 2006; Ye 2006; Xu 2004;
Zhao 2006). Seven studies applied the diagnostic criteria of ICD-10
(Huang 2012; Luo 2009; Melzer 2009; Müller 2004; Volz 2000; Volz
2002; Wang 2003). Four studies used the diagnostic criteria of DSMIII (Altamura 1991; Eberhard 1988; Pilowsky 1990; Zitman 1991).
Four studies used the diagnostic criteria of DSM-IV (Aragona 2005;
Han 2008a; Han 2008b; Sanada 2010). Two studies used criteria
of multisomatoform disorder that corresponded with the criteria
of an undifferentiated somatoform disorder (Kroenke 2006; Muller
2008).
Most of the studies provided no information about the procedures
for gaining the diagnosis (Altamura 1991; Huang 2012; Jiang 2005;
Ju 2003; Kong 2004; Li 2006; Luo 2009; Melzer 2009; Ouyang
2006; Sanada 2010; Volz 2002; Wang 2003; Xu 2004; Yang 2006;
Ye 2006; Zhao 2006). However, for these studies we assumed that
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a non-structured, psychiatric interview was conducted because
psychiatric diagnoses corresponding to explicit diagnostic criteria
were made.
In two studies, a structured clinical interview (M.I.N.I. International
Neuropsychiatric Interview; Sheehan 1998) was administered in
order to make the diagnosis (Kroenke 2006; Muller 2008). Two
studies applied diagnostic checklists (International Diagnostic
Checklists (IDCL); Janca 1996) in order to make the diagnosis. In
one study, a diagnostic assessment and clinical examination by a
neurologist, a clinical assessment of the role of psychopathological
components in the pain were conducted, as well as rating scales,
checklists, and projective tests were available to be used by a
clinical psychologist if psycho(patho)logical functioning had to
be further explored (Aragona 2005). Trial authors of one study
stated that participants had to have undergone a structured
clinical interview in order to explore the type and severity
of somatic symptoms as well as previous and existing comedication (Eberhard 1988). In two studies, the diagnosis of an
undifferentiated somatoform disorder was evaluated according
to DSM-IV criteria by consensus between two board-certified
psychiatrists upon study entry (Han 2008a; Han 2008b). In
one study, a diagnostic evaluation of participants over a twoweek period was conducted that also included an interview
with the psychiatrist who explored the phenomenology of
pain experience; evidence of psychiatric syndrome; aspects of
the participant's development; interpersonal relationships and
life stresses; participant's attitudes, beliefs, and expectation
concerning pain and its management; and participant's affect
(Pilowsky 1990). The probable diagnosis was discussed by the
panel members. Finally, in one study, it was stated that a psychiatric
interview was conducted to obtain other DSM-III-R diagnoses and
to gather demographic data (Zitman 1991).
Ten studies used additional cut-off scores on a measure of MUPS
or depression (Huang 2012; Jiang 2005; Ju 2003; Kroenke 2006; Li
2006; Luo 2009; Müller 2004; Volz 2000; Volz 2002; Wang 2003).
Length of time since diagnosis of somatoform disorder

Thirteen studies provided information about the length of time
since the diagnosis of somatoform disorder (Eberhard 1988; Han
2008a; Han 2008b; Huang 2012; Ju 2003; Li 2006; Luo 2009; Ouyang
2006; Wang 2003; Yang 2006; Ye 2006; Zhao 2006; Zitman 1991). The
mean length of symptom duration in these studies ranged between
0.6 and 39.8 years (see also Characteristics of included studies).
Co-morbidity

Twelve studies included information about the actual co-morbid
conditions of included participants (see Table 2). Of these
studies, five excluded people with co-morbid mental disorders.
The remaining seven studies included people with different
co-morbid mental disorders. Mentioned co-morbid conditions
were major depression, dysthymia, atypical depression, anxiety
disorders (panic disorder, agoraphobia, social anxiety disorder,
generalised anxiety disorder, anxiety disorder not otherwise
specified), hypochondriasis, nicotine abuse, and benzodiazepine
abuse. Fourteen studies provided no information about actual comorbid conditions of the included participants (see Table 2).
With the exception of six studies (see Table 2), studies provided
information about the exclusion of specific mental conditions. In
the trials that did not exclude participants with any form of co-
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morbid mental condition, the common excluded conditions were:
mania, bipolar disorder, schizophrenia or other psychotic disorder,
schizo-affective disorder, alcohol or drug abuse/dependence,
dementia, severe depression including suicidal tendencies, and
depressive symptoms occurring before the somatic symptoms
started or were judged to be secondary to a psychiatric disorder
other than the somatoform disorder.
Interventions
The 26 included studies primarily researched the efficacy of the
following antidepressants for somatoform disorders in adults:
TCAs, TeCAs, SSRIs, NRIs, SNRIs, NaSSAs, and SARIs.
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TCA (amitriptyline: Ouyang 2006; Zhao 2006; clomipramine: Ye
2006), or an SNRI (venlafaxine: Han 2008a). In four studies, the
SNRI, venlafaxine, was examined as experimental intervention
(Jiang 2005; Ju 2003; Yang 2006; Xu 2004). In all four studies, the
SNRI was compared with a TCA (doxepin: Ju 2003; amitriptyline:
Jiang 2005; Yang 2006; Xu 2004). One study compared the
TeCA, maprotiline, as experimental intervention with the TCA,
clomipramine (Eberhard 1988). Another study compared the SARI,
trazodone, as experimental intervention with the non-steroidal
anti-inflammatory drug (NSAID) ibuprofen (Wang 2003). One study
compared an AP, levosulpiride, with another AP, racemic sulpiride
(Altamura 1991).

Three studies examined the efficacy of NPs (butterbur root, valerian
root, passionflower herb, lemon balm leaf-Ze 185 4-combination
and valerian root, passionflower herb, lemon balm leaf-Ze 185 3combination without butterbur: Melzer 2009; St. John's wort LI
160: Müller 2004; Volz 2002). One study examined the efficacy of
APs (Altamura 1991), and three studies examined the combination
treatment of an antidepressant and an AP (Huang 2012; Li 2006;
Zitman 1991).

The efficacy of a combined treatment was examined in three trials.
Two of these studies examined the combination of an SSRI and an
AP with SSRI alone (citalopram plus paliperidone versus citalopram
alone: Huang 2012; paroxetine plus quetiapine versus paroxetine
alone: Li 2006). One study compared the efficacy of a combination
of a TCA and an AP with the TCA only (amitriptyline plus flupentixol
versus amitriptyline alone: Zitman 1991).

Maximum and daily mean dose, frequency of medication, and the
mode of administration of the medication are described in detail
in the Characteristics of included studies table. Fourteen studies
implemented a flexible dosing scheme (Han 2008a; Han 2008b;
Jiang 2005; Ju 2003; Kong 2004; Kroenke 2006; Li 2006; Muller 2008;
Ouyang 2006; Pilowsky 1990; Sanada 2010; Xu 2004; Ye 2006; Zhao
2006), 11 studies implemented a fixed dosing scheme (Altamura
1991; Aragona 2005; Eberhard 1988; Huang 2012; Luo 2009; Melzer
2009; Müller 2004; Volz 2000; Volz 2002; Wang 2003; Zitman 1991),
and one study provided no information about the dosing scheme
(Yang 2006).

All trials provided information about the duration of the treatment,
which ranged between 14 and 84 days. Efficacy measures were
collected throughout the treatment period and at completion
of the trial. There were only two trials where follow-ups were
implemented after the completion of the treatment phase (months
3, 6, and 12 post treatment) (Eberhard 1988; Pilowsky 1990).
However, in one of these studies, these follow-up assessments
did not take place in a standardised way (Eberhard 1988). The
trial report stated that after the sixth week of study treatment the
code for the individual participant could be broken and the person
could continue the treatment in an open way. One of these trials
mentioned that the follow-up assessments were conducted by a
blinded research assistant; however, the research report included
no data on the follow-up assessments (Pilowsky 1990).

Comparators

We included eight studies comparing pharmacotherapy and
placebo in the narrative literature but also in the meta-analytical
part of our review (Kroenke 2006; Luo 2009; Melzer 2009; Müller
2004; Muller 2008; Pilowsky 1990; Volz 2000; Volz 2002).
We included 15 studies comparing pharmacotherapy and another
medication in the narrative literature review. Of these 15 studies,
14 could be included in the meta-analytical part of our review
(Aragona 2005; Eberhard 1988; Han 2008a; Han 2008b; Jiang 2005;
Ju 2003; Kong 2004; Ouyang 2006; Sanada 2010; Wang 2003; Xu
2004; Yang 2006; Ye 2006; Zhao 2006). We excluded one study from
the meta-analytical calculations since means and SD were only
provided in a graph in the trial report and according to the reply of
the trial author were not available anymore (Altamura 1991).

Treatment duration and study visits

Adverse effects and adverse effect-specific drop-outs

Detailed information about adverse effects for each trial are
reported in the Characteristics of included studies table. It was
difficult to give a summarising description of adverse effects, given
the non-standard way in which the adverse effects were reported.
Detailed information about the rate of drop-outs due to adverse
effects or inefficacy of the treatment are summarised in the
Characteristics of included studies table. Four studies provided
no information about drop-outs due to adverse effects (Luo 2009;
Pilowsky 1990; Zhao 2006; Zitman 1991).
Concomitant treatments

In the following, we listed the studies according to the medication
class and chemical agent. The chemical agent that was stated as
experimental intervention in the trial report will also be seen as
experimental intervention in the following listing. In four studies
an SSRI was examined as experimental intervention (paroxetine:
Kong 2004; Sanada 2010; citalopram: Aragona 2005; fluoxetine: Han
2008b). The SSRI was compared either with an NRI (reboxetine:
Aragona 2005), with another SSRI (sertraline: Han 2008b), a TCA
(amitriptyline: Kong 2004), or with an SNRI (milnacipran: Sanada
2010). In another four studies, the NaSSA, mirtazapine, was
examined as experimental intervention (Han 2008a; Ouyang 2006;
Ye 2006; Zhao 2006). The NaSSA was compared with either a

Detailed information about concomitant treatments of participants
or about which concomitant treatments were allowed or excluded
are summarised in Table 3.
Outcomes
The most often assessed outcomes in the included studies of this
review were the primary outcomes 'severity/intensity of MUPS'
and 'depression'. Eighteen studies measured 'severity/intensity of
MUPS' with several different self report scales (Aragona 2005;
Eberhard 1988; Han 2008a; Han 2008b; Huang 2012; Kroenke 2006;
Li 2006; Luo 2009; Melzack 1987; Müller 2004; Muller 2008; Pilowsky
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1990; Sanada 2010; Ye 2006; Volz 2000; Volz 2002; Zhao 2006;
Zitman 1991). Five studies used clinician-rated scales (Huang 2012;
Müller 2004; Muller 2008; Volz 2000; Volz 2002). 'Depression' was
assessed in 20 included studies with self rating as well as clinicianrated scales (Aragona 2005; Eberhard 1988; Han 2008a; Han 2008b;
Huang 2012; Ju 2003; Kong 2004; Kroenke 2006; Li 2006; Luo 2009;
Melzer 2009; Muller 2008; Ouyang 2006; Volz 2000; Volz 2002; Wang
2003; Yang 2006; Ye 2006; Zhao 2006; Zitman 1991). The remaining
secondary outcomes were measured only in a small number of
studies. 'Anxiety' was assessed with self rating as well as clinicianrated scales in 11 studies (Huang 2012; Kong 2004; Kroenke 2006;
Li 2006; Melzer 2009; Muller 2008; Volz 2000; Volz 2002; Yang 2006;
Ye 2006; Zhao 2006). 'Treatment response' based on self rating as
well as clinician-rated scales was assessed in seven studies (Huang
2012; Müller 2004; Muller 2008; Volz 2000; Volz 2002; Ye 2006;
Zhao 2006). 'Functional disability and quality of life' (measured
in three studies: Kroenke 2006; Muller 2008; Pilowsky 1990) and
'dysfunctional cognitions, emotions, or behaviours' (measured in
one study: Muller 2008) were assessed only in a small number of
included studies. More information on the measures used can be
found in the Characteristics of included studies table.
Regarding the outcome 'acceptability', 24 studies calculated the
proportion of people who dropped out during the experimental
as well as the comparator intervention. Table 4 displays the
acceptability for the different medication classes, chemical agents,
and comparisons. The acceptability could not be calculated for
four studies for the following reasons. The trial by Luo 2009
stated that two participants quit the study due to side effects.
However, it was not clear how these adverse effects related to
drop-outs were distributed between the treatment and placebo
group. The trial by Zhao 2006 mentioned only the drop-out
rate for the total sample; however, the rate was not provided
separately for control and treatment group. The trial by Zitman
1991 originally randomised 45 people; nine participants dropped
out, resulting in a completer sample of 36 people. Afterwards,
two people had to be excluded because of undetectable levels of
amitriptyline and metabolites indicating non-compliance resulting
in a sample of 34 participants (amitriptyline alone group: 16 people,
amitriptyline plus flupentixol group: 18 people). Unfortunately, it
is unclear how many participants of the originally randomised
sample were distributed among the amitriptyline alone group and
the amitriptyline plus flupentixol group. Trial authors could only be
partly contacted. Authors of the study by Luo 2009 did not reply to
our request. For trial by Zhao 2006, no contact details of the authors
were available (the article states only the affiliation of the authors
and an online search for the authors' names was without result).
The trial by Zitman 1991 was too old and we could not contact the
author.
Excluded studies
After assessing the full-texts, we excluded 30 studies (see Figure
1). We summarised the reasons for exclusion in the Characteristics
of excluded studies table. The primary reason for exclusion (in
24 studies) was that the participants' diagnosis did not fit the
inclusion criteria, especially in older studies that were conducted
at a time where standardised diagnostic criteria had not been
established, yet often old diagnostic concepts such as 'neurosis'
or 'hysteria' were used to make a diagnosis. These definitions
include a range of different diagnostic concepts such as generalised
anxiety disorder, phobias, de-personalisation disorder, dysthymic
disorder, conversion disorder, obsessive-compulsive disorder, or
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dissociative disorders, and so do not fulfil the strict diagnostic
inclusion criteria of the current review. In addition, there were some
studies with people diagnosed with 'psychosomatic disorders'.
Furthermore, several studies included people only with very
specific functional syndromes such as IBS (Davis 1988; Loldrup
1989; Pach 1976; Smouvelich 1996; Tanum 1996; Turkington 2002),
which did not correspond with the inclusion criteria of the current
review. One study comprised healthy participants (Lee 2012),
or participants with reactive depression (Poinso 1988), and was
therefore excluded. We excluded two studies because the criteria of
treatment were not fulfilled. The study by Farnbach 2013 examined
the efficacy of quetiapine fumarate as an adjunctive therapy
to current pain treatment. However, the current pain treatment
was not a standardised treatment. In the study by Xu 2006, the
comparator intervention acupuncture did not correspond with the
inclusion criteria of the current review. We excluded one study
because it was just a case report (Kozian 2003). Another study
implemented a cross-over design (Onghena 1993); however, no
data for the unbiased first study phase were provided. For this
reason, this study could not contribute to this review, either in
the narrative or the meta-analytic sections. We excluded another
study because it was not randomised (Altamura 2003). The status
of randomisation in this study was not clear after screening the fulltext. Therefore, we contacted the authors of the trial who replied
that the study was not randomised.
Ongoing studies
We identified one ongoing study (Agger 2014). The trial's
registration documentation as well as the personal contacting of
the principal investigators of this trial suggests that this study is
planned to be completed in December 2014. The trial is being
conducted in Denmark. In this randomised, placebo-controlled,
double-blind study on the efficacy of the TCA, imipramine.
The study will include participants diagnosed with the bodily
distress syndrome (multi-organ type) that is characterised by
chronic MUPS (of a duration of at least two years) from at
least three out of four symptoms that have moderate to severe
impact on daily life. Included participants are aged 20 to 50
years. The primary outcome is CGI - Improvement Scale and
the secondary outcomes are functional level measured by the
SF-36 and symptom characterisation measured by VAS of the
Functional Illness Checklist. The time points of evaluation are the
following: participant-rated improvement measured by the CGI
- Improvement Scale after 10 weeks of sufficient-dosage study
medication (minimum 25 mg/day). The SF-36 will be administered
before inclusion and after 10 weeks of sufficient-dosage study
medication. The VAS and the Functional Illness Checklist are
completed before inclusion, after starting treatment, and after 10
weeks of sufficient-dosage study medication. A sample size of 140
participants is planned with a study duration of 19 weeks for each
participant. For detailed information see the Characteristics of
ongoing studies table.
Studies awaiting classification
We identified no studies awaiting classification.

Risk of bias in included studies
For full details of risk of bias judgements for included studies see
the Characteristics of included studies table. Figure 2 shows the
proportion of studies with each of the judgements; the graph in
Figure 3 shows all the judgements in a cross-tabulation by trial.
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Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3. (Continued)

Allocation
Random sequence generation
All studies were reported to be randomised trials. Only nine
studies provided detailed information about the means of random
sequence generation (Aragona 2005; Han 2008a; Han 2008b; Huang
2012; Li 2006; Melzer 2009; Müller 2004; Muller 2008; Pilowsky 1990).
The studies used random number tables, a computer random
number generator, and coin tossing as means of random sequence
generation. One study used blocked randomisation (Müller 2004).
We rated the nine studies as low risk of bias and 17 trials as unclear
risk of bias for random sequence generation.
Allocation concealment
Two studies provided detailed information about allocation
concealment (Huang 2012; Müller 2004). In both studies, the
allocation concealment was conducted by a study-independent
institution. Huang 2012 used sequentially numbered, sealed
envelopes. Müller 2004 applied sequentially numbered drug
containers of identical appearance. We rated these two studies as
low risk of bias and 24 trials as unclear risk of bias for allocation
concealment.
Blinding
Blinding of study participants and personnel
Of the 26 included studies, 14 were stated to be double-blind
trials. Six of these 14 trials provided insufficient information about
methods of blinding participants or study personnel (Altamura
1991; Aragona 2005; Kroenke 2006; Pilowsky 1990; Volz 2000; Volz
2002). The remaining eight studies described the methods of
blinding participants and study personnel in detail (Eberhard 1988;
Luo 2009; Melzer 2009; Müller 2004; Muller 2008; Wang 2003; Zhao
2006; Zitman 1991). The studies usually used medication that was
of identical appearance as the strategy to blind participants and
study personnel. In summary, we judged four studies to be at high
risk of bias, 14 to be at unclear risk of bias, and eight studies to be
at low risk of bias for blinding of participants and study personnel.
Blinding of outcome assessment
Most of the studies provided no information to determine whether
the assessors were blinded. Three studies described their strategies
in detail (Huang 2012; Müller 2004; Pilowsky 1990). We judged
studies that stated that the trial was double-blind without any
information about blinding participants, study personnel, or

assessors as at unclear risk of performance bias or detection bias.
We judged two studies to be at high risk of bias, 21 studies to be at
unclear risk of bias, and three studies to be at low risk of bias for
blinding of assessors.
Incomplete outcome data
We judged studies to have a low risk of attrition bias when 1. they
dealt adequately with missing values in the sense of conducting an
ITT analysis and replacing missing values with adequate statistical
methods (e.g. LOCF), 2. when the ITT sample corresponded to the
number of originally randomised participants, and 3. when the
number of drop-outs and reasons for the drop-out were balanced
between the groups. We also judged a low risk of bias when there
were no drop-outs. In summary, we judged nine studies to be at
high risk of attrition bias, four studies to be at unclear risk of bias,
and 13 studies to be at low risk of bias. Seven studies had no
drop-outs (Jiang 2005; Ju 2003; Kong 2004; Ouyang 2006; Wang
2003; Xu 2004; Yang 2006). Interestingly, these studies were all
Chinese trials and almost all of them took place in an inpatient
setting. There were drop-outs in the remaining 19 studies. Eleven of
these 19 studies with drop-outs conducted an ITT analysis (Aragona
2005; Han 2008a; Han 2008b; Huang 2012; Kroenke 2006; Luo 2009;
Melzer 2009; Müller 2004; Muller 2008; Volz 2000; Volz 2002). All
11 studies replaced missing values with LOCF. However, in five of
these 11 studies, the size of the ITT population did not correspond
with the number of originally randomised participants (Aragona
2005; Han 2008a; Kroenke 2006; Müller 2004; Volz 2000). In these
cases, the study authors included only participants who received
at least one post-baseline outcome assessment in the ITT sample.
Six studies conducted statistical analyses only with the data of
participants completing the trial and complying with the study
protocol (Eberhard 1988; Li 2006; Pilowsky 1990; Sanada 2010; Ye
2006; Zitman 1991). Two of the 19 studies with drop-outs provided
no information about how the authors dealt with the missing values
(Altamura 1991; Zhao 2006).
Selective reporting
The reporting bias was difficult to assess as none of the included
trials had pre-published study protocols. We judged studies as
trials with low selective reporting bias - even if there was no study
protocol - when they included a broad range of different outcomes,
covered primary and secondary outcomes, as well as when these
outcomes were assessed with validated measures. Furthermore,
the outcomes had to be mentioned in the methods section of the
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trial report and findings of these outcomes had to be completely
reported in the results section. Only three studies fulfilled these
criteria (Muller 2008; Volz 2000; Volz 2002). We judged a further
nine studies to be at unclear risk of reporting bias (Aragona 2005;
Eberhard 1988; Huang 2012; Jiang 2005; Li 2006; Müller 2004; Ye
2006; Zhao 2006; Zitman 1991). They included a small range of
primary and secondary outcomes. Because of the missing study
protocols, it was not possible to make statements about the risk
of reporting bias. Finally, we judged 14 studies to be at high
reporting bias. Five of these trials only assessed treatment effects
for secondary outcomes (e.g. depression, anxiety) whereas primary
outcomes, such as severity of physical symptoms, were neglected
(Ju 2003; Kong 2004; Melzer 2009; Ouyang 2006; Yang 2006). One
study assessed only secondary outcomes with validated scales,
whereas the primary outcome was assessed with a non-validated
clinician-rated scale constructed by the trial authors (Wang 2003).
One study administered clinician-rated and non-validated scales
created by the trial authors (Xu 2004). Furthermore, three studies
reporting no SD for post-assessment values (Han 2008a; Han 2008b;
Kroenke 2006). We contacted authors in order to gain these missing
values, but they did not reply. One of these three studies did
not report baseline values for all outcomes for which baselineto-endpoint changes were indicated (Kroenke 2006). Therefore,
post-assessment values could not be calculated. We contacted the
author requesting these missing values but he did not reply. Finally,
one study only reported means and SD for the primary outcome
in a graph and the numerical values were not available (Altamura
1991). The trial author informed us that the study was too old and
that these missing data were no longer available. Another study
only reported treatment effects for the primary outcome but not for
the secondary outcome (depression) (Luo 2009). We contacted the
trial author but we received no reply. One study assessed several
validated scales but only at baseline (Pilowsky 1990). One study
was available only as conference abstract in which means and SD
were reported for one outcome (Sanada 2010). We contacted study
authors but they did not reply to our request.

were identified between the group that was assigned to the study
and the group that was not assigned to the study.

Other potential sources of bias

We conducted meta-analyses for all comparisons planned in
the review protocol with the exception of the comparison
'pharmacotherapy versus treatment as usual'. For this comparison,
we found no trial that comprised usual treatment as control group.
Furthermore, we were unable to assess at two of the three predefined time points stated in our protocol (within 12 months' post
treatment, or more than 12 months' post treatment) because in
all included trials of this review data were only available for post
treatment. As part of a sensitivity analysis, we compared effect sizes
based on random-effects and fixed-effect analyses. In the following
analyses, we reported results using the random-effects model
unless the results of the fixed-effect analysis differed considerably,
in which case we reported both. We classes a 'considerable'
difference between results as a change in level of significance or
where 95% CIs did not overlap.

We judged 20 trials to be at low risk or unclear risk of other
potential sources of bias. We judged six studies to be at high risk
of other potential sources of bias (Altamura 1991; Müller 2004;
Pilowsky 1990; Volz 2000; Volz 2002; Xu 2004). These relevant other
potential sources of bias in the included studies are discussed in the
following.
Pre-randomisation intervention that could influence the effect
of the subsequent randomised intervention
In two studies, there was a placebo run-in phase before
randomisation (Volz 2000; Volz 2002). In two studies, there
was a placebo run-in phase after the randomisation (Altamura
1991; Müller 2004). Three studies excluded placebo-responders,
participants exceeding a specific pre-defined cut-off score, after
this run-in phase (Altamura 1991; Müller 2004; Volz 2000). One
trial offered treatments such as transcutaneous nerve stimulation,
physiotherapy, regional nerve blocks, psychopharmacotherapy,
and psychotherapy, for a finite period (Pilowsky 1990). It was
then decided if the participant would be assigned to the study or
not. Where it was thought that musculoligamentous or myofascial
problems had not been adequately treated physiotherapeutically
this was provided again before participants were entered into the
trial. Furthermore, significant differences regarding demographics

Baseline imbalance
Two studies had statistically significant differences between the
study groups at baseline (Pilowsky 1990; Xu 2004).
Compliance
Twenty-four trial reports did not describe any method for assessing
compliance with an intervention. The remaining two trials assessed
compliance by pill counts (Volz 2000; Volz 2002). The second study
reported that compliance ranged from 85.7% to 110.1% (Volz 2002).
Multiple intervention trials
There were three multiple intervention trials (Kong 2004; Melzer
2009; Pilowsky 1990). All three trials presented the data separately
for each group.
Cross-over trials
We included one trial with cross-over design (Zitman 1991). The
trial randomised the order of receiving a treatment and presented
unbiased data of the first treatment phase separately for the two
study arms.

Effects of interventions
See: Summary of findings for the main comparison Tricyclic
antidepressants versus placebo for somatoform disorders in adults;
Summary of findings 2 New-generation antidepressants versus
placebo for somatoform disorders in adults; Summary of findings
3 Natural products versus placebo for somatoform disorders in
adults; Summary of findings 4 Tricyclic antidepressants versus
another medication for somatoform disorders in adults; Summary
of findings 5 Antidepressants versus a combination of medications
for somatoform disorders in adults

Comparison 1: pharmacotherapy versus placebo
1. Tricyclic antidepressants versus placebo
Two studies (258 participants) provided data for comparing TCAs
with placebo.
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Primary outcomes
1.1 Severity/intensity of medically unexplained physical symptoms
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-0.13; 95% CI -0.39 to 0.13; 2 studies, 239 participants). There was
consistency in the data (I2 = 2%) (Analysis 1.1; Figure 4).

There was no difference in the severity or intensity of MUPS
between participants taking a TCA and those taking placebo (SMD

Figure 4. Forest plot of comparison: 1 Pharmacotherapy versus placebo, outcome: 1.1 Severity/intensity of
medically unexplained physical symptoms (post-treatment score on self report scales).

1.2 Acceptability

The studies comparing TCAs with placebo found the rates of
all-cause drop-outs to be 13.5% to 25.0% with TCAs versus
12.4% to 31.0% with placebo (Table 4). We identified one study
comparing TCAs versus placebo for acceptability rate, which found
no significant difference between groups (RR 1.08; 95% CI 0.53 to
2.18; 208 participants) (Analysis 1.2) (Volz 2000).
Secondary outcomes
1.3 Anxiety

We identified one study comparing TCAs versus placebo for anxiety,
which found no significant difference in effect size between groups
(SMD -0.01; 95% CI -0.29 to 0.26; 200 participants) (Analysis 1.3)
(Volz 2000).
1.4 Depression

We identified one study comparing TCAs versus placebo for
depression, which indicated no significant difference between
groups (SMD -0.27; 95% CI -0.55 to 0.01; 200 participants) (Analysis
1.4) (Volz 2000).
1.5 Dysfunctional cognitions, emotions, and behaviours

We found no data comparing TCAs with placebo for dysfunctional
cognitions, emotions, and behaviours.
1.6 Adverse effects

We identified one study comparing TCAs versus placebo for dropout rate due to adverse effects (Volz 2000). In both TCA and placebo
arms, 2.9% of participants withdrew from treatment. There was

no significant difference between groups (RR 1.00; 95% CI 0.21 to
4.84; 208 participants) (Analysis 1.6; see Characteristics of included
studies table).
1.7 Treatment response

We identified one study comparing TCAs versus placebo for
treatment response, which found no significant difference between
groups in the number of participants experiencing remission (RR
1.29; 95% CI 0.95 to 1.73; 208 participants; definition treatment
response: 'very good' or at least 'good' treatment success on the
CGI - Improvement Scale) (Analysis 1.7) (Volz 2000).
1.8 Functional disability and quality of life

We identified one study comparing TCAs versus placebo for
functional disability and quality of life, which indicated no
significant benefit of a TCA compared with placebo (SMD 0.01; 95%
CI -0.58 to 0.60; 44 participants) (Analysis 1.8) (Pilowsky 1990).
2. New-generation antidepressants versus placebo
Three studies (248 participants) provided data for comparing NGAs
with placebo.
Primary outcomes
2.1 Severity/intensity of medically unexplained physical symptoms

Compared with placebo, taking an NGA (SNRI, SSRI) was
considerably more effective in reducing the severity or intensity of
MUPS (SMD -0.91; 95% CI -1.36 to -0.46; 3 studies, 243 participants;
random-effects model). Substantial heterogeneity was identified
in the data (I2 = 63%). This comparison included one study
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that for different outcomes and in comparison to other studies
demonstrated obvious high effect sizes (Muller 2008). The values in
the original trial report that were indicated as SD by the trial authors
appeared to be very small and too homogeneous over the time
points of assessment and between the different treatment groups.
We assumed that in this trial report, SEs but not SDs were reported.
Therefore, we used the common formula in order to convert SEs
to SDs. However, the effect sizes still remained obviously high
in comparison to the remaining studies. When we excluded this
outlier study from analysis, the SMD was slightly decreased (SMD
-0.74; 95% CI -1.17 to -0.31; 2 studies; 192 participants). Although
the I2 statistic decreased, there was still a substantial level of
heterogeneity (I2 = 52%) (Analysis 1.1).
2.2 Acceptability

The studies comparing NGAs (SNRI, SSRI) with placebo found the
rates of all-cause drop-outs to be 4.0% to -38.2% with NGAs versus
0% to 38.6% with placebo (Table 4). There was no significant
difference in the acceptability rate between NGAs (SNRI, SSRI) and
placebo (RR 1.01; 95% CI 0.64 to 1.61; 2 studies, 163 participants).
The I2 statistic of 0% indicated consistency in the data (Analysis 1.2).
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was considerable heterogeneity (I2 = 76%). However, it should be
noted that this comparison included an outlier study (Muller 2008).
The RR became significant in favour of NGA when calculated using
a fixed-effect model (RR 1.82; 95% CI 1.28 to 2.58; I2 = 76%).
2.8 Functional disability impairment and quality of life

NGA (SNRI, SSRI) was significantly more effective than placebo at
reducing functional impairment or in increasing life quality (SMD
-0.52; 95% CI -1.00 to -0.04; 2 studies; 163 participants). However,
there was substantial heterogeneity (I2 = 51%) (Analysis 1.8).
3. Natural products versus placebo
Three studies (508 participants) provided data for comparing NPs
with placebo. One of these studies used a combined placebocontrolled, parallel-group design comprising three study arms
(Melzer 2009). In two of the three study arms, a specific NP
combination was examined whereas in the third study arm
a placebo was administered. For the following analyses, we
combined the two combinations in one group.
Primary outcomes

Secondary outcomes

3.1 Severity/intensity of medically unexplained physical symptoms

2.3 Anxiety

In comparison to placebo, NPs were significantly effective in
reducing the severity of MUPS (SMD -0.74; 95% CI -0.97 to -0.51; 2
studies; 322 participants). There was high consistency in the data
(I2 = 0%) (Analysis 1.1).

There was no significant difference between an NGA (SNRI, SSRI)
and placebo for reducing anxiety (SMD -0.88; 95% CI -1.81 to 0.05;
2 studies; 163 participants) (Analysis 1.3). The I2 statistic indicated
considerable heterogeneity in the data (I2 = 85%). However, it
should be noted that this comparison included the outlier study by
Muller 2008. The SMD decreased when calculated with a fixed-effect
model and became statistically significant in favour of NGA (SMD
-0.69; 95% CI -1.02 to -0.37; I2 = 85%).
2.4 Depression

Results showed that NGAs (SNRI, SSRI) were significantly effective
at reducing depressive symptoms compared with placebo (SMD
-0.56; 95% CI -0.88 to -0.25; 2 studies; 163 participants). There was
consistency in the data (I2 = 0%) (Analysis 1.4).
2.5 Dysfunctional cognitions, emotions, and behaviours

We identified one study comparing NGA (SSRI) versus placebo for
dysfunctional cognitions, emotions, and behaviours (Muller 2008).
The effect size indicated no significant difference between groups
(SMD 0.26; 95% CI -0.29 to 0.81; 51 participants) (Analysis 1.5).
2.6 Adverse effects

The drop-out rate due to adverse effects ranged from 4.0% to 7.3%
for the NGA group and from 0% to 3.5% for the placebo group (see
Characteristics of included studies table). There was no significant
difference between groups (RR 2.26; 95% CI 0.52 to 9.81; 2 studies;
163 participants). There was consistency in the data (I2 = 0%)
(Analysis 1.6).

3.2 Acceptability

The studies comparing NPs with placebo found the rates of allcause drop-outs to be 0% to 8.3% with NPs versus 7.0% to 8.2%
with placebo (Table 4). There was no significant difference in the
acceptability rate between the groups (RR 0.85; 95% CI 0.40 to 1.78;
3 studies; 506 participants). There was high consistency in the data
(I2 = 0%) (Analysis 1.2).
Secondary outcomes
3.3 Anxiety

NPs were significantly more effective than placebo in reducing
anxiety symptoms (SMD -0.83; 95% CI -1.13 to -0.52; 2 studies, 321
participants). There was moderate heterogeneity in the data (I2 =
39%) (Analysis 1.3).
3.4 Depression

NPs were significantly more effective than placebo in reducing
depressive symptoms (SMD -0.64; 95% CI -0.87 to -0.41; 2 studies;
321 participants). There was consistency in the data (I2 = 0%)
(Analysis 1.4).
3.5 Dysfunctional cognitions, emotions, and behaviours

We found no data comparing NPs with placebo for dysfunctional
cognitions, emotions, and behaviours.

2.7 Treatment response

3.6 Adverse effects

There was no difference in the percentage of participants who
achieved remission between the NGA (SNRI, SSRI) and placebo
groups (RR 2.00; 95% CI 0.90 to 4.43; 2 studies; 163 participants;
definition treatment response: Kroenke 2006: PHQ-15 less than 10;
Muller 2008: CGI - Improvement Scale 2 or less) (Analysis 1.7). There

The drop-out rate due to adverse effects ranged from 0% to 1.7%
with NPs and 0% to 2.7% with placebo (see Characteristics of
included studies table). Three studies (506 participants) provided
sufficient data for calculating an RR. There was no significant
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difference between groups (RR 0.54; 95% CI 0.08 to 3.50). There was
consistency in the data (I2 = 0%) (Analysis 1.6).

Comparison 2: pharmacotherapy versus another medication

3.7 Treatment response

Ten studies (616 participants) provided data comparing TCAs with
another medication (exclusively NGAs). In one of these studies,
there were three study arms (paroxetine versus 'open paroxetine'
versus amitriptyline; Kong 2004). For the following analyses,
we have combined the treatment arms paroxetine and 'open
paroxetine' in one group.

Compared with the placebo group, there was a significantly higher
percentage of participants who achieved remission in the NP group
(RR 1.77; 95% CI 1.34 to 2.34; 2 studies; 324 participants; randomeffects model; definition treatment response: Müller 2004: CGI Improvement Scale 2 or less, Volz 2002: 'very much', 'much', or
'minimal' treatment success on the CGI - Improvement Scale).
There was low heterogeneity in the data (I2 = 24%) (Analysis 1.7).
The NNTB was 4.
3.8 Functional disability and quality of life

We found no data comparing NPs with placebo for functional
disability and quality of life.

4. Tricyclic antidepressants versus another medication

Primary outcomes
4.1 Severity/intensity of medically unexplained physical symptoms

The results showed no difference between TCAs and NGAs (TeCA,
NaSSA) in reducing the severity of MUPS (SMD -0.16; 95% CI -0.55 to
0.23; 3 studies; 177 participants; random-effects model). There was
moderate heterogeneity in the data (I2 = 42%) Analysis 2.1; Figure 5.

Figure 5. Forest plot of comparison: 2 Tricyclic antidepressants versus new-generation antidepressants, outcome:
2.1 Reduction of the level of severity/intensity of medically unexplained physical symptoms (post-treatment score
on self report scales).

4.2 Acceptability

4.6 Adverse effects

Rates of attrition due to all causes for the comparison of TCAs
versus NGAs (TeCA, NaSSA, SNRI, SSRI) were 0% to 32.4% for
TCAs versus 0% to 16.7% with NGAs (Table 4). There was no
significant difference in the acceptability rate between TCAs and
NGAs (SNRI, TeCA, NaSSA) (RR 1.48; 95% CI 0.59 to 3.72; 8 studies,
556 participants). There was low heterogeneity in the data (I2 = 14%)
(Analysis 2.2).

The drop-out rate due to adverse effects ranged from 0% to 20.0%
with TCAs versus 0% to 5.71% with NGAs (NaSSA, SNRI, SSRI,
TeCA) (see Characteristics of included studies table). There was no
significant difference between groups for the number of drop-outs
due to adverse effects (RR 2.37; 95% CI 0.39 to 14.28; 8 studies; 556
participants). There was moderate heterogeneity in the data (I2 =
40%) (Analysis 2.5).

Secondary outcomes

4.7 Treatment response

4.3 Anxiety

Compared with the NGAs (NaSSA) group, there was no difference in
the percentage of participants who achieved remission when taking
a TCA (RR 0.93; 95% CI 0.73 to 1.19; 2 studies; 130 participants;
definition treatment response: Ye 2006/Zhao 2006: 'full recovery' or
'significant improvement' on the CGI - Improvement Scale). There
was consistency in the data (I2 = 0%) (Analysis 2.6).

There were no differences in levels of anxiety between TCAs and
NGAs (NaSSA, SNRI, SSRI) (SMD 0.37; 95% CI -0.21 to 0.95; 4
studies; 255 participants) (Analysis 2.3). There was considerable
heterogeneity in the data (I2 = 80%). The SMD changed slightly and
became significant in favour of NGAs when we used a fixed-effect
model (SMD 0.36; 95% CI 0.10 to 0.62; I2 = 80%).
4.4 Depression

There were no differences between TCAs and NGAs (NaSSA, SNRI,
TeCA) for reducing depressive symptoms (SMD 0.17; 95% CI -0.07
to 0.40; 6 studies; 395 participants). There was low heterogeneity in
the data (I2 = 29%) (Analysis 2.4).
4.5 Dysfunctional cognitions, emotions, and behaviours

We found no data comparing TCAs with NGAs for dysfunctional
cognitions, emotions, and behaviours.

4.8 Functional disability and quality of life

We found no data comparing TCAs with NGAs for functional
disability and quality of life.
5. New-generation antidepressants versus another medication
Primary outcomes

Five studies (336 participants) provided data for comparing NGAs
with another medication (TCAs, NGAs, NSAIDs). In the following
analyses, the experimental condition of included studies was the
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5.1 Severity/intensity of medically unexplained physical symptoms
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There were no significant differences for reducing the severity of
MUPS between NGAs (NaSSA, SSRI) and another NGA (NRI, SNRI,
SSRI) (SMD -0.16; 95% CI -0.45 to 0.14; 4 studies; 182 participants).
There was consistency in the data (I2 = 0%) (Analysis 3.1; Figure 6.

See results for the comparison TCA versus NGAs in section 4 above
(tricyclic antidepressants versus another medication) and Analysis
2.1.

Figure 6. Forest plot of comparison: 3 New-generation antidepressants (serotonin antagonist and reuptake
inhibitors (SARI), noradrenergic and specific serotonergic antidepressant (NaSSA), selective serotonin reuptake
inhibitor (SSRI)) versus other new-generation antidepressants, outcome: 3.1 Reduction of the level of severity/
intensity of medically unexplained physical symptoms (post-treatment score on self report scales).

5.2 Acceptability

Rates of attrition rates comparing NGAs with another medication
were:
• NGAs versus TCAs: see results for the comparison TCAs versus
NGAs in section 4 above (tricyclic antidepressants versus
another medication) (Analysis 2.2);
• NGAs (NaSSA, SSRI) versus another NGAs (NRI, SNRI): 22.0% to
35.3% with NGAs (NaSSA, SSRI) versus 28.9% to 50.0% with NGAs
(NRI, SNRI);
• NGA (SARI) versus NSAID (ibuprofen): 0% with NGA (SARI) versus
0% with NSAID.
See also Table 4. Information about the RR comparing NGAs
versus TCAs for acceptability is given in section 4 above (tricyclic
antidepressants versus another medication) (Analysis 2.2). Four
studies contributed sufficient data to compare the acceptability
rate between NGAs (NaSSA, SSRI) and another NGAs (NRI, SNRI,
SSRI), which found no significant difference between groups (RR
0.92; 95% CI 0.60 to 1.40; 4 studies; 182 participants). There was
consistency in the data (I2 = 0%) (Analysis 3.2).
Secondary outcomes
5.3 Anxiety

See results for the comparison NGAs versus TCAs in section 4 above
(tricyclic antidepressants versus another medication) (Analysis
2.3). We found no data comparing the efficacy of NGAs with forms
of medication other than TCAs.
5.4 Depression

See results for the comparison NGAs versus TCAs in section 4 above
(tricyclic antidepressants versus another medication) (Analysis
2.4).
We identified one study comparing an NGA (SARI) with an NSAID,
which demonstrated that SARI was significantly more effective in
reducing depressive symptoms compared with NSAID (SMD -3.87;
95% CI -4.44 to -3.31; 140 participants) (Analysis 3.3) (Wang 2003).

Three studies compared an NGA (NaSSA, SSRI) with another NGA
(NRI, SNRI, SSRI). There was no significant difference between
groups (SMD 0.41; 95% CI 0 to 0.82; 3 studies; 169 participants)
(Analysis 3.3). There was moderate heterogeneity in the data (I2 =
36%). The SMD and its CI changed only slightly when we used a
fixed-effect model but became significant in favour of the other NGA
(NRI, SNRI, SSRI) (SMD 0.46; 95% CI 0.15 to 0.77; I2 = 36%).
5.5 Dysfunctional cognitions, emotions, and behaviours

We found no data comparing an NGA (NaSSA, SSRI) with another
NGA (NRI, SNRI, SSRI) for dysfunctional cognitions, emotions, and
behaviours.
5.6 Adverse effects

Rates of attrition due to adverse effects of the treatment were:
• NGAs (NaSSA, SNRI, SSRI, TeCA) versus TCAs: see results for
the comparison TCAs versus NGAs in section 4 above (tricyclic
antidepressants versus another medication) (Analysis 2.5);
• NGA (NaSSA, SSRI) versus another NGA (NRI, SNRI, SSRI): 6.0% to
27.27% with NGA (NaSSA, SSRI) versus 0% to 22.22% with NGA
(NRI, SNRI, SSRI);
• NGA (SARI) versus NSAID: 0% with NGA (SARI) versus 0% with
NSAID.
See also the Characteristics of included studies table for detailed
information about adverse effects in the single studies. Four studies
(196 participants) provided sufficient data to compare the attrition
rates due to adverse events between NGAs (NaSSA, SSRI) and other
NGAs (NRI, SNRI, SSRI). The effect size indicated no significant
difference between groups (RR 0.84; 95% CI 0.35 to 2.03). There was
consistency in the data (I2 = 0%) (Analysis 3.4).
5.7 Treatment response

See results for the comparison NGAs versus TCAs in section 4 above
(tricyclic antidepressants versus another medication) (Analysis
2.6).
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5.8 Functional disability and quality of life

6.5 Dysfunctional cognitions, emotions, and behaviours

We found no data comparing NGAs with another medication for
functional disability and quality of life.

We found no data comparing pharmacotherapy versus a
combination of medications for dysfunctional cognitions,
emotions, and behaviours.

Comparison 3: pharmacotherapy versus a combination of
medications

6.6 Adverse effects

The literature search identified three studies (163 participants)
where a single antidepressant treatment was compared with a
combined treatment of an antidepressant and an AP. In two of these
studies, the AP was combined with an SSRI (Huang 2012; Li 2006),
and in the other study, a TCA was combined an AP (Zitman 1991).
Primary outcomes
6.1 Severity/intensity of medically unexplained physical symptoms

We identified one study comparing a TCA alone versus TCA plus AP,
which found no significant difference between groups (SMD 0.26;
95% CI -0.42 to 0.94; 34 participants) (Zitman 1991). We found two
studies comparing SSRI alone versus SSRI plus AP. SSRI plus AP
had a significantly higher effect than SSRI alone (SMD 0.77; 95% CI
0.32 to 1.22; 2 studies, 107 participants). There was a low level of
heterogeneity in the data (I2 = 23%) (Analysis 4.1).
6.2 Acceptability

The studies comparing an antidepressant
antidepressant plus AP found attrition rates of:

alone

Drop-out rates due to adverse effects were 0% to 10.0% with SSRI
alone versus 0% to 16.7% with SSRI plus AP. In order to calculate a
RR, only the study authors of Huang 2012 provided data. The study
by Li 2006 had no drop-outs in either group and, therefore, could
not be used for RR calculations. For the study by Huang 2012, there
was no significant difference in drop-outs related to adverse effects
between SSRI plus AP and SSRI alone (RR 0.60; 95% CI 0.16 to 2.29;
60 participants). For the study by Zitman 1991 comparing TCA plus
AP with TCA alone, we could not calculate an RR value because of
missing data. We could not contact the authors of the study, as the
study was too old.
6.7 Treatment response

We identified one study comparing SSRI plus AP with SSRI alone,
which found no significant difference between groups for treatment
response (RR 1.70; 95% CI 0.94 to 3.08; 60 participants; definition
of treatment response: 50% reduction on the SOMS-7; Analysis 4.6)
(Huang 2012).

with

• SSRI alone versus SSRI plus AP: 7.1% to 30.0% with SSRI alone
versus 0% to 30.0% with SSRI plus AP;
• TCA alone versus TCA plus AP: was not calculated due to missing
data.
See also Table 4. There was no significant difference in the
acceptability rate between SSRI alone and SSRI plus AP (RR 0.80;
95% CI 0.25 to 2.52; 2 studies, 118 participants). There was low
heterogeneity in the data (I2 = 16%) (Analysis 4.2).
Secondary outcomes
6.3 Anxiety

There was no significant difference between an SSRI plus AP
and SSRI alone (SMD 0.95; 95% CI -0.91 to 2.82; 2 studies, 107
participants) (Analysis 4.3). There was considerable heterogeneity
in the data (I2 = 95%). The effect size was significant when
calculated using a fixed-effect model (SMD 0.73; 95% CI 0.32 to 1.15;
I2 = 95%).
6.4 Depression

We identified one study comparing a TCA alone versus TCA plus
AP for depression (Zitman 1991). There was a significant benefit
of TCA plus AP compared with TCA alone (SMD 0.79; 95% CI 0.09
to 1.49; 34 participants) (Analysis 4.4). There was no significant
difference between SSRI plus AP and SSRI alone (SMD 0.58; 95% CI
-0.33 to 1.48; 2 studies, 107 participants) (Analysis 4.4). There was
considerable heterogeneity in the data (I2 = 81%). The effect size did
not change considerably when we used a fixed-effect model, but did
reach a significant level in favour of SSRI plus AP (SMD 0.53; 95% CI
0.14 to 0.93).

6.8 Functional disability and life quality

We found no data comparing pharmacotherapy versus a
combination of medications for functional disability and life
quality.
Subgroup analyses
We conducted all subgroup analyses that were originally planned in
the review protocol with the only exception of the analysis 'gender'.
All included studies had both men and women in their samples.
Subgroup analysis 1: co-morbidity (based on pharmacotherapy
versus placebo)
Table 2 gives an overview of the studies where information on comorbid mental disorders was provided.
1.1 Severity/intensity of medically unexplained physical symptoms

In the included studies with participants having co-morbid
mental disorders there was a significant effect in favour of
pharmacotherapy (SMD -0.91; 95% CI -1.36 to -0.46; 3 studies;
243 participants; random-effects model). However, there was
substantial heterogeneity in this subgroup (I2 = 63%). A test for
subgroup differences could not be applied because we identified
only one study in the subgroup of no co-morbid mental disorder
that found no significant difference between pharmacotherapy and
placebo (SMD -0.07; 95% CI -0.35 to 0.21; 200 participants) (Analysis
5.1) (Volz 2000).
1.2 Acceptability

The studies comparing pharmacotherapy with placebo in
participants with co-morbid mental disorders found all-cause
attrition rates to be 4.0% to 38.2% with pharmacotherapy versus
0% to 38.6% with placebo. The studies in participants with no comorbid mental disorders found all-cause attrition rates to be 8.1%
to 13.5% with pharmacotherapy versus 8.2% to 12.4% with placebo
(Table 4). There were no significant differences on acceptability
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rates between pharmacotherapy and placebo for participants with
or without co-morbid mental disorders (with co-morbid mental
disorders: RR 1.01; 95% CI 0.64 to 1.61, 2 studies; 163 participants;
with no co-morbid mental disorders: RR 1.05; 95% CI 0.59 to 1.89;
2 studies; 390 participants). There was consistency in the data in
both groups (with co-morbidity mental disorders: I2 = 0%; with no
co-morbidity mental disorders: I2 = 0%). The test of differences
between subgroups indicated no significant effect (I2 = 0%, Chi2 =
0.01, degrees of freedom (df) = 1, P value = 0.920) (Analysis 5.2).
Subgroup analysis 2: source of funding (based on
pharmacotherapy versus placebo)
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3.2 Acceptability

This subgroup analysis could only be conducted for outcomes that
were assessed by self report or clinician-rated measures but not for
the acceptability rate.
Sensitivity analyses
For reasons of clarity and comprehensibility most of
the sensitivity analyses were reported in the sections of
'Comparison 1: pharmacotherapy versus placebo', 'Comparison 2:
pharmacotherapy versus another medication', and 'Comparison 3:
pharmacotherapy versus a combination of medications'.

The Characteristics of included studies table provided information
about the funding of the included studies or if study authors were
involved in pharmaceutical industry.

Best-case/worst-case analysis (based on outcome 'treatment
response')

2.1 Severity/intensity of medically unexplained physical symptoms

In order to deal with missing data in analyses of dichotomous
outcomes we conducted best-case/worst-case scenarios. For the
comparison TCA versus placebo, there were not enough studies
available for conducting this analysis.

In the subgroup comprising studies with funding by
pharmaceutical industry there was a significant effect to reducing
the severity and intensity of MUPS in favour of pharmacotherapy
(with funding: SMD -0.64; 95% CI -1.02 to -0.27; 5 studies; 685
participants; random-effects model; with no funding SMD -0.75;
95% CI -1.29 to -0.21; 2 studies; 119 participants; random-effects
model). In the subgroup with funding, there was considerable
heterogeneity in the data (I2 = 81%), whereas in the group with no
funding, there was moderate heterogeneity in the data (I2 = 48%).
The test of subgroup differences revealed no significant effect (I2 =
0%, Chi2 = 0.10, df = 1, P value = 0.760) (Analysis 6.1).
2.2 Acceptability

The studies with funding from pharmaceutical industry reported
the attrition rate to be 0% to 38.2% with pharmacotherapy versus
0% to 38.6% with placebo. There was only one study with no
financial support where we could calculate the attrition rate for
every study arm (Pilowsky 1990). In this study, the attrition rate
was 25.0% for pharmacotherapy and 31.0% for placebo (Table
4). In studies with funding by the pharmaceutical industry, there
was no significant difference in the acceptability rate between
pharmacotherapy and placebo (RR 0.99; 95% CI 0.70 to 1.40; 6
studies; 877 participants). There was consistency in the data (I2 =
0%) (Analysis 6.2). We could not calculate subgroup differences of
acceptability because we identified no placebo-controlled study
with no financial support from pharmaceutical industry.
Subgroup analysis 3: source of outcome rating (based on
pharmacotherapy versus placebo)
3.1 Severity/intensity of medically unexplained physical symptoms

In the subgroup comprising self report scales, there was a
significant effect size in favour of pharmacotherapy compared
with placebo (SMD -0.66; 95% CI -0.97 to -0.36; 7 studies;
804 participants; random-effects model). There was considerable
heterogeneity in the data (I2 = 76%). In the subgroup comprising
clinician-rated scales, there was a high, significant effect size in
favour of pharmacotherapy (SMD -0.91; 95% CI -1.42 to -0.40;
4 studies; 573 participants; random-effects model). There was
considerable heterogeneity in the data (I2 = 87%). The test of
subgroup differences revealed no significant difference between
data based on self report and clinician-rated scales (I2 = 0%, Chi2 =
0.66, df = 1, P value = 0.420) (Analysis 7.1).

Comparison: pharmacotherapy versus placebo

NGA versus placebo: the first analysis that was based on complete
cases showed that there was no significant difference between
NGA and placebo (RR 2.02; 95% CI 0.82 to 4.97; 2 studies;
119 participants; random-effects model). There was considerable
heterogeneity in the data (I2 = 84%). The second analysis was
based on a best-case scenario, which means that drop-outs
in the active treatment group were assumed to have positive
outcomes and drop-outs in the control group were assumed to
have negative outcomes. Results showed that NGA was significantly
more effective than placebo (RR 2.59; 95% CI 1.90 to 3.53; 2
studies; 163 participants; random-effects model). There was high
consistency in the data (I2 = 0%). The third analysis was based on
a worst-case scenario, which means that drop-outs in the active
treatment group had negative outcomes and drop-outs in the
control group had positive outcomes. Results showed that there
was no significant difference between NGA and placebo (RR 1.41;
95% CI 0.30 to 6.63; 2 studies; 163 participants; random-effects
model). There was considerable heterogeneity in the data (I2 = 95%)
(Analysis 8.1). In summary, the complete cases as well as the worstcases scenario demonstrated no differences between NGAs and
placebos whereas the best-case scenario did.
NP versus placebo: there was a statistically significant effect in
favour of NP for the complete-case analysis (RR 1.75; 95% CI
1.29 to 2.36; 2 studies; 311 participants; random-effects model),
the best-case analysis (RR 1.92; 95% CI 1.26 to 2.94; 2 studies;
324 participants; random-effects model), and the worst-case
analysis (RR 1.57; 95% CI 1.27 to 1.93; 2 studies; 324 participants;
random-effects model). In the complete-case analysis there was
moderate heterogeneity (I2 = 33%), in the best-case analysis there
was substantial heterogeneity (I2 = 63%), and in the worst-case
consistency there was consistency in the data (I2 = 0%) (Analysis
9.1).
Comparison: pharmacotherapy versus other medication

There were not enough data available for comparing
pharmacotherapy and placebo in a sensitivity analysis.
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Comparison: pharmacotherapy versus combination of medication

Comparison 1: pharmacotherapy versus placebo

There were not enough data available for comparing
pharmacotherapy and placebo in a sensitivity analysis.

Tricyclic antidepressants versus placebo

Reporting bias
Originally, we planned to assess for a publication bias by
implementing funnel plots. However, creating funnel plots would
only make sense for the medication versus placebo comparisons.
It would be difficult to interpret studies where a medication
was compared with another medication. For the comparison of
medication versus placebo we included only eight studies for
meta-analytical calculations, which is below the number of trials
recommended by the Cochrane Handbook for Systematic Reviews
of Interventions (there should be at least 10 studies) (Sterne 2011).
However, in order to prevent publication bias, we made every
attempt to include unpublished trials (e.g. by searching online trial
registries or registries of unpublished doctoral theses).
Studies that did not contribute data that allowed them to be
included in the meta-analysis
The following study could only contribute to the narrative literature
part of the review. For detailed information about study, see the
Characteristics of included studies table.
Altamura 1991
This randomised, parallel-group, double-blind, fixed-dose trial
included two arms comparing the efficacy of two APs - levosulpiride
and racemic sulpiride in 30 participants with somatisation disorder
or undifferentiated somatoform disorder (Altamura 1991). We could
not include the study in our meta-analysis because all results
presented graphically. We contacted the trial authors but they
replied that the study was too old and that they no longer had
access to the data. Thus, we have summarised the most important
findings of this study narratively. The severity of MUPS was
assessed with the somatisation subscore of the SCL-90. There were
no significant differences between groups. Starting in the treatment
week two, there was a significant decrease of somatic symptoms
with every further week until the end of treatment in both groups.
Depressive symptoms (depression subscore of the SCL-90) started
to decrease significantly from the second treatment week until the
end of treatment. With anxiety (using HARS), the sulpiride group
obtained a significant decrease of symptoms in week two whereas
the racemic sulpiride group revealed a decrease of symptoms in
week one. In both groups, this reduction of anxiety remained stable
until the end of treatment. In both treatment arms, there was a
drop-out rate of 13.3%. Extrapyramidal and anticholinergic adverse
effects were more frequent with racemic sulpiride.

DISCUSSION
Summary of main results
See also a summary of the main results for the main comparison
pharmacotherapy versus placebo in Summary of findings for
the main comparison; Summary of findings 2; and Summary
of findings 3; and for the comparisons of 'TCAs versus another
medication' (Summary of findings 4) and 'pharmacotherapy versus
a combination of medications' (Summary of findings 5).

Evidence from two studies in 239 people contributing data to the
primary outcomes of this review showed that the TCAs given for
between six and 12 weeks did not reduce the severity of MUPS more
than placebo. There were not enough data available to conduct
meta-analyses for our secondary outcomes. The attrition rates due
to adverse effects and the rates of all-case drop-outs in these
studies were comparable between medication and placebo group.
In summary, the evidence for the efficacy of a TCA in comparison to
a placebo is low quality. Statements about efficacy are only possible
for the severity of MUPS, but not secondary outcomes.
New-generation antidepressants versus placebo
Results from three studies with 243 people showed that the
severity of MUPS could be reduced significantly by treatment with
NGAs for between eight and 12 weeks compared with placebo.
Evidence from two studies with 163 people demonstrated that
administering NGAs for 12 weeks significantly reduced depressive
symptoms and functional disability, while increasing quality of
life. For anxiety symptoms and treatment response, there were no
differences between NGAs and placebo. In summary, the impact
of NGAs compared with placebo was inconsistent across outcomes
at post-treatment. For an adequate interpretation, it has to be
noted that the results for NGAs had high levels of heterogeneity.
Furthermore, the analyses included one study with outlier values
(Muller 2008). The exclusion of this study in a sensitivity analysis
did not change the SMD considerably. It still remained significant in
favour of an impact of NGAs on the severity of MUPS. Results did not
considerably change under further sensitivity analyses. However,
best-case/worst-case analysis did cast some doubt over the results.
The attrition rates in these studies were comparable between NGAs
and placebo groups, as well as the number of drop-outs due to
adverse effects of treatment.
Natural products versus placebo
Two studies with 322 people showed that treatment with an NP
over six weeks significantly reduced the severity of MUPS and led
to a significantly higher number of participants with symptom
remission. Evidence from two studies with 321 participants
contributing data to the secondary outcomes showed that NPs
given for two to six weeks significantly reduced anxiety and
depressive symptoms. Results did not change considerably under
sensitivity analyses and were confirmed by the best-case/worstcase analysis. For functional disability and quality of life, we did not
find enough data to conduct a meta-analysis. Attrition rates due to
all causes and due to adverse effects of treatment were quite low
and similar in NP and placebo groups.
Comparison 2: pharmacotherapy versus another medication
Tricyclic antidepressants versus another medication
There were only enough studies available for the comparison
between TCAs and NGAs. Results were based on 10 studies
with 616 participants contributing data partly to primary and
secondary outcomes of this review. The central finding was that
TCAs administered over four to 17 weeks were as effective as
administering NGAs at reducing the severity of MUPS, at decreasing
depressive and anxiety symptoms, and in symptom remission.
Results did not change considerably under sensitivity analyses.
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The attrition rates due to all causes and due to adverse effects
were about three times as high with TCA compared with NGA.
However, due to the considerable levels of heterogeneity in the data
this difference between the study conditions was not statistically
significant.
New-generation antidepressants versus another medication
In addition to the studies comparing NGAs with TCAs (see summary
of the findings of this analysis in section 4 above (tricyclic
antidepressants versus another medication), we found four studies
with 196 participants comparing the efficacy of one NGA with
another NGA. Evidence from this analysis showed that different
NGAs taken over eight to 12 weeks were comparably effective at
reducing the severity of MUPS depressive symptoms. The attrition
rates due to all causes and due to adverse effects were similar for
the different types of NGAs.
Comparison 3: pharmacotherapy versus a combination of
medications
For the comparison of a TCA alone versus a TCA plus AP, we found
only one study (Zitman 1991). However, for the comparison of SSRIs
alone versus SSRIs plus AP over six to eight weeks, evidence was
based on two studies with 118 people contributing data partly to
the primary and secondary outcomes of this review. The findings
showed that the combined treatment was more successful in
reducing the intensity of MUPS and depressive symptoms than
single pharmacotherapy. Both treatments were similarly effective
at decreasing anxiety. The attrition rates due to all causes and due
to adverse effects were comparable in both treatment groups.
Subgroup analyses
Subgroup analyses for co-morbid mental disorders of included
participants and the funding of trials by pharmaceutical companies
did not reveal any significant effects. However, results have to be
interpreted with caution due to high heterogeneity. For severity of
MUPS, analyses clearly demonstrated a considerably higher effect
when the assessment was done with clinician-rated scales than
with self report scales.

Overall completeness and applicability of evidence
The objective of the current review was to assess the effects
of pharmacological interventions for somatoform disorders
(specifically somatisation disorder, undifferentiated somatoform
disorder, somatoform autonomic dysfunction, and pain disorder)
in adults. We performed a thorough literature search of
different electronic databases and many other resources such
as conference proceedings, international trial registers, grey
unpublished literature, and reference lists, which resulted in 26
studies that could be included in this review. In comparison to other
existing reviews on this topic, this number of eligible studies was
quite high (e.g. Kroenke 2007; O'Malley 1999; Sumathipala 2007).
Due to the connection of the CCDANCTR database to many Asian
journals to which other common databases have no access, we had
the opportunity to screen studies that have never been mentioned
in existing reviews. However, it has to be emphasised that the
provenance of some of the other Chinese studies in the CCDANCTR
was less clear and probably dated back to an opportunistic search
of Wang Fang Data (c/o The British Library) in 2007. While we
ensured searches were run on sources other than the CCDANCTR,
we did not run a comprehensive, up-to-date search of the Chinese
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biomedical literature and so the studies analysed in this review may
be an incomplete list of relevant research from China and other
Asian countries. However, we retrieved a considerable number of
studies in order to address our questions.
Our review has several limitations. The studies that we identified
focused primarily on antidepressants and our objectives focused
on pharmacological interventions in general. A critical issue
was that maybe our results were of 'artificial' nature because
we focused very specifically on studies with participants
with somatoform disorders characterised by chronic MUPS.
However, somatoform disorders are conceptually overlapping with
functional somatic syndromes (Wessely 1999), which we excluded
from the current review. The results of the current review should
be interpreted as part of a portfolio of five Cochrane reviews
covering somatoform disorders (Hoedeman 2010; Ipser 2009;
Ruddy 2005; Thomson 2007), as well as Cochrane reviews focusing
on different functional syndromes (e.g. Huertas-Ceballos 2014;
Moore 2012). A further problem of this review was dealing with
missing data for meta-analytic calculations. Although we tried
to contact study authors in order to be provided with missing
data, we had to exclude one study from the meta-analytic part
of our review because data were no longer available (Altamura
1991). Unfortunately, this study examined a medication class
that had to be neglected in the current review due to a lack
of studies, that is, APs. Another problem of the current review
was that there were not enough studies to assess the reporting
bias with funnel plots. Creating funnel plots would only make
sense for the medication versus placebo comparisons. Bringing
together the studies where a medication was compared with
another medication would be very difficult to interpret. For the
medication versus placebo comparisons, we could only include
eight studies for meta-analytical calculations. This is below the
number of trials recommended by the Cochrane Handbook for
Systematic Reviews of Interventions, which states that there should
be at least 10 studies (Sterne 2011). We could report adverse effects
of the different medication classes in the treatment of somatoform
disorders only in a narrative way in the Characteristics of included
studies table. Adverse effects were reported in an unstandardised
way in all reports. Therefore, it was not possible to code them in a
standardised way in order to include them in our meta-analytical
calculations. We have to emphasise again that the inclusion of
RCT and CRCT studies is not sufficient to gain information about
the more rare or long-term adverse events. A further consequence
of the lack of a sufficient number of studies was that we could
not conduct many of our pre-planned subgroup and sensitivity
analyses. These analyses - and potentially additional interesting
subgroup analyses (e.g. according to the duration of symptoms) can hopefully be considered in future updates of this review.
Finally, it should be noted that none of the included studies
examined the efficacy of pharmacotherapy over the long term.
This means that the trial reports comprised no follow-up data
but only that of post-treatment assessments. Furthermore, the
pharmacological interventions in the included studies had a
maximum duration of 12 weeks and can therefore be declared
as short-term treatments. This is particularly since included
participants had the MUPS over a long period and it could be
considered as a chronic population. It is questionable whether
short-term interventions can really provide a realistic estimation
of the efficacy of pharmacotherapy in the sample of people with
somatoform disorders.
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Quality of the evidence
According to the first quality criterion risk of bias defined by the
guidelines by GRADE (Guyatt 2008), Figure 2 and Figure 3 show
that for different types of biases, most of our included studies
show an unclear or high risk of bias. Although many studies are
classified as 'randomised' and 'double-blind', detailed descriptions
of random sequence generation; allocation concealment; blinding
of participants and study personnel, and outcome assessment were
missing. For example, even if a study described how participants
and study personnel were blinded with regard to the study
condition, there was no study that attempted to blind participants
with regard to adverse effects. Because there was only a small
number of studies showing low risk of bias, it was often not possible
to conduct sensitivity analyses in order to check for the biases.
Another important quality problem of the included studies was
with attrition bias and the way missing data were dealt with. There
were several studies that did not define the ITT sample as a sample
of originally randomised participants. Usually only participants
with at least one post-baseline efficacy evaluation were included
in this population. This procedure can lead to an overestimation
of effects. We checked this problem with sensitivity analyses that
revealed no impact.
For reporting bias, there was another problem. Although several
studies implemented a broad range of different outcomes in the
form of self report and clinician-rated scales, there were also some
studies that assessed outcomes that we classified as secondary in
our review. An important outcome such as the severity of physical
symptoms was neglected in such studies. In addition, there were
several studies with a low variety in the form of assessment self report versus clinician-rated scales. In our subgroup analyses,
we could demonstrate that clinician-rated scales can lead to
higher effect sizes than self report scales. However, we had to be
careful with interpreting these results because tests of subgroup
differences were not significant and there was high heterogeneity
in the data of the subgroups and there are also other studies
that could demonstrate this effect (Lambert 1994; Lambert 1986;
Rief 2009). Furthermore, the study protocols were not available as
publications in an international trial register for any of the included
studies. This increases the risk of reporting bias. In addition,
reporting bias could not be checked with funnel plots because there
was not a sufficient number of studies. One specific problem that
appeared in the context of reporting bias was that three trial reports
did not report SDs for the post assessment (Han 2008a; Han 2008b;
Kroenke 2006). After contacting trial authors and receiving no reply,
we replaced these missing SD with SD from the pre-assessment. We
are aware that this procedure can produce bias in the results - in
both the form of underestimation or overestimation of the effects.
However, it is discussed as a common procedure in the evaluation
of therapeutic outcome (Bergin 1971), and appeared to us to be a
better alternative than excluding these studies. We used sensitivity
analyses to determine the impact of a possible bias but could not
identify one.
There are still some other sources of risk of bias in our included
studies that have to be considered. For example, there were four
studies that implemented a placebo run-in phase before they
started with the treatment. This design feature severely endangers
accurate estimates of the placebo response rate (Fournier 2010).
Because early placebo responders were removed from the trial
before they can contribute data, the true rate of placebo response
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may be underestimated in trials that use this feature. We checked
the impact of this pre-intervention before the study treatment
started in sensitivity analyses, which revealed no considerable
impact. Furthermore, compliance of participants in taking their
medication was reported only in one trial. Without this compliance
check, trial authors cannot ensure that participants complied
with the treatment protocol, which in turn can produce biases,
especially in pharmacological interventions with considerable
adverse effects. Although all included studies were randomised
trials there was a small number of studies where significant
baseline differences between the study arms in the outcomes
appeared. Finally, the funding of studies by the pharmacological
industry or the involvement of study authors in pharmacological
companies can have an influence on the results. We checked for this
bias using sensitivity analyses and could not find any influence for
our included studies. However, heterogeneity in the data was very
high in the funded studies compared with the non-funded studies.
With regard to the GRADE criterion 'inconsistency' it must be noted
that under the included placebo-controlled trials there was one
study that demonstrated outlier values for almost all outcomes
(Muller 2008). Sensitivity analyses showed that the exclusion of this
study reduced the level of heterogeneity in the data. The values in
the original trial report that were indicated as SD by the trial authors
appeared to be very small and too homogenous over the time
points of assessment and between the different treatment groups.
We assumed that in this trial reported SE and not SD. Therefore, we
used the common formula in order to convert SEs to SDs. However,
the effect sizes still remained obviously high compared with the
remaining studies.
For the GRADE criterion 'imprecision', we had to downgrade the
ratings in several cases. The central limitation was that the total
(cumulative) sample size was too small or that the 95% CI around
the pooled effect included both no effect and appreciable benefit
or appreciable harm. Although we identified 26 studies, each
comparison only contained a few studies and had a relatively small
number of participants.
For the GRADE criterion 'publication bias', it should be emphasised
for our review in general that we neglected literature search
of biomedical electronic databases of Asian countries. The
implications of this limitation are difficult to gauge. Due to a lack of
data, we could not conduct sensitivity analyses where Asian studies
were excluded.
The criteria of quality defined by GRADE 'indirectness' was less
of a problem in our included studies. Finally, it has to be noted
that several of the included studies were performed before the
publication and implementation of current quality criteria for
conducting and reporting RCTs (Moher 2001).

Potential biases in the review process
Although this review has several strengths, such as a pre-published
protocol, an experienced librarian who performed thorough
searches, the collection of data from various sources, two review
authors to select studies/data extract/assess risk of bias, and a
third review author to resolve disputes, there were also post hoc
decisions in the review process that could have had a bias effect.
The management of antidepressant classes was one. For example,
it would be logical to consider SSRIs as an NGA separately from the
other NGAs. This is because SSRIs build an important medication
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class that is often used off-label for treating somatoform pain.
However, for the medication versus placebo comparisons, there
were not enough studies available to calculate analyses separately
for SSRIs. Therefore, we decided to combine SSRI studies and trials
on other NGAs for all meta-analytic calculations.
Another problem appeared with the high number of included
Asian studies (40.0%). Research on mental and somatic disorders
in various cultures shows cross-national differences occurring
in somatic distress. Although the patterns of these differences
seem not to follow clear cultural lines, the role of culture cannot
be excluded (Gureje 2004). Research on cultural aspects shows
that there are differences in experiencing, presenting, and coping
with physical symptoms between Asian and Western cultures.
For example, one study demonstrated that Chinese outpatients
reported more somatic symptoms on spontaneous problem report
and structured clinical interview compared with Euro-Canadians,
who in turn reported more psychological symptoms (Ryder 2008).
It appears that other factors are also associated with the cultural
background of the studies. For example, whereas an outpatient
setting was chosen in almost all studies that were conducted in
Western cultures, an inpatient setting was used only in the Asian
studies. This factor maybe confounded with the attrition rate. In
an inpatient setting, the barrier to withdraw study participation
is maybe higher than in outpatient settings. Interestingly, there
were several studies with no drop-outs in each study arm and
these studies were all Asian studies. Furthermore, although a
high proportion of our included studies was of Asian origin, we
cannot claim that this review is a complete list of relevant research
from China and other Asian countries because, while we ensured
searches were run on sources other than the CCDANCTR, we
did not run a comprehensive, up-to-date search of the Chinese
biomedical literature and so the studies analysed in this review
may be an incomplete list of relevant research from China and
other Asian countries. We also have to emphasise that we had no
restrictions regarding language for including studies. This means
that of the included studies, we had to translate one Italian and
eight Chinese articles. There were three translators who supported
us. All of them were native speakers in the language in which
the article was written and lived for a longer time in a country
with English as principal language. Furthermore, they were all
graduate clinical psychologists. However, they were not specialist
in pharmacotherapy.
Another post hoc decision in the review process that could have
a bias effect was the combination of study arms with different
NP combinations (Melzer 2009), or with the same medication
administered in different settings (Kong 2004). We did this
combination of study arms in order to prevent a unit-of-analysis
error.

Agreements and disagreements with other studies or
reviews
We could not find an existing meta-analysis; however, we identified
four literature reviews that were very close to the topic of our
review (Fallon 2004; Kroenke 2007; Somashekar 2013; Sumathipala
2007). Fallon 2004 identified only one open-label study on the
pharmacological treatment of people with a variety of somatoform
disorders. The authors concluded that there was a research
gap regarding pharmacological interventions for people with
primarily somatic cluster of somatoform disorders. Kroenke 2007
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included four RCTs on the pharmacological treatment of multiple
MUPS (antidepressants and NPs). The authors found that three
of the four pharmacological trials demonstrated efficacy of the
medication. The authors concluded that preliminary but not
conclusive evidence existed for antidepressant treatment of MUPS.
Somashekar 2013 examined the efficacy of antidepressants in
somatoform and related disorders. The authors concluded that
there was evidence that antidepressants with both serotonergic
and noradrenergic activity were more effective than SSRIs for
somatoform pain disorder. Furthermore, they stated that although
TCAs, especially amitriptyline, have been commonly used in clinical
practice, it is not systematically evaluated specifically in somatic
symptoms disorders. Sumathipala 2007 described the results of the
review by O'Malley 1999 (see below). Sumathipala 2007 concluded
that there was evidence for the effectiveness of antidepressants
available for different subgroups of somatoform disorders, but that
there was not much evidence on other medications.
We found one meta-analysis and two other reviews that focused
on specific functional syndromes. These publications also have
important parallels with our review. The review and meta-analysis
by O'Malley 1999 examined the efficacy of antidepressant therapy
on six symptom syndromes: headache, fibromyalgia, functional
gastrointestinal syndromes, idiopathic pain, tinnitus, and chronic
fatigue. They judged the quality of the included studies as
fair. They identified studies focusing on TCAs, anti-serotonin
antidepressants, SSRIs, or multiple agents. They quoted an SMD
of 0.87 (95% CI 0.59 to 1.14). Unfortunately, it is unclear to which
outcome this SMD refers. The authors found high drop-out rates
(40% of the included studies had drop-out rates greater than 20%).
Jackson 2006a examined the efficacy of antidepressant therapy
in 11 somatic syndromes (IBS, chronic back pain, headache,
fibromyalgia, chronic fatigue syndrome, tinnitus, menopausal
symptoms, chronic facial pain, non-cardiac chest pain, interstitial
cystitis, and chronic pelvic pain). The authors concluded that there
was good RCT evidence of benefit from antidepressant therapy for
headaches, fibromyalgia, and IBS. The evidence of improvement
with antidepressant therapy was rather weak for back pain and
chronic fatigue syndrome. The authors criticise many studies
of somatic syndromes that have used subtherapeutic doses of
antidepressants for relatively short durations, making it less likely
that the benefit is entirely due to antidepressant properties of these
drugs. The systematic review by Raine 2002 primarily focused on
mental healthcare interventions for people with common somatic
symptoms in general (chronic fatigue syndrome, IBS, chronic back
pain). They identified 18 trials that investigated the efficacy of TCA,
TeCA, anxiolytic plus TCA, SSRIs, and MAOIs. The authors concluded
that antidepressants seem to be effective in IBS but ineffective in
chronic fatigue syndrome.
In summary, these reviews and the one meta-analysis suggested
that particularly antidepressants might be effective in the
treatment of MUPS. They emphasise that there is not much
research on the efficacy of medications other than antidepressants.
Furthermore, the quality of the studies was judged as moderate.
Drop-out rates were high. Therefore, the results of these reviews
were consistent with our findings.
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AUTHORS' CONCLUSIONS
Implications for practice
The results of this review demonstrated only low or very low quality
evidence for the efficacy of pharmacological interventions for
somatoform disorders in adults. This evidence is limited and refers
only to two specific classes of pharmacological interventions: newgeneration antidepressants (NGAs) and natural products (NPs).
Placebo-based comparisons demonstrated consistent efficacy only
for NPs for diverse primary and secondary outcomes. For NGAs, the
evidence was very inconsistent across outcomes. Findings showed
no difference between TCAs and placebo for the severity of MUPS
but there was not enough evidence to assess any other outcomes.
A small number of studies compared different medications for
somatoform disorders. The findings of these studies suggested that
NGAs seemed to be as effective as TCAs; however, the evidence was
of low to very low quality. Furthermore, the results showed that
different NGAs seem to be similarly effective for diverse outcomes.
Finally, meta-analyses on studies comparing selective serotoninreuptake inhibitors (SSRIs) with combined treatments of SSRIs
and antipsychotics suggest that there could be a benefit of a
combination of medications only for reducing the severity of MUPS
and depression. For other outcomes, such as anxiety symptoms, no
effects of the study arm were identified. Here again the evidence
was of low or very low quality.
Overall, these results have to be considered with caution given
several shortcomings associated with the included studies, such
as the imprecision of the data (due to the small numbers of
studies and sample sizes contributing to each comparison), the
bias possibly produced by cultural factors and the inclusion of
a high number of Asian studies, or the lack of studies with
follow-up assessments (see also Summary of findings for the
main comparison Summary of findings 2; Summary of findings 3;
Summary of findings 4; and Summary of findings 5). Furthermore,
the significant effects of antidepressant treatment have to be
balanced against the relatively high rates of adverse effects. For
people experiencing somatic symptoms without medical causes,
adverse effects of medication can have amplifying effects on
symptom perceptions. In addition, drop-out rates as indicators
of a low treatment acceptability were quite high for the different
antidepressants compared with NPs.

Implications for research
This review revealed that the evidence base is lacking in
studies that examine the efficacy of medication class (such as
antipsychotics) other than antidepressants or NPs for somatoform
disorders in adults. Therefore, research on other medication
classes in the treatment of somatoform disorders and chronic
medically unexplained physical symptoms (MUPS) should be
facilitated. Furthermore, there were some implications particularly
regarding antidepressant trials. There was not enough evidence or
the existing evidence was not of good enough quality to support
the common off-label use of antidepressants - especially TCAs in the treatment of somatoform disorders and MUPS. This review
only partly allowed conclusions to be made about differences in
the efficacy between different chemical agents based on included
randomised controlled trials (RCTs) where different medications
were compared. However, with this low number of studies per
medication class, and the sometimes high heterogeneity in the
data, the findings from our review have to be interpreted with
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caution. Replication studies comparing different antidepressant
agents - NGAs but also TCAs - would be desirable and should ensure
that they address the elements of bias that we found for existing
antidepressant trials. Furthermore, an important limitation of the
included studies was the lack of examining the long-term effects
of pharmacological interventions. This would be very important
especially for the comparability with other interventions for
somatoform disorders for which long-term stability of the effects
has already been confirmed (e.g. cognitive-behavioural therapy;
Kleinstäuber 2011).
For several outcomes, only a small number studies was available
(e.g. functional impairment or cognitive/emotional/behavioural
symptoms). Therefore, another idea for future research would
be to include other outcomes such as functional impairment or
dysfunctional behaviours and cognitions as well as the classical
outcomes such as symptom severity, depression, and anxiety.
This is also important for the comparison of pharmacological
interventions with other interventions. In this context, it would
be also important to push forward research of the impact
of different modes of measures on the results in studies on
the efficacy of pharmacotherapy for somatoform disorders. An
important research question could be, for example, if clinician
ratings overestimate improvement. In addition, more research
is needed on the mechanisms of efficacy in the different
medication classes. Research shows that somatoform disorders
have a high co-morbidity with other mental disorders such as
depression or anxiety disorders. This, and the fact that medications
that were originally developed for the treatment of such comorbid disorders are administered 'off-label' to treat somatoform
syndromes, could motivate research on connections between
MUPS and co-morbid mental disorders. Such research could
provide important information about the efficacy mechanisms
of 'off-label' pharmacotherapy in somatoform disorders. Typical
examples could be immunoregulatory mechanisms that could
play a role in somatoform disorders as well as in depression.
Furthermore, distinctive cognitive-affective biases related to
attention or encoding and recall processes could be important
connections between anxiety or depression and somatoform
disorders.
Our review and other previous studies (Rief 2009) could
demonstrate that there seems to be differences between clinicianrated and self report measures. In addition, Lambert 1994 and
Lambert 1986 demonstrated that not only the mode of assessment
for itself but in interaction with the blinding of the assessor
has an important impact on effect sizes. This important aspect
could unfortunately not be considered in this review because the
number studies with blinded assessors was too small. Finally,
in future research guidelines for conducting and reporting highquality RCTs should be followed more strictly (Guyatt 2008;
Moher 2001). Interesting research questions for further studies
could be to compare the efficacy of different dosages of one
chemical agent. It would be also interesting to investigate if the
benefit that people with somatoform disorders experience in a
pharmacological treatment is dependent on specific participant
variables.
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CHARACTERISTICS OF STUDIES
Characteristics of included studies [ordered by study ID]
Altamura 1991
Methods

Randomised, parallel-group, double-blind, fixed-dose triala,f

Participants

n(randomised/ITT) = 30
Diagnosis: somatisation disorder, undifferentiated somatoform disorder (DSM-III-R)
Inclusion criteria: no information provided
Exclusion criteria: no information provided
Age: mean (± SD) 49.20 ± 9.64 years, range 18-77 years; sex: 43.3% women; mean length of time since diagnosis of a somatoform disorder: ns; country: Italy; setting: no information provided

Interventions

Levosulpiride (n = 15; AP; mean dose = 150 mg/day, max dose = 150 mg/day; no information regarding
mode/frequency of administration provided)
Racemic sulpiride (n = 15; AP; mean dose= 300 mg/day, max dose = 300 mg/day; no information regarding mode/frequency of administration provided)
Treatment duration: 21 days

Outcomes

Primary outcome:
Scale for Somatoform Disorders (Lipman 1969) - Total Score, Somatisation Score (self rated)
Secondary outcomes:
Scale for Somatoform Disorders - Depression Score (self rated): baseline, week 1, 2, 3, 4, 5
HARS - Total Score (clinician-rated): baseline, week 1, 2, 3, 4, 5
Simpson & Angus Scale (extrapyramidal adverse effects): baseline, week 1, 2, 3, 4, 5
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Anticholinergic Side Effects Check List: baseline, week 1, 2, 3, 4, 5
All-cause drop-outs: n = 2 (levosulpiride), n = 2 (racemic sulpiride)
Drop-outs due to adverse effects: n = 1 (levosulpiride), n = 1 (racemic sulpiride)
Reported drug-related adverse effects:
Levosulpiride: anticholinergic adverse effects (n = 1, 6.6%)
Racemic sulpiride: extrapyramidal adverse effects (n = 2, 13.3%), anticholinergic adverse effects (n = 3,
20.0%)
No information about the total rate of participants with drug-related adverse events provided. There
were no significant differences between groups regarding severity of anticholinergic adverse effects
Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Authors states that participants were randomly assigned to 1 of 2 treatment
groups (p. 26); no information provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about method of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

Participants "were treated under double blind conditions" (p. 25); insufficient
information provided about who was and was not blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about method of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Drop-out rate in total sample: 13.3%; although reasons for missing outcome
data were partly likely to be related to true outcome, missing outcome data
were balanced in number across intervention with similar reasons for missing
data across groups; however, no information was provided about how missing
values were replaced; furthermore, no information was provided about how
many of the randomised participants (placebo-responder) were excluded from
the trial after the 1-week placebo run-in phase before the treatment started

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used. Means and SD
only presented in a graph, but not as concrete values in a table or text

Other bias

High risk

"After one week of placebo treatment, not responders were treated under
double blind conditions" (p. 25), "A placebo week followed the treatment" (p.
25), participants were randomised and passed a 1-week placebo run-in phase
before they started the treatment, only placebo-non-responders (improvement < 20% on clinical rating scales) were included to the study. This exclusion of placebo-responders before the treatment started could have led to a
change of the magnitude of the effect estimation
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Aragona 2005
Methods

Randomised, parallel-group, double-blind, fixed-dose trial

Participants

n(randomised) = 35; n(ITT) = 29
Diagnosis: pain disorder associated with psychological factors (DSM-IV-TR)
Inclusion criteria: presence of psychological factors that might have influenced the onset or the clinical
course (or both) of pain; passing the 2 steps of diagnostic procedure; aged > 18 years
Exclusion criteria: pregnancy, medical conditions of clinical importance, direct organic explanation
of symptoms, a diagnosis of another mental disorder, use of psychotropic drugs endowed with an
analgesic effect (e.g. amitriptyline) and anti-inflammatory medications (were suspended in 1-week
washout phase before randomisation)
Age b: mean (± SD) 53.64 ± 15.79 years, range 18-77 years; sex b: 72.4% women; mean length of time
since diagnosis of a somatoform disorder: ns; country: Italy; setting: outpatient

Interventions

Citalopram (n = 17; SSRI; mean dose = 40 mg/day, max dose = 40 mg/day; 1 tablet twice/day)
Reboxetine (n = 18; SNRI; mean dose = 8 mg/day, max dose = 8 mg/day; 1 tablet twice/day)
Treatment duration: 56 days

Outcomes

Primary outcome:
McGill Pain Questionnaire - Present Pain Intensity, Pain Rating Index (self rated): baseline, week 2, 4, 8
Secondary outcomes:
Zung Self-Rating Depression Scale (self rated): baseline, week 2, 4, 8
Treatment Emergent Symptom Scale: baseline, week 2, 4, 8
All-cause drop-outs: n = 6 (citalopram), n = 9 (reboxetine)
Drop-outs due to adverse effects: n = 2 (citalopram), n = 4 (reboxetine)
Reported drug-related adverse effects:
Citalopram: dry mouth (n = 2, 11.7%); somnolence (n = 6, 35.3%); insomnia (n = 4, 23.5%); tremor (n
= 5, 29.4%); tachycardia (n = 2, 11.7%); increased motor activity (n = 5, 29.4%); nausea (n = 2, 11.7%);
blurred vision (n = 2, 11.7%); dizziness (n = 1, 5.8%); diarrhoea (n = 2, 11.7%)
Reboxetine: dry mouth (n = 9, 50.0%); somnolence (n = 4, 22.2%); insomnia (n = 6, 33.3%); tremor (n
= 4, 22.2%); tachycardia (n = 7, 38.8%); increased motor activity (n = 2, 11.1%); nausea (n = 3, 16.6%);
blurred vision (n = 3, 16.6%); dizziness (n = 4, 22.2%); diarrhoea (n = 1, 5.5%); sweating (n = 2, 11.1%)
100% of people in both groups reported adverse effects. Both treatments were similarly tolerated

Notes

Funding: no information provided
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"Patients were randomly assigned (by random tables)" (p. 35)
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Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

"Under double-blind conditions" (p. 35); insufficient information provided
about who was and was not blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided; only self rating scales were used; however, it was not clear who was and was not
blinded in this trial

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 42.9%; only participants who received at least
1 outcome assessment were included in the ITT sample: originally, 35 participants were randomised (citalopram: n = 17; reboxetine: n = 18), 6 participants
abandoned treatment before the first outcome assessment and were excluded from ITT sample (n = 29) that was used for statistical analyses; although
reasons for missing outcome data were partly likely to be related to true outcome, missing outcome data were balanced in number across interventions
with similar reasons for missing data across groups; LOCF was used to replace
missing values for statistical analyses (p. 35)

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

No significant differences were found in the baseline demographic or clinical
characteristics between groups; participants who had previously used psychotropic/analgesic drugs were similarly distributed in the 2 groups

Eberhard 1988
Methods

Randomised, parallel-group, double-blind, fixed-dose trial

Participants

n(randomised/ITT) = 70
Diagnosis: idiopathic pain syndrome according to the definition by Williams 1982 (comparable to psychogenic pain disorder of the DSM-III-TR)
Inclusion criteria: no further inclusion criteria
Exclusion criteria: severe somatic disease, MDD (DSM-III-TR), other psychiatric illnesses, clinically relevant contraindications towards the use of antidepressive agents, antidepressive treatment for the previous 3 months, intake of other CNS active drug, abuse of drugs
Age: mean (± SD) 50.29 ± 12.60 years, range 21-73 years; sex: 72.9% women; mean (± SD) length of time
since diagnosis of a somatoform disorder: 60.0 ± 67.11 months; country: Sweden; setting: outpatient

Interventions

Maprotiline (n = 30; TCA; mean dose = 100 mg/day, max dose = 150 mg/day; 1 tablet twice/day)
Clomipramine (n = 40; TeCA; mean dose = 97.2 mg/day, max dose = 150 mg/day; 1 tablet twice/day)
Treatment duration: 42 days

Outcomes

Primary outcomes:
2 VAS on pain and on bodily discomfort (Johansson 1982) (self rating): week 2, 6, month 3, 6, 12
Secondary outcomes:
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Depressive SCL (clinician-rated): baseline, week 6, month 3, 6, 12
4 VAS (Johansson 1982)on sadness, inner tension, concentration difficulties, memory disturbances
(self rated): week 2, 6, month 3, 6, 12
Global Assessment of degree of disease and improvement (clinician-rated): baseline, week 6, month 3,
6, 12
Side effect checklist: baseline, week 6
Spontaneously reported side effects: baseline, week 1, 2, 4, 6
All-cause drop-outs: n = 5 (maprotiline), n = 13 (clomipramine)
Drop-outs due to adverse effects: n = 1 (maprotiline), n = 8 (clomipramine)
Reported drug-related adverse effects:
Maprotiline: tremor (n = 3, 10.0%), tachycardia (n = 3, 10.0%), headache (n = 1, 3.3%), dry mouth (n = 7,
60.0%), sweating (n = 7, 23.3%), micturition disturbances (n = 4, 13.3%), constipation (n = 5, 16.7%), asthenia (n = 2, 6.7%), dizziness (n = 2, 6.7%), orthosatism (n = 4, 13.3%), sedation (n = 1, 3.3%)
Clomipramine: tremor (n = 12, 30.0%), tachycardia (n = 2, 5.0%), headache (n = 2, 5.0%), dry mouth (n
= 20, 50.0%), sweating (n = 12, 30.0%), micturition disturbances (n = 4, 10.0%), constipation (n = 10,
25.0%), asthenia (n = 7, 17.5%), dizziness (n = 2, 5.0%), orthosatism (n = 3, 7.5%), sedation (n = 1, 2.5%),
vertigo (n = 4, 10%), gastritis (n = 1, 2.5%)
No information about the total rate of participants with drug-related adverse events was provided or if
both treatment groups differed in the number of adverse effects
Notes

Funding: medication in both study groups was provided by the Ciba-Geigy AG
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomized, double-blind multicenter study" (p. 27); no information provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Randomized, double-blind multicenter study" (p. 27); "Both drugs were given
in 25-mg tablets of identical shape, taste, and color" (p. 29)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 25.7%; reasons for missing outcome data were
partly likely to be related to true outcome. Furthermore, missing outcome
data were not balanced in number across interventions. More participants
dropped out of the clomipramine than of the maprotiline group because of adverse effects; missing values were not replaced, statistical analyses were based
only on the sample of participants who complied with the protocol; "patients
did not complete at least 2 weeks of treatment […] were not included in the ef-
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ficacy analysis" (p. 32). However, it was not clear how many participants were
excluded for this reason
Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

Clients who were recruited in a pain clinic or in a psychiatric clinic were compared with the rest of the participants who were recruited from general practitioner practices "with regard to sex, age, duration of illness, and to treatment outcome and no special trends were found" (p. 27). "The two treatment
groups were compared as concerns age, sex, and duration of symptoms. No
significant differences emerged" (p. 28)

Han 2008a
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised) = 95; n(ITT) = 77
Diagnosis: undifferentiated somatoform disorder (DSM-IV)
Inclusion criteria: aged ≥ 18 years; somatic symptoms almost every day for ≥ 6 months, not taking any
active prescription medications to control somatic symptoms (non-prescription medications, e.g.
paracetamol (acetaminophen) 2 g/day or ibuprofen 1.2 g/day were allowed), women of reproductive
age had to agree to use adequate contraception
Exclusion criteria: history of (or current, or both) psychotic disorders (such as schizophrenia, schizoaffective disorder, and bipolar disorder); current DSM Axis I disorders that could possibly account for
the somatic symptoms (e.g. MDD, anxiety disorders, factitious disorder, malingering or another somatoform disorder such as somatisation disorder), substance abuse or dependence in the previous 12
months, history of hypersensitivity to venlafaxine or mirtazapine, people currently treated with any
psychotropic medication; participation in any clinical trials in the previous 30 days; people involved in
workers' compensation, disability or related litigation, breast-feeding or pregnant women
Age: mean (± SD) 45.20 ± 12.59 years, range ns; sex: 61.1% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 32.5 ± 22.5 months; country: South Korea; setting: no information provided, but outpatient setting was assumed due to affiliations of study authors

Interventions

Mirtazapine (n = 50; NaSSA; mean dose = 31.70 mg/day, max dose = 60 mg/day; no information regarding mode/frequency of administration provided)
Venlafaxine (n = 45; SNRI; mean dose = 105.50 mg/day, max dose = 225 mg/day; no information regarding mode/frequency of administration provided)
Treatment duration: 84 days

Outcomes

Primary outcome:
PHQ-15 (self rated): baseline, week 1, 2, 4, 8, 12
Secondary outcomes:
Beck Depression Inventory (self rated): baseline, week 1, 2, 4, 8, 12
12-item General Health Questionnaire (self rated): baseline, week 1, 2, 4, 8, 12
Treatment Emergent Events-General Inquiry: baseline, week 1, 2, 4, 8, 12
All-cause drop-outs: n = 11 (mirtazapine), n = 13 (venlafaxine)
Drop-outs due to adverse effects: n = 3 (mirtazapine), n = 4 (venlafaxine)
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Reported drug-related adverse effects:
Mirtazapine: nausea (n = 2, 4.0%), vomiting (n = 1, 2.0%), somnolence (n = 4, 8.0%), dry mouth (n = 5,
10.0%), anorexia (n = 1, 2.0%), yawning (n = 3, 6.0%), sweating (n = 2, 4.0%), dizziness (n = 3, 6.0%),
headache (n = 1, 2.0%)
Venlafaxine: nausea (n = 4, 8.9%), vomiting (n = 2, 4.4%), somnolence (n = 1, 2.2%), dry mouth (n = 6,
13.3%), anorexia (n = 2, 4.4%), sweating (n = 1, 2.2%), insomnia (n = 2, 4.4%), dizziness (n = 2, 4.4%),
headache (n = 1, 2.2%)
Both treatments were well tolerated. No information about the total rate of participants with drug-related adverse events was provided
Notes

Funding: Dr Han: research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013E00033), Korea University Neuropsychiatric Alumni Grant, member of speaker's bureaux of GlaxoSmithKline Korea, Janssen Pharmaceuticals Korea, and Otsuka Korea
Dr. Pae: received research grants from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea,
Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka
Korea, Wyeth Korea, and the Korean Institute of Science and Technology Evaluation and Planning; received honoraria from/is on the speaker's bureaux of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and
Speciality Inc. And Otsuka Korea
Dr Patkar: consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the
speaker's bureaux of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; received research
support from the National Institutes of Health, Astra Zeneca, Bristol Myers Squibb, Forest Laboratories
Inc., GlaxoSmithKline, Janssen, McNeil Consumer and Speciality Inc., Organon, Jazz Pharmaceuticals
and Pfizer
Dr Masand: consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest
Laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Organon,
Pfizer Inc., Targacept Inc., and Wyeth Pharmaceuticals; is on speaker's bureaux of Astra Zeneca, Bristol Myers Squibb Company, Forest Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer Inc., and Wyeth Pharmaceuticals; received research support from Astra Zeneca, Bristol Myers Squibb
Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical Inc., Janssen Pharmaceuticals, and Wyeth Pharmaceuticals
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"Computer-generated randomization code" (p. 253)

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

"Observer bias should be considered" (p. 259); because the study report included no information about blinding procedures it is assumed that neither
participants nor study personnel were blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

"Observer bias should be considered" (p. 259); because the study report includes no information about blinding procedures it is assumed that outcome
assessment was not blinded; only self report scales were used; however, it is
not clear if participants were blinded to the treatment
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Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 25.2%; only participants who received at least
1 dose of a study medication and had at least 1 post-baseline visit assessment
were included in the ITT sample: originally, 95 participants were randomised
(citalopram: n = 17; reboxetine: n = 18), 6 participants abandoned treatment
before the first outcome assessment and were excluded from ITT sample (n =
7) that was used for statistical analyses; although reasons for missing outcome
data were partly likely to be related to true outcome, missing outcome data
were balanced in number across intervention with similar reasons for missing
data across groups; LOCF was applied for replacing missing values (p. 254)

Selective reporting (reporting bias)

High risk

SD for outcomes at post-assessment were not provided. No protocol available;
generally accepted outcomes were used

Other bias

Low risk

No significant differences were found in the baseline demographic or clinical
characteristics between groups

Han 2008b
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 45
Diagnosis: undifferentiated somatoform disorder (DSM-IV)
Inclusion criteria: aged ≥ 18 years, somatic symptoms almost every day for ≥ 6 months, not taking any
active prescription medications to control their somatic symptoms (non-prescription medications, e.g.
paracetamol (acetaminophen) 2 g/day or ibuprofen 1.2 g/day were allowed), women of reproductive
age had to agree to use adequate contraception
Exclusion criteria: history of (or current, or both) psychotic disorders (such as schizophrenia, schizoaffective disorder, and bipolar disorder); current DSM Axis I disorders that could possibly account for
the somatic symptoms (e.g. MDD, anxiety disorders, factitious disorder, malingering or another somatoform disorder such as somatisation disorder); substance abuse or dependence in the previous 12
months; history of hypersensitivity to venlafaxine or mirtazapine; people currently treated with any
psychotropic medication; participation in any clinical trials in the previous 30 days; people involved in
workers' compensation, disability, or related litigation; breast-feeding or pregnant women
Age: mean (± SD) 37.64 ± 11.90 years, range ns; sex: 57.8% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 38.9 ± 27.5 months; country: South Korea; setting: no information provided, but outpatient setting was assumed due to affiliations of study authors

Interventions

Fluoxetine (n = 28; SSRI; mean dose = 36.10 mg/day, max dose = 60 mg/day; no information regarding
mode/frequency of administration provided)
Sertraline (n = 17; SSRI; mean dose = 167.70 mg/day, max dose = 350 mg/day; no information regarding
mode/frequency of administration provided)
Treatment duration: 84 days

Outcomes

Primary outcome:
PHQ-15 (self rated): baseline, week 1, 2, 4, 8, 12
Secondary outcomes:
Beck Depression Inventory (self rated): baseline, week 1, 2, 4, 8, 12
12-item General Health Questionnaire (self rated): baseline, week 1, 2, 4, 8, 12
Treatment Emergent Events-General Inquiry: baseline, week 1, 2, 4, 8, 12
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All-cause drop-outs: n = 8 (fluoxetine), n = 5 (sertraline)
Drop-outs due to adverse effects: n = 0 (fluoxetine), n = 0 (sertraline)
Reported drug-related adverse effects:
Fluoxetine: nausea (n = 5, 17.9%), vomiting (n = 2, 7.1%), somnolence (n = 1, 3.6%), dry mouth (n =
3, 10.7%), anorexia (n = 3, 10.7%), sweating (n = 1, 3.6%), insomnia (n = 2, 7.1%), constipation (n = 1,
3.6%), dizziness (n = 1, 3.6%)
Sertraline: nausea (n = 3, 17.6%), vomiting (n = 1, 5.9%), somnolence (n = 3, 17.6%), dry mouth (n = 2,
11.8%), anorexia (n = 1, 5.9%), constipation (n = 2, 11.8%), dizziness (n = 2, 11.8%)
Both treatments were well tolerated. No information about the total rate of participants with drug-related adverse events was provided
Notes

Funding: Dr Han: research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013E00033), Korea University Neuropsychiatric Alumni Grant
Dr. Pae: received research grants from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea,
Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka
Korea, Wyeth Korea, and the Korean Institute of Science and Technology Evaluation and Planning; received honoraria from/is on the speaker's bureaux of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and
Speciality Inc. And Otsuka Korea
Dr Patkar: consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the
speaker's bureaux of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; received research
support from the National Institutes of Health, Astra Zeneca, Bristol Myers Squibb, Forest Laboratories
Inc., GlaxoSmithKline, Janssen, McNeil Consumer and Speciality Inc., Organon, Jazz Pharmaceuticals,
and Pfizer
Dr Masand: consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest
Laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Organon,
Pfizer Inc., Targacept Inc. and Wyeth Pharmaceuticals; is on speaker's bureaux of Astra Zeneca, Bristol
Myers Squibb Company, Forest Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer
Inc., and Wyeth Pharmaceuticals; received research support from Astra Zeneca, Bristol Myers Squibb
Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical Inc., Janssen Pharmaceuticals, and Wyeth Pharmaceuticals
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"Computer-generated randomization code" (p. 438)

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

"Observer bias should be considered" (p. 442); because the study report included no information about blinding procedures it was assumed that neither
participants nor study personnel were blinded

Blinding of outcome assessment (detection bias)
All outcomes

High risk

"Observer bias should be considered" (p. 259); because the study report included no information about blinding procedures it is assumed that outcome
assessment was not blinded; only self report scales were used; however, it was
not clear if participants were blinded to the treatment
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Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 28.9%; only participants who received at least
1 dose of a study medication and had at least 1 post-baseline visit assessment
were included in the ITT sample: originally, 45 participants were randomised
(fluoxetine: n = 28; sertraline: n = 17), because all participants returned for at
least 1 post-baseline follow-up visit in both treatment groups yielding an ITT
sample of n = 45; although reasons for missing outcome data were partly likely to be related to true outcome, missing outcome data were balanced in number across intervention with similar reasons for missing data across groups;
LOCF was applied for replacing missing values (p. 439)

Selective reporting (reporting bias)

High risk

SD for outcomes at post-assessment were not provided; no protocol available;
generally accepted outcomes were used

Other bias

Low risk

No significant differences were found in the baseline demographic or clinical
characteristics between groups

Huang 2012
Methods

Randomised, parallel-group, fixed-dose trial

Participants

n(randomised/ITT) = 60
Diagnosis: somatisation disorder (F45.0), undifferentiated somatoform disorder (F45.1), SAD (F45.3)
(ICD-10)
Inclusion criteria: duration of the disorder > 6 months, somatic subscore of HARS ≥ 12 and ≥ 5 points
higher than the Psychic Subscore of the HARS, the SOMS-7 score had to be ≥ 12
Exclusion criteria: 17-item HDRS score ≥ 17, had other mental disorders (e.g. panic disorder, MDD, or
substance abuse), exhibited a severe and unstable physical illness (e.g. epilepsy, severe renal or hepatic impairment, or cancer), pregnant or breast-feeding women
Age: mean (± SD) 44.40 ± 9.75 years, range ns; sex: 65.0% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 30.9 ± 18.1 months; country: China; setting: no information provided,
but outpatient setting was assumed due to affiliations of study authors

Interventions

Citalopram + paliperidone (n = 30; SSRI + AP; mean dose citalopram = 20 mg/day, mean dose paliperidone = 3 mg/day, max dose citalopram = 20 mg/day, max dose paliperidone = 3 mg/day; no mode/frequency of administration provided)
Citalopram (n = 30; SSRI; mean dose = 20 mg/day, max dose = 20 mg/day; no information regarding
mode/frequency of administration provided)
Treatment duration: 42 days

Outcomes

Primary outcome:
SOMS-7 (self rated): baseline, week 2, 4, 6
Secondary outcomes:
HARS - Total Score, Somatisation Score (clinician-rated): baseline, week 2, 4, 6
HDRS (clinician-rated): baseline, week 2, 4, 6
Response rate (50% reduction in SOMS-7 score; SOMS-7 score < 12): week 6
Treatment Emergent Symptom Scale: baseline, week 2, 4, 6
All-cause drop-outs: n = 9 (citalopram + paliperidone), n = 9 (citalopram)
Drop-outs due to adverse effects: n = 3 (citalopram), n = 5 (citalopram + paliperidone)
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Reported drug-related adverse effects:
Citalopram + paliperidone: drowsiness (n = 2, 6.7%), dry mouth (n = 6, 20.0%), somnolence (n = 4,
13.3%), constipation (n = 3, 10.0%), nasal obstruction (n = 1, 3.3%), sweating (n = 2, 3.3%), nausea or
vomiting (n = 2, 6.7%), dizziness (n = 3, 10.0%), headache (n = 2, 6.7%), elevated prolactin (n = 1, 3.3%)
Citalopram: drowsiness (n = 1, 3.3%), dry mouth (n = 4, 13.3%), somnolence (n = 1, 3.3%), constipation
(n = 1, 3.3%), sweating (n = 1, 3.3%), nausea or vomiting (n = 2, 6.7%), dizziness (n = 1, 3.3%), headache
(n = 1, 3.3%)
86.7% of the citalopram + paliperidone group and 40.0% of the citalopram group experienced adverse
effects. Both groups did not differ statistically significant regarding the adverse effects
Notes

Funding: no information provided. Authors state that there are no conflicts of interest
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"The allocation of each medication was on the basis of a computer-generated
randomization code" (p. 152)

Allocation concealment
(selection bias)

Low risk

"Each code was sealed in an envelope saved in the Clinical Research Center.
In addition, another researcher who did not know the code helped with the
process. Only when a patient fulfilled the inclusion criteria and was enrolled in
the study was the corresponding coded envelope opened and the code of the
group given" (p. 152)

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

"This is not a double-blind study, but only a randomized study. But in order to
ensure the reliability and validity of research results, we carried out the study
in accordance with the requirements of a double-blind study as much as possible. [...] Therefore, the patients were completely randomly assigned to receive citalopram plus paliperidone treatment or receive citalopram treatment
alone." "Only when a patient met the inclusion criteria and was enrolled in
the study was the corresponding coded envelope opened and the code of the
group given." (p. 152); no means of blinding participants/study personnel after
randomisation and opening the envelope were described; it was assumed that
according to the statement of the trial authors the current trial was not double-blinded and that, therefore, there was a high risk regarding blinding participants/study personnel after randomisation

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

"The rater was blinded to the kind of treatment patients received" (p. 151);
"The data management personnel and statistical analyst participating this
study were not aware of the kind of treatment patients received" (p. 153)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 30.0%; although reasons for missing outcome
data were partly likely to be related to true outcome, missing outcome data
were balanced in number across intervention with similar reasons for missing
data across groups; missing values were replaced by LOCF (p. 153)

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

"No statistically significant difference was observed between the two groups
at the baseline" (p. 153); "We chose a moderate dose of 20 mg of citalopram as
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the FDA [Food and Drug Administration] and European Medicines Agency have
recently advised against using 40 mg of citalopram because of concerns of
cardiotoxicity (08/24/2011 - Drug Safety Communication3 - FDA http://www.fda.gov/Safety/
MedWatch/SafetyInformation/SafetyAlertsforhumanmedicalproducts/ucm269481.htm)" (p.157)

Jiang 2005
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 68
Diagnosis:somatoform disorder (CCMD-III)
Inclusion criteria: SCL-90 Total Score ≥ 3, CGI - Severity Scale ≥ 3, aged 18-58 years, time since diagnosis
of somatoform disorder > 6 months
Exclusion criteria: drug dependence, severe psychosis, paranoia, organic brain disease, physical illness,
pregnant or breastfeeding women, epilepsy
Age: mean (± SD) 37.04 ± 10.40 years, range ns; sex: 67.7% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 168.49 ± 97.92 months; country: China; setting: inpatient

Interventions

Venlafaxine (n = 36; SNRI; mean dose = 105.0 mg/day, max dose = 200 mg/day; no information regarding mode/frequency of administration provided)
Amitriptyline (n = 32; TCA; mean dose = 168.0 mg/day, max dose = 200 mg/day; no information regarding mode/frequency of administration provided)
Treatment duration: 42 days

Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
CGI - Severity Scale (clinician-rated): baseline, week 1, 2, 4, 6
SCL-90 (self rated): baseline, week 1, 2, 4, 6
Effectiveness rate (no further information about this measure provided): week 6
Treatment Emergent Symptom Scale: week 1, 2, 6
All-cause drop-outs: n = 0 (venlafaxine), n = 0 (amitriptyline)
Drop-outs due to adverse effects: n = 0 (venlafaxine), n = 0 (amitriptyline)
Reported drug-related adverse effects:
Venlafaxine: nausea (n = 20; 55.6%), dizziness (n = 10, 27.8%), anxiety (n = 7, 19.4%), insomnia (n = 5,
13.9%)
Amitriptyline: dry mouth (n = 21, 65.6%), constipation (n = 17, 53.1%), blurred vision (n = 14, 43.8%),
dizziness (n = 12, 37.5%), tremor (n = 9, 28.1%), sweating (n = 8, 25.0%), micturition disturbances (n = 1,
3.1%), abnormalities on electrocardiograph (n = 2, 5.6%).
In the amitriptyline group, statistically significantly more participants experienced adverse effects
compared with the venlafaxine group in treatment weeks 1, 2, and 6. No information about the total
rate of participants with drug-related adverse events was provided

Notes

Funding: no information provided
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Underlined outcome measures and time points were considered in the meta-analytical part of the review
Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Patients [...] were randomly assigned to receive venlafaxine or amitriptyline" (p. 1177); no information provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants/study personnel provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

There were no significant differences in gender, age, and duration of symptoms between groups (p. 1177)

Ju 2003
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 68
Diagnosis: somatisation disorder (CCMD-III)
Inclusion criteria: inpatient of Wutaishan Hospital of Yangzhou (Jiangsu, China) between May 2001 and
January 2002; HARS ≥ 14
Exclusion criteria: psychotic symptoms, severe brain injury, substance abuse, pregnant and breast-feeding women
Age: mean (± SD) 41.75 ± 9.57 years, range ns; sex: 77.9% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 154.8 ± 82.3 months; country: China; setting: inpatient

Interventions

Venlafaxine (n = 34; SNRI; mean dose: ns, max dose = 150 mg/day; no information regarding mode/frequency of administration provided)
Doxepin (n = 34; TCA; mean dose: ns, max dose = 150 mg/day; no information regarding mode/frequency of administration provided)
Treatment duration: 42 days
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Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
HDRS - Total Score, responder rate (clinician-rated): baseline, week 1, 2, 4, 6
Treatment Emergent Symptom Scale: week 1, 2, 4, 6
All-cause drop-outs: n = 0 (venlafaxine), n = 0 (doxepin)
Drop-outs due to adverse effects: n = 0 (venlafaxine), n = 0 (doxepin)
Reported drug-related adverse effects:
Venlafaxine: headache (n = 5, 14.7%), dry mouth (n = 5, 14.7%), insomnia (n = 3, 8.8%)
Doxepin: fatigue, headache, dry mouth, constipation (no information about the number of participants
with each adverse effect provided), micturition disturbances (n = 1, 2.9%), irregularities on electrocardiograph (n = 3, 8.8%)
In the doxepin group, statistically significantly more participants experienced adverse effects compared with the venlafaxine group. 29.4% of the venlafaxine group and 82.4% of the doxepin group experienced adverse effects

Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomly assigned to venlafaxine group and doxepin group" (p. 590); no information provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants/study personnel provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Selective reporting (reporting bias)

High risk

No protocol available; only 2 outcomes (depression, adverse effects) were assessed, important common primary outcomes (such as severity of MUPS) were
neglected
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Other bias

Low risk

No differences were found between groups regarding age and symptom duration at baseline (p. 590)

Kong 2004
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 60
Diagnosis:somatoform disorder (CCMD-III)
Inclusion criteria: aged 24-71 years
Exclusion criteria: somatic disorder that explains somatoform symptoms, people who used or stopped
using a specific medication (anti-anxiety drugs, antidepressants, AP medication) for ≥ 2 weeks before
treatment started
Age: mean (± SD) 48.50 ± 10.92 years, range 23-70 years; sex: 48.3% women; mean length of time since diagnosis of a somatoform disorder: ns; country: China; setting: ns

Interventions

Paroxetine (n = 15; SNRI; mean dose: ns, max dose = 50 mg/day; twice/day; no information regarding
mode of administration provided)
Amitriptyline (n = 15; TCA; mean dose: ns, max dose = 150 mg/day; 3 times/day; no information regarding mode administration provided)
Open paroxetine (n = 30; no information regarding mean dose, max dose, and frequency/mode of administration provided)
Treatment duration: 42 days

Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
HDRS - Total Score; anxiety, de-realisation, retardation, weight, sleep disturbance score; responder rate
(clinician-rated): baseline, week 1, 2, 4, 6
HARS (clinician-rated): baseline, week 1, 2, 4, 6
CGI - Severity Scale (clinician-rated): baseline, week 1, 2, 4, 6
Treatment Emergent Symptom Scale: baseline, week 1, 2, 4, 6
All-cause drop-outs: n = 0 (paroxetine), n = 0 (amitriptyline), n = 0 (open paroxetine)
Drop-outs due to adverse effects: n = 0 (paroxetine), n = 0 (amitriptyline), n = 0 (open paroxetine)
Reported drug-related adverse effects:
Paroxetine: dry mouth (n = 4, 26.6%), constipation (n = 2, 13.3%), micturition disturbances (n = 2,
13.3%), headache + nausea (n = 3, 20.0%), blurred vision (n = 2, 13.3%), headache (n = 4, 26.6%), insomnia (n = 1, 6.6%), increased blood pressure (n = 1, 6.6%), increased motor activity (n = 3, 20.0%)
Amitriptyline: dry mouth (n = 6, 40.0%), constipation (n = 5, 33.3%), headache + nausea (n = 4, 26.6%),
blurred vision (n = 7, 46.6%), headache (n = 5, 33.3%), insomnia (n = 4, 26.6%), hypersomnia (n = 7,
46.6%), increased blood pressure (n = 4, 26.6%)
Open paroxetine: dry mouth (n = 8, 26.6%), constipation (n = 3, 10.0%), micturition disturbances (n = 1,
3.3%), headache + nausea (n = 5, 16.6%), blurred vision (n = 3, 10.0%), headache (n = 5, 16.6%), insomnia (n = 4, 13.3%), hypersomnia (n = 2, 6.6%), increased blood pressure (n = 3, 10.0%), increased motor
activity (n = 4, 13.3%)
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No information about the total rate of participants with drug-related adverse events was provided or if
both treatment groups differed in the number of adverse effects
Notes

Funding: medication in all 3 study groups was provided by the Zhejiang Huahai Pharmaceutical Co., Ltd
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Patients […] were randomly assigned" (p. 733); no information provided
about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

High risk

Differences in the frequency of which medication was administered between
the groups are described (p. 733), therefore, it is assumed that no blinding of
participants/study personnel was given

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals.

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however, important common primary outcomes (such as severity of MUPS) were neglected

Other bias

Low risk

In this multiple-intervention trial data were presented separately for each of
the groups to which participants were randomised

Kroenke 2006
Methods

Randomised, placebo-controlled, double-blind, flexible-dose trial

Participants

n(randomised) = 117, n(ITT) = 112
Diagnosis: MSD (≥ 3 medically unexplained symptoms with a frequency or severity beyond that expected for a known medical condition, with > 1 of these symptoms present for at least 6 months); symptoms were defined as medically unexplained when they were, in the opinion of the evaluating physician, 1. idiopathic, and 2. a symptom characteristic of a known medical disorder but reported at a frequency or severity considered out of proportion to that expected for the known medical condition; the
MSD corresponded to the criteria of an undifferentiated somatoform disorder according to the DSM-IV
or ICD-10)
Inclusion criteria: ≥ 18 years; DSM-IV diagnostic criteria for MDD, GAD, SAD, or a combination were fulfilled; met clinical criteria for MSD measured by the PHQ-15; HDRS-17 Total Score ≥ 14 and a HARS Total Score of ≥ 12; ≤ 25% decrease in the HDRS-17 Total Score or HARS Total Score from screening to randomisation

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

Cochrane

Library
Kroenke 2006

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(Continued)

Exclusion criteria: history of inability to tolerate/failure to respond to ≥ 2 antidepressants of sufficient
dose/duration of administration for the treatment of symptoms present in the current illness (depressive or anxiety); current/past history of mania, bipolar disorder, schizophrenia, or other psychotic disorder; history of seizure disorder other than childhood febrile seizure; evidence of serious or clinically
unstable medical illness or psychiatric condition; previous intolerance or hypersensitivity to (extended-release) venlafaxine; use of any non-psychopharmacological drug with psychotropic effects within
7 days of study randomisation, an MAOI of fluoxetine within 30 days of screening, or electroconvulsive
therapy within 3 months of screening; chronic use of analgesics containing opiates for > 6 months or
for ≥ consecutive weeks prior screening; known of suspected alcohol or drug abuse within 6 months of
screening; use of triptans, psychoactive herbal medications, or any other psychoactive drugs; or a positive urine drug test at screening; pregnant or breastfeeding women or women who expected becoming
pregnant during the course of study or were sexually active and were not using contraception
Age b: mean (± SD) 47.00 ± 12.06 years, range ns; sex b: 80.4% women; mean length of time since diagnosis of a somatoform disorder b: ns; country: USA; setting: outpatient
Interventions

Venlafaxine (n = 55b; SNRI; mean dose = 177 mg/day, max dose = 225 mg/day; 1 tablet once/day)
Placebo (n = 57b)
Treatment duration: 84 days

Outcomes

Primary outcome:
PHQ-15 - Total Score, responder rate (PHQ-15 score < 10) (self rated): baseline, week 4, 8, 12
Secondary outcomes:
HDRS-17 (clinician-rated): baseline, week 2, 4, 8, 12
HARS (clinician-rated): baseline, week 2, 4, 8, 12
CGI - Severity Scale (clinician-rated): baseline, week 2, 4, 8, 12
CGI - Improvement Scale (clinician-rated): week 2, 4, 8, 12
McGill Quality of Life Questionnaire Physical Symptoms Scale (self rated): baseline, week 12
Medical Outcomes Study Short-Form 36-Item Questionnaire - physical health, mental health, bodily
pain (self rated): baseline, week 12
Medical Outcomes Study Concentration Scale (self rated): baseline, week 12
Adverse effects reported by participants: baseline, week 1, 2, 4, 8, 12, post-taper
All-cause drop-outs b: n = 21 (venlafaxine extended release), n = 22 (placebo)
Drop-outs due to adverse effects b: n = 4 (venlafaxine extended release), n = 10 (placebo)
Reported drug-related adverse effects b:
Venlafaxine: nausea (n = 16, 29.1%), headache (n = 13, 23.6%), fatigue (n = 8, 14.5%), dizziness (n =
6, 10.9%), constipation (n = 6, 10.9%), tremor (n = 6, 10.9%), back pain (n = 5, 9.1%), contusion (n =
4, 7.3%), decreased appetite (n = 3, 5.5%), hypoaesthesia (n = 3, 5.5%), upper abdominal pain (n = 3,
5.5%), yawning (n = 3, 5.5%), nasopharyngitis (n = 2, 3.6%), migraine (n = 2, 3.6%), urinary tract infection (n = 2, 3.6%)
Placebo: nausea (n = 9, 15.8%), headache (n = 7, 12.3%), fatigue (n = 1, 1.8%), dizziness (n = 3, 5.3%),
constipation (n = 3, 5.3%), back pain (n = 1, 1.8%), decreased appetite (n = 1, 1.8%), nasopharyngitis (n
= 1, 1.8%), migraine (n = 1, 1.8%), urinary tract infection (n = 1, 1.8%)
No information about the total rate of participants with drug-related adverse events was provided.
There was a somewhat higher incidence of adverse effects in the venlafaxine compared with placebo

Notes

Funding: Wyeth Research, Collegeville, PA. Drs. Benattia and Graepel and Mr. Musgnung are employees
of Wyeth; Dr. Kroenke has received grant/research support from Wyeth, Eli Lilly, and Pfizer and has received honoraria from Wyeth, Pfizer, Eli Lilly, and Astra Zeneca. Dr. Messina has received grant/research
support from Vista Medical Research Inc. Dr. Graepel is a major stock shareholder of Wyeth.
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Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review
Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomized, double-blind, placebo-controlled study" (p. 74); no information
provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

"Randomized, double-blind, placebo-controlled study" (p. 74); insufficient information provided about who was and was not blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 41.0%; only participants who received at least
1 post-baseline efficacy evaluation were included in the ITT sample: originally, 117 participants were randomised (information about sample sizes of treatment and control group are missing), 5 participants abandoned treatment before the first outcome assessment and were excluded from ITT sample (n =
112) that was used for statistical analyses; although reasons for missing outcome data were partly likely to be related to true outcome, missing outcome
data were balanced in number across intervention with similar reasons for
missing data across groups; LOCF was applied for replacing missing values (p.
75)

Selective reporting (reporting bias)

High risk

SD of post-assessment not provided; baseline values were not reported for all
outcomes for which baseline-to-endpoint changes were reported; no protocol
available; generally accepted outcomes were used

Other bias

Low risk

"The proportion of patients in each group who took at least 1 concomitant
medication was almost identical" (p. 74); "Patients who could not tolerate at
least 75mg/d at any time during the study were withdrawn from the study" (p.
74); "Baseline characteristics were similar between groups" (p. 75); used dose
range in the current study was "within the dose range recommended for venlafaxine ER's [extended release] U.S. Food and Drug Administration (FDA-) approved indications for MDD, GAD, and SAD" (p. 78)

Li 2006
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 58
Diagnosis: somatoform disorder (CCMD-III)
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Inclusion criteria: SCL-90 Somatisation Subscale ≥ 3; HDRS Total Score ≥ 20; if participants also had other mental problems, somatic complaints had to appear before them; somatoform symptoms could not
be explained by a somatic disorder
Exclusion criteria: ns
Age: mean (± SD) 41.73 ± 12.34 years, range 20-68 years; sex: 60.3% women; mean (± SD) length of time
since diagnosis of a somatoform disorder: 84.60 ± 59.2 months; country: China; setting: no information
provided, but inpatient setting was assumed due to affiliations of study authors
Interventions

Paroxetine + quetiapine (n = 30; SSRI + AP; mean dose paroxetine = 26.7 mg/day, mean dose quetiapine
= 403.3 mg/day, max dose paroxetine = 40 mg/day, max dose quetiapine = 600 mg/day; no information
about mode/frequency of administration provided)
Paroxetine (n = 28; SSRI; mean dose = 27.30 mg/day, max dose = 40 mg/day; no information about
mode/frequency of administration provided)
Treatment duration: 56 days

Outcomes

Primary outcome:
SCL-90 - Somatisation Subscore (self rated): baseline, week 2, 8
Secondary outcomes:
SCL-90 - Depression Subscore, Anxiety Subscore (self rated): baseline, week 2, 8
HDRS (clinician-rated) - Total Score, responder rate: baseline, week 2, 8
Treatment Emergent Symptom Scale: no information about time points of measurement provided
Drop-outs due to adverse effects: n = 0 (paroxetine + quetiapine), n = 0 (paroxetine)
Reported drug-related adverse effects: n = 0 (paroxetine + quetiapine), n = 2 (paroxetine)
Reported drug-related adverse effects:
Paroxetine + quetiapine: fatigue (26.7%), nausea (23.3%), dry mouth (16.7%)
Paroxetine: nausea (26.9%), dizziness (23.1%), dry mouth (19.2%)
No information about the total rate of participants with drug-related adverse events was provided or if
treatment groups differed in the number of adverse effects

Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Participants were randomly assigned to 1 study groups by coin tossing, if it
was the coin's head participants were assigned to paroxetine + quetiapine
group, if it was the coin's tail it was the paroxetine group (p. 598)

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)

Unclear risk

No information about methods of blinding participants/study personnel assessment provided

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Li 2006 (Continued)
All outcomes
Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

There were only 2 drop-outs in the paroxetine group (drop-out rate: 3.4%);
missing values were not replaced; statistical analyses are based only on the
sample of participants who complied with the protocol

Selective reporting (reporting bias)

Unclear risk

No protocol available. Generally accepted outcomes were used

Other bias

Unclear risk

No information is provided

Luo 2009
Methods

Randomised, placebo-controlled, double-blind, fixed-dose trial

Participants

n(randomised/ITT) = 80
Diagnosis: persistent somatoform pain disorder (ICD-10)
Inclusion criteria: aged 18-65 years; pain existed ≥ 6 months
Exclusion criteria: co-exist depressive symptoms occurred prior to pain with HDRS-17 ≥ 17; positive family history of pain disorder or depressive episodes; severe and unstable physical illnesses; use of antidepressants for the treatment of pain or depression; pregnancy
Age: mean (± SD) 40.96 ± 12.69 years, range ns; sex: 57.5% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 21.02 ± 19.02 months; country: China; setting: outpatient

Interventions

Fluoxetine (n = 40; SSRI; mean dose = 20 mg/day, max dose = 10 mg/day; mode of administration:
tablet; no information about frequency of administration provided)
Placebo (n = 40)
Treatment duration: 56 days

Outcomes

Primary outcome:
Medical Outcomes Study Pain Measures (self rated): baseline, week 2, 4, 8
Secondary outcomes:
HDRS-17 (clinician-rated): baseline, week 2, 4, 8
Treatment Emergent Symptom Scale: baseline, week 2, 4, 8
Drop-outs due to adverse effects: it was stated that 2 participants quit the study due to adverse effects.
However, it is not unclear how these adverse effect-related drop-out were distributed between groups
Reported drug-related adverse effects:
Fluoxetine: drowsiness (n = 1, 2.5%), dry mouth (n = 2, 5.0%), constipation (n = 1, 2.5%), sweating (n = 1,
2.5%), nausea or vomiting (n = 10, 25.0%)
Placebo: dry mouth (n = 2, 5.0%), nasal obstruction (n = 1, 2.5%), sweating (n = 1, 2.5%), nausea or vomiting (n = 4, 10.0%), dizziness (n = 1, 2.5%)
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35.0% of the fluoxetine group and 22.5% of the placebo group reported adverse effects. There was no
statistically significant difference between groups regarding the adverse effects
Notes

Funding: Shanghai Science and Technology Committee
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"All patients were randomly allocated to either treatment group or control
group" (p. 1523); no information provided about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Double-blind, placebo-controlled, […] study" (p. 1523); "placebo capsules
[…] having the same color, weight, shape and taste like the fluoxetine capsules" (p. 1523)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Insufficient information was provided for incomplete outcome data; it was
only stated that "intention-to-treat (ITT) analysis was performed and last observation carry forward (LOCF) was used for missing values" (p. 1524), thus it
can be concluded that there were no losses to follow-up; the only information
about drop-outs stated that "2 patients quit the study due to" adverse effects
(p. 1524); however, it is not clear how these 2 patients were distributed among
the fluoxetine and placebo groups

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however,
treatment effects were only reported for the primary outcome and not for
HDRS-17 (depression)

Other bias

Low risk

"No statistically significant difference was observed between the fluoxetine
and placebo group at the baseline" (p. 1523)

Melzer 2009
Methods

Combined randomised, placebo-controlled, parallel-group, double-blind, fixed-dose trial

Participants

n(randomised/ITT) = 182
Diagnosis: somatisation disorder (F45.0), undifferentiated somatoform disorder (F45.1) (ICD-10)
Inclusion criteria: aged ≥ 18 years; symptom duration ≥ 6 months
Exclusion criteria: pregnancy or lactation; known allergies to trial medication; alcohol, drug, or medication abuse; concomitant participation in another clinical trial or < 4 weeks ago; historically known or
clinical indication of: inflammatory or non-inflammatory neurological disease, endocrinological disor-
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ders, inflammatory bowel disease, psychiatric disorders, rheumatic diseases, bronchial asthma, infectious diseases, serious conditions such as cancer/uncontrolled hypertension/heart failure/endocarditis, myocarditis/primary cardiomyopathies or severe cardiac dysrhythmias/severe hepatic diseases/renal insufficiency (creatinine > 3 mg/dL) or anaemia (haemoglobin < 9 g/dL)/severe nutritional disorders
or vitamin deficiency illnesses
Age: mean (± SD) 41.64 ± 14.79 years, range ns; sex: 57.5% women; mean length of time since diagnosis
of a somatoform disorder: ns; nationality: Germany; country: no information provided, but outpatient
setting was assumed due to information about recruitment source
Interventions

Ze 185 4-combination: butterbur root, valerian root, passionflower herb, lemon balm leaf (n = 53; NP;
mean dose Ze 185 4-combination = 330 mg/day, max dose Ze 185 4-combination = 330 mg/day; 1 tablet
3 times/day)
Ze 185 3-combination: root, valerian root, passionflower herb, lemon balm leaf (n = 58; NP; mean dose
Ze 185 3-combination = 330 mg/day, max dose Ze 185 3-combination = 330 mg/day; 1 tablet 3 times/
day)
Placebo (n = 61)
Treatment duration: 14 days

Outcomes

Primary outcome:
Pain diary (self rated): days 1-14
Secondary outcomes:
VAS anxiety (Rickels 1994) (self rated): baseline, day 14
Beck Depression Inventory (self rated): baseline, day 14
CGI - Severity Scale (clinician-rated): baseline, day 14
Participant's rating of treatment efficacy: day 14
Treatment responder (50% improvement on VAS Anxiety or Beck Depression Inventory, self rated): day
14
All-cause drop-outs: n = 4 (Ze 185 4-combination), n = 6 (Ze 185 3-combination), n = 5 (placebo)
Drop-outs due to adverse effects: n = 0 (Ze 185 4-combination), n = 2 (Ze 185 3-combination), n = 1
(placebo)
Reported drug-related adverse effects:
Ze 185 4-combination: vomiting (n = 1, 1.6%), flatulence (n = 1, 1.6%)
Ze 185 3-combination: nausea (n = 2, 3.4%), constipation (n = 1, 1.7%)
Placebo: nausea (n = 1, 1.6%)
3.2% of the Ze 185 4-combination group, 5.2% of the Ze 185 3-combination, and 1.6% of the placebo
group reported adverse effects. The distribution of adverse events did not differ significantly between
groups

Notes

Funding: study medication was supplied by Zeller AG (sponsor). Every investigator received a grant
from the sponsor. The sponsor covered the costs for monitoring and data management (contract research organisation) as well as for the auditing (Chair of Medical Informatics, University of Giessen, Germany)
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review
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Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"The allocation to the respective treatment group was carried out based on a
computer-generated randomization list" (p. 1305); "Stratification was carried
out using the computer program STATXACT" (p. 1305)

Allocation concealment
(selection bias)

Unclear risk

"Patients were assigned a patient number and the corresponding numbered
medication box in the order of their admission into the trial" (p. 1305); insufficient information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Tablets of all three treatment groups were identical in color, odor, and consistency" (p.1304); "The double-blind nature of the trial was guaranteed by adherence to standard procedures and audits" (p. 1305)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 8.2%; "The ITT population included all randomized patients who used treatment at least once and had a postbaseline value
for comparison" (p. 1305), however, it was unclear if and how many participants were not included to the ITT sample for this reason, in Table 2 (p. 1305).
The difference between the sample of randomised participants and the ITT
sample was explained only by justifications such as withdrawal of consent or
adverse events; although reasons for missing outcome data were partly likely
to be related to true outcome, missing outcome data were balanced in number across intervention with similar reasons for missing data across groups;
LOCF was used to replace missing values (p. 1305)

Selective reporting (reporting bias)

High risk

No protocol available; treatment effects are only reported for the secondary
outcomes such as depression and anxiety; important primary outcomes such
as severity of physical symptoms were not assessed

Other bias

Low risk

At baseline, there were no significant differences between groups regarding
demographic or clinical characteristics (p. 1305); "At the end of the trial, 99%
of patients had taken at least 75% of the medication" (p. 1305); in this multiple-intervention trial data were presented separately for each of the groups to
which participants were randomised

Muller 2008
Methods

Randomised, placebo-controlled, double-blind, flexible-dose trial

Participants

n(randomised/ITT) = 51
Diagnosis: MSD (bothersome medically unexplained ≥ 3 symptoms within the past month, together
with a history of ≥ 1 somatoform symptoms for at ≥ 2 years; the MSD corresponded to the criteria of an
undifferentiated somatoform disorder according to the DSM-IV or ICD-10)
Inclusion criteria: ns
Exclusion criteria: people with somatic symptoms that were judged to be secondary to a psychiatric disorder other than MSD, current or past psychotic disorder, significant suicidal risk, any serious unstable
medical illness (as assessed by medical history, physical examination, and standard laboratory investigations), pregnancy or breastfeeding, use of recent or concomitant psychotropics, concurrent cognitive-behavioural therapy
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Age: mean (± SD) 39.64 ± 9.75 years, range 18-65 years; sex: 57.5% women; mean length of time since diagnosis of a somatoform disorder: ns; country: South Africa; setting: no information provided, but outpatient setting was assumed due to information about recruitment source
Interventions

Escitalopram (n = 25; SSRI; mean dose = 14.4 mg/day, max dose = 20 mg/day; no information about
mode/frequency of administration provided)
Placebo (n = 26)
Treatment duration: 84 days

Outcomes

Primary outcomes:
PHQ (self rated): baseline, week 2, 4, 6, 8, 12
PHQ - responder rate (PHQ score < 10) (self rated): week 2, 4, 6, 8, 12
Visual Analogue Pain Rating Scale (Katz 1999) (self rated): baseline, week 4, 8, 12
Secondary outcomes:
CGI - Improvement Scale (clinician-rated): week 2, 4, 6, 8, 12
CGI - Severity Scale (clinician-rated): baseline, week 2, 4, 6, 8, 12
CGI - Severity Scale - remission rate (clinician-rated): week 2, 4, 6, 8, 12
HARS - Total, Psychic, Somatic Score (clinician-rated): baseline, week 4, 8, 12
Montgomery-Åsberg Depression Rating Scale (self rated): baseline, week 4, 8, 12
Scale for the Assessment of Illness Behaviour (self rated): baseline, week 12
Sheehan Disability Scale (self rated): baseline, week 4, 8, 12
All-cause drop-outs: n = 1 (escitalopram), n = 0 (placebo)
Drop-outs due to adverse effects: n = 1 (escitalopram), n = 0 (placebo)
Reported drug-related adverse effects:
Escitalopram:
Week 0-2: headache (n = 11, 44%), nausea (n = 10, 40%), abdominal discomfort (n = 3, 12%), insomnia (n
= 3, 12%), yawning (n = 3, 12%), nasopharyngitis (n = 2, 8%), diarrhoea (n = 2, 8%), tremor/anxiety (n = 2,
8%), drowsiness (n = 2, 8%), dry mouth (n = 2, 8%)
Week 2-12: headache (n = 9, 36%), nasopharyngitis (n = 4, 16%), diarrhoea (n = 3, 12%), nausea (n = 3,
12%), insomnia (n = 3, 12%), urinary tract infection (n = 2, 8%), staphylococcal skin infection (n = 1, 4%)
Placebo:
Week 0-2: headache (n = 7; 27%), nausea (n = 6; 23%), abdominal discomfort (n = 2; 8%), insomnia (n =
1; 4%), yawning (n = 1; 4%), nasopharyngitis (n = 4; 15%), diarrhoea (n = 3; 12%), tremor/anxiety (n = 1;
4%), drowsiness (n = 2; 8%), dry mouth (n = 1; 4%)
Week 2-12: headache (n = 11; 42%), nasopharyngitis (n = 8; 31%), diarrhoea (n = 6; 23%), nausea (n = 5;
19%), staphylococcal skin infection (n = 2; 8%); abdominal discomfort (n = 4; 15%); dizziness (n = 2; 8%)
No information about the total rate of participants with drug-related adverse events was provided or if
both treatment groups differed in the number of adverse effects

Notes

Funding: H. Lundbeck A/S; at the time this study was conducted, Professor Stein, Professor Seedat, and
Dr. Muller were funded by the Medical Research Council of South Africa
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review
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Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"Patients were randomly assigned (via computer-generated randomization
lists)" (p. 44)

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Escitalopram and placebo medication were identical in appearance" (p. 44)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 2.0%; reasons for missing outcome data were
very unlikely to be related to true outcome (there was only 1 participant withdrawn due to adverse events in the escitalopram group); missing outcome data were balanced in number across groups with similar reasons for missing data across groups; LOCF was be used to replace missing values (p. 45); trial authors stated that ITT included "all randomized patients with at least one valid
post-baseline efficacy measure" (p. 45). However, there was no difference in
the number of randomised participants and the ITT sample. Therefore, it was
concluded that all randomised participants had at least 1 valid post-baseline
efficacy measure

Selective reporting (reporting bias)

Low risk

No protocol available; generally accepted outcomes were used and data were
reported for a broad variety of primary and secondary outcomes (self report
and clinician-rated scales)

Other bias

Low risk

"The trial consisted of a 2-week screening phase for medication washout (if required) and for obtaining results of selected laboratory investigations" (p. 44);
"no significant difference existed in the extent of comorbidity across the medication and placebo groups" (p. 45)

Müller 2004
Methods

Randomised, placebo-controlled, double-blind fixed-dose triala

Participants

n(randomised) = 175, n(ITT) = 173
Diagnosis: somatisation disorder (F45.0), undifferentiated somatoform disorder (F45.1), persistent somatoform pain disorder (F45.3) (ICD-10)
Inclusion criteria: aged 18-65 years; baseline HARS - Somatisation Score ≥ 12; baseline HARS - Psychic
Subscore ≥ 5 and < HARS - Somatisation Score; baseline HDRS - Total Score ≤ 12; baseline SOMS-2 score
≥ 4 (men) and ≥ 6 (women); SOMS-7 score 12-30; standardised good clinical practice criteria for study
participation
Exclusion criteria: people exhibiting a decrease in SOMS-7 score of 6 during the placebo run-in phase
("placebo responders"), current diagnoses of major depression, drug and alcohol abuse, epilepsy,
organic mental disorder, any other serious unstable acute or chronic medical condition, current or
anamnestic diagnosis of schizophrenia or schizoaffective disorder, use of psychotropic drugs 4 weeks
before and during the study, concurrent psychotherapy, increased suicidal risk, need for concomitant
treatment with phenprocoumon or cyclosporin (or both)
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Age b: mean (± SD) 47.65 ± 11.35 years, range ns; sex b: 57.5% women; mean length of time since diagnosis of a somatoform disorder: ns; country: Germany; setting: outpatient
Interventions

St. John's wort (n = 87b; NP; mean dose = 600 mg/day, max dose = 600 mg/day; 1 tablet twice/day)
Placebo (n = 86b)
Treatment duration: 42 days

Outcomes

Primary outcomes:
SOMS-7 (self rated): baseline, week 2, 4, 6
SCL-90-R - Somatisation Score (self rated): baseline, week 2, 4, 6
Secondary outcomes:
HARS - Psychic Anxiety Score, Somatisation Score (clinician-rated): baseline, week 2, 4, 6
CGI - Severity Scale (clinician-rated): baseline, week 2, 4, 6
CGI - Improvement Scale (clinician-rated): baseline, week 2, 4, 6
Responder rate (decrease of ≥ 50% of the SOMS-7 and 'very much better'/'much better' rating on the
CGI - Improvement Scale): week 6
Adverse effects were assessed in an open question fashion: week 2, 4, 6
Tolerability was assessed in analogy to the CGI 'therapeutic risks' (1 = no adverse effect, 2 = impairment not significant, 3 = significant impairment, 4 = risks outweighing therapeutic effect): week 6
All-cause drop-outs: n = 5 (St. John's wort), n = 6 (placebo)
Drop-outs due to adverse effects: n = 0 (St. John's wort), n = 0 (placebo)
Reported drug-related adverse effects:
St. John's wort: nightmares (n = 1, 1.1%)
Placebo: no adverse effects
Tolerability and safety of St. John's wort treatment was comparable to that of placebo. 1.1% of the St.
John's wort and 0% of the placebo group reported adverse effects

Notes

Funding: Medical Services, Berlin, Germany (Marcus Mannel); Lichtwer Pharma GmbH, Berlin, Germany
(Harald Murck); data analysis and experimental design, Gauting, Germany (Volker W. Rahlfs); Study
medications were provided by Lichtwer Pharma AG (Berlin, Germany)
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

"Randomized, placebo-controlled […] trial" (p. 539); "Patients [...] were randomly assigned in a 1:1 ratio to receive either SJW [St. John's wort] or placebo" (p. 539); "Computer-aided randomization and preparation of a coding list
(Rancode; Wiedey, Konstanz, Germany) was performed in blocks of six" (p.
539)

Allocation concealment
(selection bias)

Low risk

"Randomization […] was performed […] by the independent Quality Assurance Unit of the sponsor" (p. 539); "Blistered study medication and medication containers were labeled sequentially according to the coding list by the
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manufacturing department of the sponsor and provided to the investigators in
blocks of six" (p. 539)
Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Double-blind trial" (p. 539); "placebo tablets identical in shape, size, taste,
and color were administered" (p. 541); "Tolerability ratings and adverse events
of SJW LI 160 were indistinguishable from corresponding placebo figures.
Therefore, both investigators and patients could not have been unblinded by
recognizing a specific side effect pattern of SJW LI 160, which further validates
the study results" (p. 543)

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

All investigators, personnel of contracted partners and of the sponsor who
were actively involved in the trial were blinded to group assignment until the
code was broken at the end of the trial. Success of blinding was not been evaluated systematically in this trial, because experience from previous trials with
identical formulations has revealed good results (p. 539)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 7.5%; 175 participants were originally randomised (St. John's wort: n = 87, placebo: n = 88); however, due to loss of participant documentation for visits 1-4 following a fire the ITT population comprises only 173 participants (St. John's wort: n = 87, placebo: n = 86); reasons
for missing outcome data were very unlikely to be related to true outcome (no
participant was withdrawn due to adverse events in either groups), missing
outcome data were balanced in number with similar reasons for missing data
across groups; "Results in the PP [treated per protocol] population were nearly
identical, thereby corroborating the ITT results" (p. 542); "Missing values were
handled conservatively according to the Last Value Carried Forward (LVCF)" (p.
541)

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

High risk

"Patients exhibiting a decrease in SOMS-7 score 6 during the placebo run-in
phase ("placebo responders") were not to be included in the trial" (p. 539) this
placebo run-in phase was single-blind, randomisation was conducted just after the placebo run-in phase, 9 participants were excluded from the trial after
this placebo run-in phase; "Baseline demographics and clinical characteristics
did not differ significantly between groups, except for small-sized differences
regarding sex ratio and CGI subscore "severity" " (p. 539); "It further remains
open whether 600 mg of SJW [St. John's wort] daily is the optimal dose and if
higher dosages may result in increased efficacy" (p. 545)

Ouyang 2006
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 80
Diagnosis: somatoform pain disorder (CCMD-III)
Inclusion criteria: ns
Exclusion criteria: people whose pain was caused by depression, anxiety, schizophrenia, lung or physical illness
Age: mean (± SD) 37.85 ± 9.71 years, range ns; sex: 58.8% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 39.8 ± 7.10 months; country: China; setting: inpatient
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Interventions

Mirtazapine (n = 40; NaSSA; mean dose: ns, max dose = 275 mg/day; medication was administered
twice/day; no information regarding mode of administration provided)
Amitriptyline (n = 40; TCA; mean dose: ns, max dose: ns; medication was administered twice/day; no information regarding mode of administration provided)
Treatment duration: 56 days

Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
HDRS - Total Score, responder rate (clinician-rated): baseline, week 1, 2, 4, 6, 8
Treatment Emergent Symptom Scale: baseline, week 1, 2, 4, 6, 8
All-cause drop-outs: n = 0 (mirtazapine), n = 0 (amitriptyline)
Drop-outs due to adverse effects: n = 0 (mirtazapine), n = 0 (amitriptyline)
Reported drug-related adverse effects:
Mirtazapine: dry mouth, constipation, micturition disturbances, palpitation, sexual difficulty, electrocardiograph irregularities
Amitriptyline: dizziness, hypersomnia, increased appetite, weight gain, limb swallow, hypertension
In week 1 in the mirtazapine group, the Treatment Emergent Symptom Scale score was significantly
higher than in amitriptyline group; in week 2, 4, 6, and 8 the score was significantly higher in amitriptyline compared with mirtazapine. No information about the total rate of participants with drug-related
adverse events was provided

Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Trial authors stated that participants were randomly assigned to the 2 groups
(p. 560); no information provided about random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants/study personnel provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ouyang 2006 (Continued)
All outcomes
Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however,
treatment effects were only reported for the secondary outcomes such as depression, adverse effects, and general symptom improvement; important primary outcomes such as severity of physical symptoms were not assessed

Other bias

Low risk

There was no significant difference between groups regarding demographic variables; 1 week before treatment started participants were instructed to
wash-out other medication (p. 560); groups did not significantly differ in HDRS
scores before treatment (p. 560)

Pilowsky 1990
Methods

Combined randomised, placebo-controlled, parallel-group, double-blind, flexible-dose trialc

Participants

n(complete cases) = 50
Diagnosis: somatoform pain disorder (DSM-III-R)
Inclusion criteria: pain for ≥ 1 month that was not responding adequately to appropriate treatment; absence of objective evidence for the presence of any significant organic disease sufficient to explain the
presence or severity of the pain experience and degree of disability; impairment of functioning by at
least 25% taking into account biological, personal, social, occupational, and recreational aspects; absence of a psychotic illness (including major depressive syndrome), organic brain syndrome, or alcohol
dependence; adequate comprehension of English; absence of any physical disorder contraindicating
the use of a TCA
Exclusion criteria: major depression
Age: ns; sex: ns; mean length of time since diagnosis of a somatoform disorder: ns; country: Australia; setting: outpatient

Interventions

Amitriptyline + support (n: ns; TCA; mean dose: ns, max dose: ns; medication was administered as
tablets; no information regarding frequency of administration provided)
Placebo (n: ns)
Treatment duration: 84 days

Outcomes

Primary outcomes (all primary outcome measures were assessed at baseline, week 4, 8, 12, month 3, 6,
12)
Global pain assessment over the last week (location, intensity, character, distribution, chronicity, tune
relationship) (self rated)
McGill Pain Questionnaire (self rated)
Pain diary (VAS over 2 weeks)
Secondary outcomes (all secondary outcome measures were assessed at baseline, week 4, 8, 12, month
3, 6, 12):
VAS-productivity (self rated)
Sickness Impact Profile (self rated)
Activity diary (VAS over 2 weeks) (self rated)
Illness Behaviour Assessment Schedule (self rated)
Illness Behaviour Questionnaire (self rated)
Affective Status - Clinical assessment on 4-point scales (self rated)
Zung Depression Questionnaire (self rated)

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

Cochrane

Library
Pilowsky 1990

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(Continued)

Levine-Pilowsky Depression Questionnaire (self rated)
Spielberger State-Trait Anxiety Questionnaire (self rated)
Semi-structured interview where participants had to judge their progress concerning 3 'global areas':
well-being, pain, activity
VAS on mean intensity of pain, amount of pain, and degree of impairment or 'productivity' (self rated)
All-cause drop-outs/drop-outs due to adverse effects: no information provided
Reported drug-related adverse effects: no information provided
Notes

Funding: financial support for the study by National Health and Medical Research Council
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Participants were "allocated to 1 of 4 treatment groups with the use of a table
of random numbers" (p. 6)

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

"At the end of therapy, i.e., after 12 weeks, the therapist broke the code to establish whether the patient had been on the active or inert preparation and
wrote a summary of the treatment and progress with a recommendation concerning further management" (p. 6); insufficient information about blinding of
participants provided

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

"Patients were followed up […] by one of the research assistants who had not
carried out the baseline measures and who was also blind to the drug treatment and, as far as possible, to the non-drug treatment" (p. 7)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

In this study, the following 4 groups were examined: amitriptyline + psychotherapy (n = 26); amitriptyline + support (n = 26); placebo tablet + psychotherapy (n = 26); placebo tablet + support (n = 24). In the context of the current review, only results for amitriptyline + support vs. placebo tablet + support were considered, originally, 129 participants were randomised to the 4
study groups, 102 participants completed the trial, drop-out rates for the single groups were given only as percentage (amitriptyline + support group: 25%,
placebo + support group: 31%). Because ITT sample size in the single groups
was not mentioned, percentages cannot be converted in absolute values. Trial authors only state that "There was no significant difference in dropout numbers between the 4 groups" (p. 9); no information was provided about how
drop-outs were distributed between the 4 study groups, therefore, no dropout rate can be estimated; statistical analyses were based only on the sample
of participants who complied with the protocol

Selective reporting (reporting bias)

High risk

Study authors only evaluated outcome measures based on 3 ratings of the participants of improvement in well-being, pain, activity, as well as the following
3 continuous variables (VAS): mean intensity of pain, amount of pain, and degree of impairment or 'productivity'; scores on validated scales such as McGill
Pain Questionnaire, Pain diary, Zung Depression Scale, or Spielberger StateTrait Anxiety Questionnaire were only assessed at baseline but were not used
to evaluate the therapy efficacy, these variables were only used as predictors
of therapy efficacy (p. 7); follow-up month 3, 6, and 12 post treatment was re-
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ported in the study report but no follow-up data were provided; no protocol
available
Other bias

High risk

"Patients were offered treatments like transcutaneous nerve stimulation,
physiotherapy, regional nerve blocks, to psychopharmacotherapy and psychotherapy, in each case, the treatment is offered for a finite period of time after which the patient returns to the panel for a review. Where it was thought
that musculoligamentous or myofascial problems had not been adequately
treated physiotherapeutically this was provided before patients were entered
into the trial, even if considered suitable" (p. 5); participants who were admitted to the study were compared with people who were not: "Those admitted
were more likely to be women, more highly educated, more likely to be employed, less likely to be on an invalidity pension and younger" (p. 8); "marked
baseline differences" between the [study] groups regarding specific dependent variables were identified (p. 11); in this multiple-intervention trial data
were presented separately for each of the groups to which participants were
randomised

Sanada 2010
Methods

Randomised, parallel-group, flexible-dose triale

Participants

n(randomised/ITT) = 21
Diagnosis: pain disorder (DSM-IV-TR)
Inclusion criteria: ns
Exclusion criteria: ns
Age d: mean (± SD) 48.17 ± 14.26 years, range ns; sex d: 58.8% women; mean length of time since diagnosis of a somatoform disorder: ns; country: Japan; setting: outpatient

Interventions

Paroxetine (n = 11; SSRI; mean dose: ns, max dose = 40 mg/day; no information about mode/frequency
of administration provided)
Milnacipran (n = 10; SNRI; mean dose: ns, max dose = 150 mg/day; no information about mode/frequency of administration provided)
Treatment duration: 56 days

Outcomes

Primary outcome:
Short-Form McGill Pain Questionnaire - Total Pain Rating Index, Present Pain Intensity, VAS (self rated):
baseline, week 4, 8
Secondary outcomes:
HDRS (clinician-rated): baseline, week 4, 8
Zung Self-Rating Depression Scale (self rated): baseline, week 4, 8
All-cause drop-outs: n = 3 (paroxetine), n = 5 (milnacipran)
Drop-outs due to adverse effects: n = 3 (paroxetine), n = 2 (milnacipran)
Reported drug-related adverse effects: no information provided

Notes

Funding: no information provided
Ethics approval: no information provided
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Underlined outcome measures and time points were considered in the meta-analytical part of the review
Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Patients were randomly assigned" (p. S543); no information provided about
the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants/study personnel provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 38.1%; although reasons for missing outcome
data were partly likely to be related to true outcome, missing outcome data
were balanced in number across intervention with similar reasons for missing data across groups; however, sample size was very small and the drop-out
rate was very high, therefore, the chance of a bias produced by incomplete data was high; statistical analyses were based only on the sample of participants
who complied with the protocol

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; for this trial only a conference abstract was available in which data were only reported
completely for 1 outcome (severity of pain)

Other bias

Unclear risk

No information was provided

Volz 2000
Methods

Randomised, placebo-controlled, double-blind fixed-dose triala

Participants

n(randomised) = 208; n(ITT) = 200
Diagnosis: somatisation disorder (F45.0), undifferentiated somatoform disorder (F45.1), persistent somatoform pain disorder (F45.3) (ICD-10)
Inclusion criteria: aged 18-76 years, no significant actual or history of other Axis I diagnoses (e.g. panic
disorder, MDD, schizophrenia, substance abuse), no relevant concomitant diseases (e.g. epilepsy, severe renal or hepatic impairment, cancer), HARS - Somatisation Score ≥ 12 and ≥ 5 points than HARS Psychic Score; HDRS ≤ 24
Exclusion criteria: pregnant or breastfeeding women, contraindication to the use of the study medication
Age b: mean (± SD) 45.61 ± 13.00 years, range ns; sex b: 63.5% women; mean length of time since diagnosis of a somatoform disorder: ns; country: Germany; setting: ns

Interventions

Opipramol (n = 104; TCA; mean dose = 200 mg/day, max dose = 200 mg/day; 1 capsule twice/day)
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Placebo (n = 104)
Treatment duration: 42 days
Outcomes

Primary outcomes:
SCL-90-R - Somatic Subscore (self rated): day -7, 0, 7, 14, 28, 42
HARS - Somatic Score (clinician-rated): day -7, 0, 7, 14, 28, 42
Secondary outcomes:
HARS - Total Score, Psychic Score (clinician-rated): day -7, 0, 7, 14, 28, 42
HDRS (clinician-rated): day -7, 0, 7, 14, 28, 42
SCL-90-R - Total Score, Anxiety Subscore (self rated): day -7, 0, 7, 14, 28, 42
CGI - Improvement Scale (clinician-rated): day -7, 0, 7, 14, 28, 42
Adverse events: day 7, 14, 28, 42
All-cause drop-outs: n = 14 (opipramol), n = 13 (placebo)
Drop-outs due to adverse effects: n = 3 (opipramol), n = 3 (placebo)
Reported drug-related adverse effects:
Opipramol:single adverse effects with a frequency of ≥5%: tiredness (n = 9, 9.1%), dizziness (n = 5, 5.1%),
nausea (n = 3, 3.0%), back pain (n = 5, 5.1%); sum of adverse effects in 1 category with a frequency of
≥5%: body as whole (n = 12, 12.1%), central or peripheral nervous system (n = 7, 7.1%), gastrointestinal
system (n = 6, 6.1%), skeletomuscular system (n = 14, 14.1%)
Placebo:single adverse effects with a frequency of ≥5%: tiredness (n = 2, 2.0%), dizziness (n = 8, 7.9%),
gastroenteritis (n = 6, 5.9%), nausea (n = 6, 5.9%), back pain (n = 3, 3.0%); sum of adverse effects in 1 category with a frequency of ≥5%: body as whole (n = 4, 4.0%), central or peripheral nervous system (n = 13,
12.9%), gastrointestinal system (n = 21, 20.8%), skeletomuscular system (n = 7, 6.9%)
37.0% of the opipramol group and 38.0% of the placebo group reported adverse effects. No information if treatment groups differed in the number of adverse effects was provided

Notes

Funding: Novartis Pharma GmbH, Nürnberg, Germany, was involved in the trial (Klaus Dieter Stoll is
employee of Novartis Pharma GmbH); however, it was not stated how
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomized, placebo-controlled trial" (p. 214); no information provided
about the random sequence generation

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

"Double-bind treatment phase" (p. 212); no sufficient information provided
about who was and was not blinded

Blinding of outcome assessment (detection bias)

Unclear risk

No information about methods of blinding outcome assessment provided
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All outcomes
Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 13.0%; originally, 208 participants were randomised (opipramol group: n = 104, placebo group: n = 104), according to the
trial authors' definition of the ITT sample (no further information about this
definition provided) 8 participants were excluded from ITT sample (n = 200)
that was used for statistical analyses; although reasons for missing outcome
data were partly likely to be related to true outcome, missing outcome data
were balanced in number across intervention with similar reasons for missing
data across groups; "The last observation was carried forward (LOCF)" (p. 213)
was used to replace missing values

Selective reporting (reporting bias)

Low risk

No protocol available; generally accepted outcomes were used and data were
reported for a broad variety of primary and secondary outcomes

Other bias

High risk

"Compliance was assessed by immediate pill-count at visits as well as by the
results of opipramol plasma concentration measurements integrated into the
data set when the whole monitoring procedures were terminated" (p. 212);
"There were no relevant differences between the treatment groups" for initial symptom severity (p. 214); "[…] patients underwent a 7-day, single blind,
washout period with four placebo capsules per day […]. After this 7-day period, placebo responders (HAMA [HARS]-SOM decrease of more than 4 points)
had to be excluded" (p. 212); the randomisation took place after the placebo
run-in phase; however, it is unclear how many participants were excluded after this placebo run-in phase

Volz 2002
Methods

Randomised, placebo-controlled, double-blind fixed-dose triala

Participants

n(randomised) = 151; n(ITT) = 149
Diagnosis: somatisation disorder (F45.0), undifferentiated somatoform disorder (F45.1), persistent somatoform pain disorder (F45.3) (ICD-10)
Inclusion criteria: aged 18-65 years; HARS - Somatic Scale ≥ 12 and ≥ 5 points than HARS - Psychic Scale;
HDRS ≤ 24
Exclusion criteria: additional diagnosis of depression, schizophrenia, schizo-affective disorder, dementia; pregnancy; nursing mothers; concomitant treatment with psychopharmacological active compounds and relevant physical diseases (i.e. severe cardiac, renal or hepatic dysfunction or disease, underlying malignant disease, bone-marrow depression or dyscrasia, clinically manifest liver dysfunction,
renal insufficiency [serum creatinine > 2.0 mg/dL], non-compensated cardiac insufficiency, epilepsy, or
organic brain disease), and laboratory value deviations (i.e. > 10% deviation from the upper/lower normal ranges of erythrocytes, haemoglobin, and haematocrit, leukocytopenia (< 2500 cells/mm3), granulocytopenia (< 1500 cells/mm3), thrombocytopenia (< 100,000 cells/mm3), GOT > 90 IU/L, bilirubin > 1.5
mg/dL)
Age b: mean (± SD) 47.74 ± 12.00 years, range ns; sex b: 62.0% women; mean length of time since diagnosis of a somatoform disorder: ns; country: Germany; setting: outpatient

Interventions

St. John's wort extract LI160 (n = 75; NP; mean dose = 600 mg/day, max dose = 600 mg/day; 1 capsules
twice/day)
Placebo (n = 74)
Treatment duration: 42 days
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Outcomes

Primary outcomes:
SCL-90-R - Somatic Subscore (self rated): day -7, 0, 14, 28, 42
HARS - Somatic Score (clinician-rated): day -7, 0, 14, 28, 42
Secondary outcomes:
HARS - Total Score, Psychic Score (clinician-rated): day -7, 0, 14, 28, 42
HDRS (clinician-rated): day -7, 0, 14, 28, 42
SCL-90-R - Total Score, Anxiety Subscore (self rated): day -7, 0, 14, 28, 42
CGI - Improvement Scale (clinician-rated): 0, 14, 28, 42
CGI - Severity Scale (clinician-rated): 0, 14, 28, 42
Adverse events: day -7, 0, 14, 28, 42
All-cause drop-outs: n = 14 (St. John's wort extract), n = 13 (placebo)
Drop-outs due to adverse effects: n = 0 (St. John's wort extract), n = 2 (placebo)
Reported drug-related adverse effects:
St. John's wort extract: abdominal pain (n = 1, 1.3%), arthritis (n = 1, 1.3%), arrhythmia (n = 1, 1.3%),
bronchitis (n = 2, 2.7%), cystitis (n = 1, 1.3%), headache (n = 2, 2.7%), neuralgia (n = 1, 1.3%)
Placebo: back pain (n = 3, 3.9%), gastroenteritis (n = 1, 1.3%), influenza-like symptoms (n = 1, 1.3%)
10.7% of the St. John's wort extract group and 5.4% of the placebo group reported adverse effects. No
information if treatment groups differed in the number of adverse effects was provided. No statistically
significant differences between groups were found regarding the physicians' and participants' ratings
of the tolerability of treatments

Notes

Funding: Lichtwer Pharma AG, Berlin, Germany, was involved in the trial (Hans Murck is employee of
Lichtwer Pharma AG); however, it was not stated how
Ethics approval: obtained
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomised treatment phase" (p. 295); no information provided about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

"Double blind, randomised treatment phase" (p. 295); insufficient information
provided about who was and was not blinded

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Drop-out rate in total sample: 17.9%; originally, 151 participants were randomised; only participants who received at least 1 outcome assessment were
included in the ITT sample: no information was provided how the original
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151 participants were distributed between the 2 groups, 2 participants abandoned treatment before the first outcome assessment and were excluded from
ITT sample (n = 149) that was used for statistical analyses; "During the double-blind treatment phase, no participant was excluded in the LI160 group,
two drop-outs occurred in the placebo group [one due to a serious adverse
event (apoplexy), the other due to an adverse event (swelling and burning
underneath the eyes)] (p. 296); reasons for missing outcome data were very
unlikely to be related to true outcome (only 2 participants withdrew due to
adverse events in the placebo group); "The last observation was carried forward" (p. 296) was used to replace missing values
Selective reporting (reporting bias)

Low risk

No protocol available; generally accepted outcomes were used and data were
reported for a broad variety of primary and secondary outcomes

Other bias

High risk

"Patient population underwent a 7-day, single blind placebo run-in period,
receiving one placebo capsule in the morning and one in the evening. At the
end of this period, placebo responders, defined as those patients exhibiting a
HDRS-SOM decrease of more than four points, were excluded from the further
trial" (p. 295), single-blind placebo run-in phase was conducted before the randomisation; however, no participant had to be excluded in this placebo run-in
phase; "Compliance was assessed by immediate pill count at visits. The compliance ranged from 85.7 to 110.1% and was therefore well in the predefined
range of 75-125%" (p. 295); for initial symptom severity "there were no relevant differences between the treatment groups" (p. 296)

Wang 2003
Methods

Randomised, parallel-group, double-blind, fixed-dose trial

Participants

n(randomised/ITT) = 140
Diagnosis: persistent somatoform pain disorder (ICD-10)
Inclusion criteria: HDRS score > 17; pain continued over the last 6 months at least 5 days/week and 30
minutes/day
Exclusion criteria: depressed, suicidal, and chronically ill people
Age: mean (± SD) 44.50 ± 21.16 years, range ns; sex: 47.1% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 7.2 ± 5.3 months; country: China; setting: inpatient

Interventions

Trazodone (n = 70; SARI; mean dose = 100 mg/day, max dose = 100 mg/day; 1 capsule twice/day)
Ibuprofen (n = 70; NSAID; mean dose = 400 mg/day, max dose = 400 mg/day; 1 capsule twice/day)
Treatment duration: 28 days

Outcomes

Primary outcome:
Effectiveness rate concerning reduction of pain (defined by authors, no further information about that
measure provided) (clinician-rated): week 4
Secondary outcomes:
HDRS (clinician-rated): baseline, week 4
Treatment Emergent Symptom Scale: week 4
All-cause drop-outs: n = 0 (trazodone), n = 0 (ibuprofen)
Drop-outs due to adverse effects: n = 0 (trazodone), n = 0 (ibuprofen)
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Reported drug-related adverse effects:
Trazodone: hypersomnia, nausea, poor appetite, lethargy
Ibuprofen: reduced white blood cells (n = 3), allergy (n = 1), stomach irritation (n = 10)
No information about the total rate of participants with drug-related adverse events was provided. The
groups differed significantly with regard to the Treatment Emergent Symptom Scale - Total Score
Notes

Funding: no information was provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomly divided into two groups" (p. 70); no information provided about
random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"The clinical effects and side-effects were double-blind evaluated" (p. 70); trial
authors stated that the trial pharmacist put the trazodone and the placebo in
similar capsules, both participants and physicians did not know the treatment
condition until the end of the treatment (p. 71)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however,
treatment effects were assessed with validated scales only for secondary outcomes such as depression and adverse effects; important primary outcome
was assessed with non-validated clinician-rated scale that was constructed by
the study authors

Other bias

Low risk

No significant differences between groups regarding gender, age, duration
of symptoms, and diagnosis (p. 71); there were no significant differences between groups in the HDRS at baseline (p. 71)

Xu 2004
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 70
Diagnosis: somatoform pain disorder (CCMD-III)
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Inclusion criteria: pain symptom presentation of ≥ 6 months; the pain that the participants experience
from onset and over the course of disorder was related to the emotional stability or to psychosocial
problems
Exclusion criteria: pain explained by a somatic disorder
Age: mean 52 years, range 26-73 years; sex: 60.0% women; mean length of time since diagnosis of a somatoform disorder: 10.65 months; country: China; setting: outpatient
Interventions

Venlafaxine (n = 35; SNRI; mean dose = 132.4 mg/day, max dose = 150 mg/day; 1 capsule twice/day)
Amitriptyline (n = 35; TCA; mean dose = 127.3 mg/day, max dose = 150 mg/day; 2 capsules twice/day)
Treatment duration: 28 days

Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
Treatment effectiveness score based on rating of degree of pain, frequency how often they felt the pain,
improvement of the activity daily living quality (no further information about that measure provided)
(clinician-rated): baseline, day 4, week 1, 2, 4
Treatment Emergent Symptom Scale: day 4, week 1, 2, 4
All-cause drop-outs: n = 0 (venlafaxine), n = 0 (amitriptyline)
Drop-outs due to adverse effects: n = 0 (venlafaxine), n = 2 (amitriptyline)
Reported drug-related adverse effects:
Venlafaxine: dry mouth (n = 4, 11.4%), constipation (n = 5, 14.3%), blurred vision (n = 4, 11.4%), increased heart rate (n = 2, 5.7%), hypersomnia (n = 3, 8.6%), headache (n = 2, 5.7%), dizziness (n = 3,
8.6%), nausea (n = 5, 14.3%)
Amitriptyline: dry mouth (n = 20, 57.1%), constipation (n = 18, 51.4%), blurred vision (n = 17, 48.6%), increased heart rate (n = 15, 42.9%), hypersomnia (n = 21, 60.0%), headache (n = 5, 14.3%), dizziness (n =
7, 20.0%), nausea (n = 7, 20.0%). With the exception of dizziness and nausea, all mentioned adverse effects appeared significantly more often in the amitriptyline compared with venlafaxine. No information
about the total rate of participants with drug-related adverse events was provided

Notes

Funding: Southwest Pharmaceutical Co., Ltd., Chengdu, Sichuan (venlafaxine); Hunan Dongting Pharmaceutical Co., Deshan, Changde City, Hunan (amitriptyline)
Ethics approval: no information provided

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"70 […] outpatients […] were randomly divided" (p. 397); no information provided about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants and study personnel
provided
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Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however, only clinician-rated and no participant self rated measures were used. Furthermore, only non-validated scales defined by the trial authors were administered

Other bias

High risk

Significant differences between groups regarding sex, age, duration of symptoms, occupational status, and pain regions at baseline were identified (p. 398)

Yang 2006
Methods

Randomised, parallel-group trial (unclear if this study was a fixed- or flexible-dose trial)

Participants

n(randomised/ITT) = 70
Diagnosis: somatoform disorder (CCMD-III)
Inclusion criteria: inpatients of the Kangning Hospital of Chaoyang City
Exclusion criteria: no information provided
Age: mean 41.60 years, range 20-72 years; sex: 70.0% women; mean length of time since diagnosis of a
somatoform disorder: 3-144 months; 61.4% were 12-36 months; country: China; setting: inpatient

Interventions

Venlafaxine (n = 35; SNRI; mean dose: ns, max dose: ns; no information about mode/frequency of administration provided)
Amitriptyline (n = 35; TCA; mean dose = 127.3 mg/day, max dose = 150 mg/day; no information about
mode/frequency of administration provided)
Treatment duration: 42 days

Outcomes

Primary outcome:
No primary outcome was assessed
Secondary outcomes:
HDRS - Total Score, responder rate (clinician-rated): baseline, week 1, 2, 4, 6
HARS (clinician-rated): baseline, week 1, 2, 4, 6
No information provided how adverse effects were assessed
All-cause drop-outs: n = 0 (venlafaxine), n = 0 (amitriptyline)
Drop-outs due to adverse effects: n = 0 (venlafaxine), n = 2 (amitriptyline)
Reported drug-related adverse effects:
Venlafaxine: poor digestion (n = 12, 23.3%), insomnia (n = 3, 8.6%), headache (n = 3, 8.6%), sweating (n
= 5, 14.3%), hypertension (n = 2, 5.7%)
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Amitriptyline: dry mouth (n = 10, 28.6%), nervousness/alertness (n = 10, 28.6%), constipation (n = 10,
28.6%), increased heart rate (n = 3, 8.6%), blurred vision (n = 6, 17.1%), whole body did not feel well (n =
3, 8.6%)
No information about the total rate of participants with drug-related adverse events was provided or if
both treatment groups differed in the number of adverse effects
Notes

Ethics approval: no information provided
Funding: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"70 patients […] were randomly assigned" (p. 262); no information provided
about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants and study personnel
provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

All participants completed the study and there were no losses to follow-up and
no treatment withdrawals

Selective reporting (reporting bias)

High risk

No protocol available; generally accepted outcomes were used; however,
treatment effects were only reported for the secondary outcomes such as depression, anxiety, and adverse effects; important primary outcomes such as
severity of physical symptoms were not assessed

Other bias

Low risk

There was no significant difference between groups in age, gender, duration of
symptoms, or HARS and HDRS scores at baseline (p. 262)

Ye 2006
Methods

Randomised, parallel-group, flexible-dose trial

Participants

n(randomised/ITT) = 70
Diagnosis: somatisation disorder (CCMD-III)
Inclusion criteria: aged 18-65 years
Exclusion criteria: people with diabetes; history of any liver, lung, kidney, or related diseases; people
with any type of drug dependence; pregnant or breastfeeding women; people who used MAOIs and
other antidepressants in the 2 week before treatment started
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Age: mean (± SD) 43.50 ± 10.0 years, range ns; sex: 72.9% women; mean (± SD) length of time since diagnosis of a somatoform disorder: 7.5 ± 5.7 months; country: China; setting: ns
Interventions

Mirtazapine (n = 35; NaSSA; mean dose: ns, max dose = 45 mg/day; medication was administered as
pills; no information about frequency of administration provided)
Clomipramine (n = 35; TCA; mean dose: ns, max dose = 150 mg/day; medication was administered as
pills; no information about frequency of administration provided)
Treatment duration: 56 days

Outcomes

Primary outcome:
SCL-90-Somatisation Subscore (self rated): baseline, week 2, 4, 8
Secondary outcomes:
SCL-90 - Interpersonal Sensitivity, Obsessive-compulsive, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, Psychoticism Subscore (self rated): baseline, week 2, 4, 8
CGI - Improvement Scale (clinician-rated): week 8
Treatment Emergent Symptom Scale: week 2, 4, 8
All-cause drop-outs: n = 2 (mirtazapine), n = 3 (clomipramine)
Drop-outs due to adverse effects: n = 2 (mirtazapine), n = 2 (clomipramine)
Reported drug-related adverse effects:
Mirtazapine: dry mouth (n = 4, 11.4%), constipation (n = 3, 8.6%), increased heart rate (n = 1, 2.9%),
blurred vision (n = 1, 2.9%), headache (n = 4, 11.4%), fatigue (n = 3, 8.6%), increased body weight (n = 6,
17.1%)
Clomipramine: dry mouth (n = 17, 48.6%), constipation (n = 9, 25.7%), nausea, (n = 7, 20.0%), loss of appetite (n = 6, 17.1%), increased heart rate (n = 13, 37.1%), hypotension (n = 6, 17.1%), blurred vision (n =
18, 51.4%), tremor (n = 7, 20%), micturition disturbances (n = 9, 25.7%), headache (n = 6, 17.1%), fatigue
(n = 5, 14.3%), increased body weight (n = 9, 25.7%)
Dry mouth, constipation, increased heart rate, and blurred vision appeared statistically more often
in the mirtazapine group than in the clomipramine group. Dry mouth, constipation, nausea, loss of
appetite, increased heart rate, hypotension, blurred vision, tremor, and micturition disturbances appeared statistically more often in the clomipramine group than in the mirtazapine group. No information about the total rate of participants with drug-related adverse events was provided

Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Seventy patients […] were randomly divided into two groups" (p. 14); no information provided about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided
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Blinding of participants
and personnel (performance bias)
All outcomes

Unclear risk

No information about methods of blinding participants and study personnel
provided

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Drop-out rate in total sample: 7.1%; although reasons for missing outcome data were partly likely to be related to true outcome, missing outcome data were
balanced in number with similar reasons for missing data across groups; missing values were not replaced, statistical analyses were based only on the sample of participants who complied with the protocol

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

There were no statistical significant differences between groups regarding sex,
age, and mean duration of somatoform symptoms (p. 14)

Zhao 2006
Methods

Randomised, parallel-group, double-blind, flexible-dose trial

Participants

n(randomised/ITT) = 60
Diagnosis: somatisation disorder (CCMD-III)
Inclusion criteria: no further information provided
Exclusion criteria: other mental disorders, history of physical illnesses, drug dependence, pregnant or
breastfeeding (or both) women; taking MAOI or other antidepressants during the first 2 weeks of treatment
Age: mean (± SD) 38.15 ± 7.58 years, range 25-51 years; sex: 68.3% women; mean (± SD) length of time
since diagnosis of a somatoform disorder: 61.8 ± 39 months; country: China; setting: inpatient

Interventions

Mirtazapine (n = 30; NaSSA; mean dose = 40 mg/day, max dose = 45 mg/day; medication was administered as capsules; no information about frequency of administration provided)
Amitriptyline (n = 30; TCA; mean dose = 116.3 mg/day, max dose = 200 mg/day; medication was administered as capsules; no information about frequency of administration provided)
Treatment duration: 56 days

Outcomes

Primary outcome:
SCL-90 - Somatisation Subscore (self rated): baseline, week 2, 4, 8
Secondary outcomes:
SCL-90 - Interpersonal Sensitivity, Obsessive-compulsive, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, Psychoticism Subscore (self rated): baseline, week 2, 4, 8
CGI - Improvement Scale: week 8
Treatment Emergent Symptom Scale: week 2, 4, 8
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All-cause drop-outs: 7 participants dropped out; however, it was unclear how they were distributed
among groups
Drop-outs due to adverse effects: no information provided
Reported drug-related adverse effects:
Mirtazapine: weight gain (n = 14, 46.7%), hypersomnia (n = 3, 10.0%), hyperventilation (n = 4, 13.3%),
hypotension (n = 2, 6.7%), blurred vision (n = 1, 3.3%), headache (n = 8, 26.7%), constipation (n = 10,
33.3%), nausea (n = 6, 20.0%)
Amitriptyline: weight gain (n = 2, 6.7%), hypersomnia (n = 15, 50.0%), hyperventilation (n = 15, 50.0%),
hypotension (n = 12, 40.0%), blurred vision (n = 17, 56.7%), micturition disturbances (n = 7, 23.3%),
headache (n = 7, 23.3%), constipation (n = 12, 40.0%), nausea (n = 7, 23.3%)
Weight gain appeared statistically more often in the mirtazapine group than in the amitriptyline group.
Hypersomnia, hyperventilation, hypotension, blurred vision, micturition disturbances, headache, constipation, and nausea appeared statistically more often in the clomipramine group than in the mirtazapine group. No information about the total rate of participants with drug-related adverse events was
provided
Notes

Funding: no information provided
Ethics approval: no information provided
Underlined outcome measures and time points were considered in the meta-analytical part of the review

Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"60 patients […] were randomly divided" (p. 175); no information provided
about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

Trial authors stated that it was a double-blind study (p. 175); both medications
were administered in identical capsules (p. 175)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

7 drop-outs (drop-out rate in total sample: 11.7%) but no information about
the reason for drop-out and how drop-outs were distributed among the 2 trial arms was provided; no information about how and if missing values were replaced in the statistical analyses was provided; in the result tables the number
of originally randomised participants was depicted, therefore, it can be concluded that an ITT analysis with replaced missing values was conducted

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

There were no significant differences in demographics and the duration of the
symptoms between groups at baseline (p. 175)
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Zitman 1991
Methods

Randomised, parallel-group, cross-over, double-blind, fixed-dose trial

Participants

n(randomised/ITT) = 45
Diagnosis: psychogenic pain disorder (307.80) (DSM-III-R)
Inclusion criteria: aged 30-60 years
Exclusion criteria: serious psychiatric disease necessitating immediate treatment; alcohol or illicit drug
dependence; renal, hepatic, or cardiac disorders; epilepsy; glaucoma; hypertension; prostate dysfunction; intake of medication consisting of enzyme-inducing drugs; use of antidepressants or neuroleptic
drugs (or both) during the previous year
Age d: mean (± SD) 41.20 ± 11.00 years, range ns; sex d: 61.1% women; mean (± SD) length of time since
diagnosis of a somatoform disordere : 113.4 ± 111.6 months; country: The Netherlands; setting: outpatient

Interventions

Amitriptyline + flupentixol (n = 16d; TCA + AP; mean dose amitriptyline = 75.0 mg/day, mean dose flupentixol = 3.0 mg/day, max dose amitriptyline = 75 mg/day, max dose flupentixol = 3 mg/day; medication was administered as capsules; no information about frequency of administration provided)
Amitriptyline alone (n = 18d; TCA; mean dose = 116.3 mg/day, max dose = 200 mg/day; medication was
administered as capsules; no information about frequency of administration provided)
Treatment duration: 35 days

Outcomes

Primary outcomes:
Participant's estimation of the amount of pain felt at that time as a percentage of the pain on day 1 (self
rated): first day of week 3, 5, 8, 10, 12, 15, 17
Pain diaries (numerical scale for rating pain intensity and the trouble the pain caused) (self rating):
baseline, week 5, 7, 9, 12, 14, 16
Secondary outcomes:
Zung Depression Scale (self rated): first day of week 1, 3, 5, 8, 10, 12, 15, 17
HDRS (clinician-rated): first day of week 1, 3, 5, 8, 10, 12, 15, 17
Adverse effects registration: combined checklist for subjective adverse effects and withdrawal symptoms developed by the study authors, clinical screening for EPS, Abnormal Involuntary Movement
Scale: first day of week 1, 3, 5, 8, 10, 12, 15, 17
All-cause drop-outs: 9 participants dropped out; however, it was not clear how they were distributed
among groups
Drop-outs due to adverse effects: no information provided
Reported drug-related adverse effects:
It was only mentioned that the adverse effect dry mouth became significantly more serious during the
treatment in the amitriptyline as well as in the amitriptyline + flupentixol groups. Withdrawal symptoms of antidepressants and neuroleptics were included in the checklist, but no statistically significant
increase in the severity of these symptoms was observed. Regarding the extrapyramidal side effects
scored on the Abnormal Involuntary Movement Scale and the EPS, there was no statistically significant
difference between groups. The mean scores were very low. On the Abnormal Involuntary Movement
Scale (range 0-42) they were 0.13-0.67, and on the EPS all participants scored 0

Notes

Funding: H. Lundbeck A/S, Copenhagen supplied the medication and financial support for the trial
Ethics approval: obtained
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Underlined outcome measures and time points were considered in the meta-analytical part of the review
Risk of bias
Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

"Randomized [...] crossover trial" (p. 26); "there were 2 treatment schemes to
which the patients were randomly assigned" (p. 26); no information provided
about random sequence

Allocation concealment
(selection bias)

Unclear risk

No information about methods of allocation concealment provided

Blinding of participants
and personnel (performance bias)
All outcomes

Low risk

"Double-blind crossover trial" (p. 26); "Four types of tablets were used: 25mg
AT [amitriptyline], 1 mg FP [flupentixol], placebo tablets looking identical to AT
tablets (ATpi) and placebo tablets looking identical to FP tablets (FPpl)" (p. 26)

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

No information about methods of blinding outcome assessment provided

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Reasons for missing outcome data and distribution of drop-outs were not provided. For this reason, we could not judge if missing outcome data were balanced in number across intervention with similar reasons for missing data
across groups. Total sample size was very small and the total drop-out rate
was relatively high (20.0%). Therefore, the chance of a bias produced by incomplete data was high. Missing values were not replaced, statistical analyses
were based only on the sample of participants who complied with the protocol
(p. 27)

Selective reporting (reporting bias)

Unclear risk

No protocol available; generally accepted outcomes were used

Other bias

Low risk

"The 2 groups to which the patients had been randomly assigned did not show
statistically significant differences with respect to demographic variables (sex,
age, marital status, level of education) or to pain variables (localization and
duration of pain, baseline pain intensity and pain trouble)" (p. 27); "is questioned if a higher dose of flupentixol [would have] have yielded better analgesic effects" (p. 29); in this cross-over trial, the order receiving a treatment
was randomised: "there were 2 treatment schemes to which the patients were
randomly assigned" (p. 26), in addition, the means/SD for pain intensity/burden and depression in Table 1 and 3 were given separately for group 1 and 2
for day 15/29/50/64/78/99/113

AP: antipsychotic; CCMD: Chinese Classification of Mental Disorders; CGI: Clinical Global Impression Scale; DSM: Diagnostic and Statistical
Manual of Mental Disorders; EPS: Extrapyramidal Side Effects; GAD: generalised anxiety disorder; HARS: Hamilton Anxiety Rating Scale;
HDRS: Hamilton Depression Rating Scale; ICD: International Classification of Diseases; ITT: intention to treat; LOCF: last observation
carried forward; MAOI: monoamine oxidase inhibitor; max: maximum; MDD: major depressive disorder; MSD: multisomatoform disorder;
MUPS: medically unexplained physical symptoms; n: number; NaSSA: noradrenergic and specific serotonergic antidepressant; NP: natural
product; ns: not specified; NSAID: non-steroidal anti-inflammatory drug; PHQ: Patient Health Questionnaire; SAD: somatoform autonomic
dysfunction; SCL: Symptom Checklist; SD: standard deviation; SNRI: serotonin noradrenaline reuptake inhibitor; SOMS: Screening for
Somatoform Symptoms; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant; TeCA: tetracyclic antidepressant; VAS:
visual analogue scale.
Notes: percentages, numbers, and mean values/SDs regarding age, sex, length of time since the diagnosis of somatoform disorder, dose,
drop-outs, and adverse effects relate to the originally randomised sample. Deviations from this rule are indicated with a footnote.
aStudy design included a single-blind placebo run-in phase after which 'placebo-responders' were excluded from the further trial.
Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

Cochrane

Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

bValues refer to the ITT sample that was not the same as the originally randomised sample. Usually participants abandoned before the

first outcome assessment or before they received at least 1 dose of a study medication were excluded from the ITT sample.
cThe trial originally involved 4 study groups: group A: amitriptyline + psychotherapy, group B: amitriptyline + support, group C: placebo
+ psychotherapy, group D: placebo + support. The following study-related information referred only to the comparison between group B
and D.
dMean values/SDs and percentages relate to the completer-sample.
eFor this study, only a conference abstract was available. Authors were contacted in order to obtain more information about the study;
however, we received no reply.
fThe study was included in the narrative but not in the meta-analytical part of the review.

Characteristics of excluded studies [ordered by study ID]
Study

Reason for exclusion

Altamura 2003

No randomisation (we contacted the authors because the article included no information about
randomisation)

Ballbe 1970

People with hysteria and anxiety neurosis (focus on conversion symptoms)

Bratfos 1967

People with neurosis

Cui 2004

People with hysteria

Davis 1988

People with a specific functional syndromes (non-ulcer dyspepsia)

Farnbach 2013

Efficacy of quetiapine fumarate as a adjunctive therapy to current pain treatment of participants
was examined

Fukuda 1971

People with psychosomatic symptoms (primary diagnoses: depression, anxiety, somatic disorders)

Hasegawa 1977

People psychosomatic disease and neurosis

Holdevici 1995

People with symptoms of anxious neurosis and somatoform disorders, no information provided
how participants were diagnosed and how long participants' symptoms had to persist

Kozian 2003

Case report

Lee 2012

Anti-stress effect of Korean red ginseng in a general population with various stress-related somatic
symptoms was examined

Liu 2011

People fulfilling CCMD-III criteria of a depressive disorder with a co-morbid somatic diagnosis were
included

Loldrup 1989

45.1% of the participants had tension headache (not classified as somatoform disorder)

Onghena 1993

Cross-over design applied but no data for the first study phase available

Pach 1976

People with functional physical symptoms in combination with anxious, depressive mood; functional physical symptoms included predominantly different heart sensations, circulation problems
or tension headache

Poinso 1988

People with reactive depression

Raich 1966

Anxious somatising neurotic medical clinic participants; no information provided how participants
were diagnosed and how long participants' symptoms had to persisted

Smith 1971

People with psychoneurotic anxiety with/without depressive symptoms
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Study

Reason for exclusion

Smouvelich 1996

People with cardioneurotic disease with an anxiety disorder (agoraphobia, generalised anxiety disorder, panic disorder) and a somatoform disorder (somatisation disorder, hypochondriasis)

Tanum 1996

People with specific functional syndromes (irritable bowel syndrome, non-ulcer dyspepsia)

Tsutsui 1984

People with a disorder in the field of internal medicine (psychosomatic medicine), geriatric medicine (focus on various sleeping problems with the frequency of symptoms of ≥ 4 times/week)

Tsutsui 1985

People with a disorder in the field of internal medicine (psychosomatic medicine), geriatric medicine (focus on various sleeping problems with the frequency of symptoms of ≥ 4 times/week)

Tsutsui 1986

People with a disorder in the field of internal medicine (psychosomatic medicine), geriatric medicine (focus on various sleeping problems with the frequency of symptoms of 4 times or more per
week)

Tsutsui 1987

People with a disorder in the field of internal medicine (psychosomatic medicine), geriatric medicine (focus on various sleeping problems with the frequency of symptoms of ≥ 4 times/week)

Tsutsui 1992

People with a disorder in the field of internal medicine (psychosomatic medicine) and geriatric
medicine (focus on insomnia)

Turkington 2002

People with 1 specific functional syndrome (prostatodynia)

Xu 2006

Interventions: paroxetine vs. acupuncture (no placebo or other medication group)

Zang 1991

People fulfilling diagnostic criteria of neurosis defined by the Chinese Neuropsychiatric Committee
in October 1985 (these criteria do not correspond to the inclusion criteria of the review regarding
the diagnosis)

Zhao 1989

People with neurosis (included anxiety, phobia, somatisation, and compulsion) and depression

Zitman 1990

People with chronic pain of various origins (only 35.9% fulfilled criteria of psychogenic pain disorder)

CCMD: Chinese Classification of Mental Disorders.

Characteristics of ongoing studies [ordered by study ID]
Agger 2014
Trial name or title

Imipramine Treatment for Patients with Multi-Organ Bodily Distress Syndrome (STreSS-3)

Methods

Randomised, placebo-controlled, double-blind, flexible-dose trial

Participants

n = 140
Diagnosis: bodily distress syndrome multi-organ type with symptoms for more than 3 of 4 symptom categories (resembles somatisation disorder in ICD-10)
a more specific set of diagnostic criteria
Inclusion criteria: moderate or severe impact on daily life; symptoms lasting for at least 2 years;
aged 20-50 years; born in Denmark or have Danish parents; participant understands, speaks,
writes, and reads Danish
Exclusion criteria: presence of other physical of psychiatric condition; continuous antidepressant
treatment because of moderate or severe depression; other severe psychiatric disorder that demands treatment or suicidality; lifetime diagnosis of psychoses, mania, or depression with psy-
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chotic symptoms (International Classification of Diseases-10: F20-29, F30-31, F32.3, F33.3); abuse
of alcohol, narcotics, or drugs; pregnancy, breastfeeding, or current pregnancy wish; fertile women
must use effective contraception; treatment with all pain-modulating drugs, e.g. all analgesics, antidepressants, antiepileptics, and other types of medication with pain-relieving properties must
be discontinued at least 2 weeks before the treatment phase; imipramine treatment in sufficient
dosage within the last year, i.e. 25 mg daily continuously for at least 8 weeks; allergy to study medication or excipients in study medication; people with previous myocardial infarction, congestive heart failure, signs of conduction defects or abnormalities on electrocardiograph, narrow-angle glaucoma, porphyria, inherited galactose intolerance, epilepsy, hepatic insufficiency, and severe renal impairment; simultaneous use of: antipsychotics, oral anticoagulants, diuretics, sympathomimetics and central nervous system-stimulating drugs (amphetamine-like drugs), all serotonergic drugs, e.g. selective serotonin reuptake inhibitor, serotonin noradrenaline reuptake inhibitor, and tricyclic antidepressant, the dietary supplement hypericum perforatum, non-selective, irreversible, or selective reversible monoamine oxidase inhibitors, triptans, tramadol, pethidine and tryptophan, cimetidine, quinidine, clonidine, fluconazole (antimycotics), clindamycin,
clarithromycin, erythromycin, droperidol, levodopa, mefloquine, phenytoin, barbiturates, carbamazepine, bupropion, celecoxib, cinacalcet, duloxetine, fluphenazine, fluoxetine, gefitinib, moclobemide, paroxetine, sertraline, terbinafine, yohimbine, fluvoxamine, ciprofloxacin, or enoxacin
Interventions

Imipramine (n = 70, 25-75 mg/day, medication administered as tablets)
Placebo (n = 70)
Treatment duration: 133 days (19 weeks)

Outcomes

Primary outcomes:
CGI - Improvement Scale (clinician-rated): week 13
Participant-rated improvement of health since the beginning of the study: week 13
Secondary outcomes:
Medical Outcomes Study Short-Form 36-Item Questionnaire (participant-rated): week 1, 13
Visual Analogue Scale for pain and worst symptom (participant-rated): week 1, 13
Symptom Checklist (participant-rated): week 1, 3, 13
Functional Illness Checklist: week 1, 3, 13
World Health Organization Disability Assessment Schedule II (interview): week 1, 13

Starting date

January 2012 (estimated study completion date: December 2014)

Contact information

Per K Fink, Dr. med; telephone: +4578464310; email: per.fink@aarhus.rm.dk
Johanne L Agger, M.D.; telephone: +4578464344; email: johanne.agger@aarhus.rm.dk
Research Clinic for Functional Disorders Recruiting
Aarhus, Denmark, 8000

Notes

Funding: Aarhus University Hospital

n: number.

DATA AND ANALYSES
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Comparison 1. Pharmacotherapy versus placebo
Outcome or subgroup title

No. of
studies

1 Severity/intensity of medically unexplained
physical symptoms (post-treatment score on self
report scales)

7

1.1 Tricyclic antidepressants versus placebo

2

1.2 New-generation antidepressants (serotonin
noradrenaline reuptake inhibitor (SNRI), selective
serotonin reuptake inhibitor (SSRI)) versus placebo

No. of
participants

Statistical method

Effect size

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

239

Std. Mean Difference (IV, Random,
95% CI)

-0.13 [-0.39,
0.13]

3

243

Std. Mean Difference (IV, Random,
95% CI)

-0.91 [-1.36,
-0.46]

1.3 Natural products (St. John's wort LI 160) versus placebo

2

322

Std. Mean Difference (IV, Random,
95% CI)

-0.74 [-0.97,
-0.51]

2 Acceptability

6

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

2.1 Tricyclic antidepressant versus placebo

1

208

Risk Ratio (M-H, Random, 95% CI)

1.08 [0.53,
2.18]

2.2 New-generation antidepressants (SNRI, SSRI)
versus placebo

2

163

Risk Ratio (M-H, Random, 95% CI)

1.01 [0.64,
1.61]

2.3 Natural products (St. John's wort LI 160, Ze
185 3-/4-combination) versus placebo

3

506

Risk Ratio (M-H, Random, 95% CI)

0.85 [0.40,
1.78]

3 Anxiety (post-treatment score on self report and
clinician-rated scales)

5

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

3.1 Tricyclic antidepressants versus placebo

1

200

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.29,
0.26]

3.2 New-generation antidepressants (SNRI, SSRI)
versus placebo

2

163

Std. Mean Difference (IV, Random,
95% CI)

-0.88 [-1.81,
0.05]

3.3 Natural products (St. John's wort LI 160, Ze
185 3-/4-combination) versus placebo

2

321

Std. Mean Difference (IV, Random,
95% CI)

-0.83 [-1.13,
-0.52]

4 Depression (post-treatment score on self report
and clinician-rated scales)

5

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

4.1 Tricyclic antidepressant versus placebo

1

200

Std. Mean Difference (IV, Random,
95% CI)

-0.27 [-0.55,
0.01]

4.2 New-generation antidepressants (SSRI, SNRI)
versus placebo

2

163

Std. Mean Difference (IV, Random,
95% CI)

-0.56 [-0.88,
-0.25]

4.3 Natural products (St. John's wort, Ze 185) versus placebo

2

321

Std. Mean Difference (IV, Random,
95% CI)

-0.64 [-0.87,
-0.41]

5 Dysfunctional cognitions, emotions, and behaviours (post-treatment score on self report scales)

1

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only
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Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

5.1 New-generation antidepressants (SSRI) versus
placebo

1

51

Std. Mean Difference (IV, Random,
95% CI)

0.26 [-0.29,
0.81]

6 Adverse effects

6

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

6.1 Tricyclic antidepressant versus placebo

1

208

Risk Ratio (M-H, Random, 95% CI)

1.0 [0.21, 4.84]

6.2 New-generation antidepressants (SNRI, SSRI)
versus placebo

2

163

Risk Ratio (M-H, Random, 95% CI)

2.26 [0.52,
9.81]

6.3 Natural products (St. John's wort LI 160, Ze
185 3-/4-combination) versus placebo

3

506

Risk Ratio (M-H, Random, 95% CI)

0.54 [0.08,
3.50]

7 Treatment response (post-treatment score on
self report and clinician-rated scales)

5

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

7.1 Tricyclic antidepressant versus placebo

1

208

Risk Ratio (M-H, Random, 95% CI)

1.29 [0.95,
1.73]

7.2 New-generation antidepressants (SNRI, SSRI)
versus placebo

2

163

Risk Ratio (M-H, Random, 95% CI)

2.00 [0.90,
4.43]

7.3 Natural products (St. John's wort LI 160) versus placebo

2

324

Risk Ratio (M-H, Random, 95% CI)

1.77 [1.34,
2.34]

8 Functional disability and quality of life (posttreatment score on self report scales)

3

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

8.1 Tricyclic antidepressant versus placebo

1

44

Std. Mean Difference (IV, Random,
95% CI)

0.01 [-0.58,
0.60]

8.2 New-generation antidepressants (SNRI, SSRI)
versus placebo

2

163

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [1.00,
-0.04]

Analysis 1.1. Comparison 1 Pharmacotherapy versus placebo, Outcome 1 Severity/intensity
of medically unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.1.1 Tricyclic antidepressants versus placebo
Pilowsky 1990

20

58.2 (23.9)

19

68 (21.2)

16.63%

Volz 2000

99

0.9 (0.8)

101

1 (0.7)

83.37%

-0.07[-0.35,0.21]

100%

-0.13[-0.39,0.13]

Subtotal ***

119

120

-0.43[-1.06,0.21]

Heterogeneity: Tau2=0; Chi2=1.02, df=1(P=0.31); I2=1.9%
Test for overall effect: Z=0.96(P=0.34)
1.1.2 New-generation antidepressants (serotonin noradrenaline reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSRI)) versus placebo
Kroenke 2006

55

9.7 (3.4)

57

11.5 (3.2)

38.94%

-0.54[-0.92,-0.16]

Luo 2009

40

33.1 (18.8)

40

55.3 (25.4)

34.11%

-0.98[-1.45,-0.52]

Favours pharmacotherapy

-2
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Experimental
N

Muller 2008

25

Subtotal ***

120

Control

Mean(SD)

N

5.6 (5)

Std. Mean Difference

Mean(SD)

26

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

12.5 (5.1)

123

26.95%

-1.34[-1.96,-0.73]

100%

-0.91[-1.36,-0.46]

-0.65[-0.96,-0.35]

Heterogeneity: Tau2=0.1; Chi2=5.38, df=2(P=0.07); I2=62.82%
Test for overall effect: Z=3.95(P<0.0001)
1.1.3 Natural products (St. John's wort LI 160) versus placebo
Müller 2004

87

12.4 (8.6)

86

18.3 (9.4)

54.59%

Volz 2002

75

6.8 (5.5)

74

12.5 (7.6)

45.41%

-0.85[-1.18,-0.51]

100%

-0.74[-0.97,-0.51]

Subtotal ***

162

160

Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%
Test for overall effect: Z=6.42(P<0.0001)
Favours pharmacotherapy

-2

-1

0

1

2

Favours placebo

Analysis 1.2. Comparison 1 Pharmacotherapy versus placebo, Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

1.2.1 Tricyclic antidepressant versus placebo
Volz 2000
Subtotal (95% CI)

14/104

13/104

100%

1.08[0.53,2.18]

104

104

100%

1.08[0.53,2.18]

21/55

22/57

97.83%

0.99[0.62,1.58]

1/25

0/26

2.17%

3.12[0.13,73.06]

80

83

100%

1.01[0.64,1.61]

Total events: 14 (Experimental), 13 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=0.21(P=0.84)
1.2.2 New-generation antidepressants (SNRI, SSRI) versus placebo
Kroenke 2006
Muller 2008
Subtotal (95% CI)
Total events: 22 (Experimental), 22 (Control)
Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%
Test for overall effect: Z=0.06(P=0.95)
1.2.3 Natural products (St. John's wort LI 160, Ze 185 3-/4-combination) versus placebo
Melzer 2009

10/121

5/61

52.17%

1.01[0.36,2.82]

Müller 2004

5/87

6/88

41.78%

0.84[0.27,2.66]

Volz 2002

0/75

2/74

6.05%

0.2[0.01,4.04]

Subtotal (95% CI)

283

223

100%

0.85[0.4,1.78]

Total events: 15 (Experimental), 13 (Control)
Heterogeneity: Tau2=0; Chi2=1.02, df=2(P=0.6); I2=0%
Test for overall effect: Z=0.44(P=0.66)
Favours pharmacotherapy

0.01

0.1
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Analysis 1.3. Comparison 1 Pharmacotherapy versus placebo, Outcome
3 Anxiety (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.3.1 Tricyclic antidepressants versus placebo
Volz 2000

99

Subtotal ***

99

0.6 (0.7)

101

0.6 (0.6)

101

100%

-0.01[-0.29,0.26]

100%

-0.01[-0.29,0.26]

Heterogeneity: Not applicable
Test for overall effect: Z=0.1(P=0.92)
1.3.2 New-generation antidepressants (SNRI, SSRI) versus placebo
Muller 2008

25

3 (4.5)

26

9.4 (4.6)

46.53%

-1.39[-2,-0.77]

Kroenke 2006

55

13.8 (7.9)

57

17.5 (8.8)

53.47%

-0.44[-0.81,-0.06]

Subtotal ***

80

100%

-0.88[-1.81,0.05]

-0.98[-1.32,-0.64]

83

Heterogeneity: Tau2=0.38; Chi2=6.62, df=1(P=0.01); I2=84.9%
Test for overall effect: Z=1.86(P=0.06)
1.3.3 Natural products (St. John's wort LI 160, Ze 185 3-/4-combination) versus
placebo
Volz 2002

75

10 (6.4)

74

17 (7.7)

49.04%

Melzer 2009

118

14.9 (18.6)

54

28.6 (23.3)

50.96%

-0.67[-1,-0.34]

Subtotal ***

193

100%

-0.83[-1.13,-0.52]

128

Heterogeneity: Tau2=0.02; Chi2=1.63, df=1(P=0.2); I2=38.78%
Test for overall effect: Z=5.35(P<0.0001)
Favours pharmacotherapy

-2

-1

0

1

2

Favours placebo

Analysis 1.4. Comparison 1 Pharmacotherapy versus placebo, Outcome 4
Depression (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.4.1 Tricyclic antidepressant versus placebo
Volz 2000

99

Subtotal ***

99

8 (5.3)

101

9.5 (5.8)

101

100%

-0.27[-0.55,0.01]

100%

-0.27[-0.55,0.01]

-0.51[-0.88,-0.13]

Heterogeneity: Not applicable
Test for overall effect: Z=1.89(P=0.06)
1.4.2 New-generation antidepressants (SSRI, SNRI) versus placebo
Kroenke 2006

55

11.6 (4.7)

57

14.3 (5.8)

69.36%

Muller 2008

25

4.3 (5.5)

26

8.2 (5.6)

30.64%

-0.69[-1.26,-0.13]

Subtotal ***

80

100%

-0.56[-0.88,-0.25]

-0.62[-0.95,-0.29]

83

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%
Test for overall effect: Z=3.53(P=0)
1.4.3 Natural products (St. John's wort, Ze 185) versus placebo
Melzer 2009

118

7.2 (6.7)

54

11.3 (6.7)

50.21%

75

5.4 (3.9)

74

8.1 (4.1)

49.79%

-0.66[-0.99,-0.33]

100%

-0.64[-0.87,-0.41]

Volz 2002
Subtotal ***

193

128

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.85); I2=0%
Test for overall effect: Z=5.38(P<0.0001)
Favours pharmacotherapy
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Analysis 1.5. Comparison 1 Pharmacotherapy versus placebo, Outcome 5 Dysfunctional
cognitions, emotions, and behaviours (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.5.1 New-generation antidepressants (SSRI) versus placebo
Muller 2008

25

Subtotal ***

25

33.9 (18.5)

26

29.2 (17.3)

26

100%

0.26[-0.29,0.81]

100%

0.26[-0.29,0.81]

Heterogeneity: Not applicable
Test for overall effect: Z=0.92(P=0.36)
Favours pharmacotherapy

-100

-50

0

50

100

Favours placebo

Analysis 1.6. Comparison 1 Pharmacotherapy versus placebo, Outcome 6 Adverse effects.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

1.6.1 Tricyclic antidepressant versus placebo
Volz 2000
Subtotal (95% CI)

3/104

3/104

100%

1[0.21,4.84]

104

104

100%

1[0.21,4.84]

Total events: 3 (Experimental), 3 (Control)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
1.6.2 New-generation antidepressants (SNRI, SSRI) versus placebo
Kroenke 2006

4/55

2/57

78.39%

2.07[0.4,10.86]

Muller 2008

1/25

0/26

21.61%

3.12[0.13,73.06]

80

83

100%

2.26[0.52,9.81]

61.67%

1.01[0.09,10.9]

Subtotal (95% CI)
Total events: 5 (Experimental), 2 (Control)

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%
Test for overall effect: Z=1.09(P=0.27)
1.6.3 Natural products (St. John's wort LI 160, Ze 185 3-/4-combination) versus placebo
Melzer 2009

2/121

1/61

Müller 2004

0/87

0/88

Volz 2002

0/75

2/74

38.33%

0.2[0.01,4.04]

Subtotal (95% CI)

283

223

100%

0.54[0.08,3.5]

Not estimable

Total events: 2 (Experimental), 3 (Control)
Heterogeneity: Tau2=0; Chi2=0.71, df=1(P=0.4); I2=0%
Test for overall effect: Z=0.65(P=0.52)
Test for subgroup differences: Chi2=1.47, df=1 (P=0.48), I2=0%
Favours pharmacotherapy

0.01

0.1
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Analysis 1.7. Comparison 1 Pharmacotherapy versus placebo, Outcome 7
Treatment response (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

1.7.1 Tricyclic antidepressant versus placebo
Volz 2000

54/104

42/104

100%

1.29[0.95,1.73]

104

104

100%

1.29[0.95,1.73]

Subtotal (95% CI)
Total events: 54 (Experimental), 42 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=1.65(P=0.1)

1.7.2 New-generation antidepressants (SNRI, SSRI) versus placebo
Kroenke 2006

28/55

21/57

54.82%

1.38[0.9,2.12]

Muller 2008

21/25

7/26

45.18%

3.12[1.62,6.01]

80

83

100%

2[0.9,4.43]

2.19[1.37,3.52]

Subtotal (95% CI)
Total events: 49 (Experimental), 28 (Control)

Heterogeneity: Tau2=0.25; Chi2=4.18, df=1(P=0.04); I2=76.09%
Test for overall effect: Z=1.7(P=0.09)
1.7.3 Natural products (St. John's wort LI 160) versus placebo
Müller 2004

39/87

18/88

28.81%

Volz 2002

61/75

37/74

71.19%

1.63[1.26,2.09]

162

162

100%

1.77[1.34,2.34]

Subtotal (95% CI)
Total events: 100 (Experimental), 55 (Control)

Heterogeneity: Tau2=0.01; Chi2=1.32, df=1(P=0.25); I2=23.98%
Test for overall effect: Z=4.03(P<0.0001)
0.2

Favours placebo

0.5

1

2

5

Favours pharmacotherapy

Analysis 1.8. Comparison 1 Pharmacotherapy versus placebo, Outcome 8
Functional disability and quality of life (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

1.8.1 Tricyclic antidepressant versus placebo
Pilowsky 1990

22

Subtotal ***

22

51.2 (25.2)

22

51 (30.2)

22

100%

0.01[-0.58,0.6]

100%

0.01[-0.58,0.6]

Heterogeneity: Not applicable
Test for overall effect: Z=0.02(P=0.98)
1.8.2 New-generation antidepressants (SNRI, SSRI) versus placebo
Kroenke 2006

55

-61.5 (16.2)

57

-56.1 (17.2)

59.98%

-0.32[-0.69,0.05]

Muller 2008

25

6.9 (8)

26

13.4 (7.7)

40.02%

-0.82[-1.39,-0.24]

Subtotal ***

80

100%

-0.52[-1,-0.04]

83

Heterogeneity: Tau2=0.06; Chi2=2.03, df=1(P=0.15); I2=50.75%
Test for overall effect: Z=2.13(P=0.03)
Favours pharmacotherapy
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Comparison 2. Tricyclic antidepressants versus another medication
Outcome or subgroup title

No. of
studies

1 Severity/intensity of medically unexplained physical
symptoms (post-treatment score on self report scales)

3

1.1 Tricyclic antidepressants versus new-generation antidepressants (noradrenergic and specific serotonergic antidepressant (NaSSA), tetracyclic antidepressant (TeCA))

3

2 Acceptability

8

2.1 Tricyclic antidepressants versus new-generation antidepressants (NaSSA, serotonin noradrenaline reuptake inhibitor (SNRI), TeCA)

8

3 Anxiety (post-treatment score on self report and clinician-rated scales)

4

3.1 Tricyclic antidepressants versus new-generation antidepressants (NaSSA, SNRI, SSRI)

4

4 Depression (post-treatment score on self report and
clinician-rated scales)

6

4.1 Tricyclic antidepressants versus new-generation antidepressants (NaSSA, SNRI, TeCA)

6

5 Adverse effects

8

5.1 Tricyclic antidepressant versus new-generation antidepressants (NaSSA, SNRI, TeCA)

8

6 Treatment response (post-treatment score on self report
and clinician-rated scales)

2

6.1 Tricyclic antidepressant versus new-generation antidepressants (NaSSA)

2

No. of
participants

177

556

255

395

556

130

Statistical method

Effect size

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

Std. Mean Difference (IV, Random, 95% CI)

-0.16 [-0.55,
0.23]

Risk Ratio (M-H, Random,
95% CI)

Subtotals
only

Risk Ratio (M-H, Random,
95% CI)

1.48 [0.59,
3.72]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

Std. Mean Difference (IV, Random, 95% CI)

0.37 [-0.21,
0.95]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

Std. Mean Difference (IV, Random, 95% CI)

0.17 [-0.07,
0.40]

Risk Ratio (M-H, Random,
95% CI)

Subtotals
only

Risk Ratio (M-H, Random,
95% CI)

2.37 [0.39,
14.28]

Risk Ratio (M-H, Random,
95% CI)

Subtotals
only

Risk Ratio (M-H, Random,
95% CI)

0.93 [0.73,
1.19]

Analysis 2.1. Comparison 2 Tricyclic antidepressants versus another medication, Outcome 1 Severity/
intensity of medically unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.1.1 Tricyclic antidepressants versus new-generation antidepressants (noradrenergic and specific serotonergic antidepressant (NaSSA), tetracyclic antidepressant (TeCA))
Eberhard 1988

27

45.4 (29)

25

62 (26.2)

30.37%

Ye 2006

32

1.5 (0.6)

33

1.5 (0.6)

35.61%

0[-0.49,0.49]

Zhao 2006

30

1.5 (0.7)

30

1.5 (0.7)

34.03%

0.06[-0.45,0.56]

Favours TCA
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Experimental
N

Subtotal ***

Mean(SD)

89

Control
N

Std. Mean Difference

Mean(SD)

Weight

Std. Mean Difference

Random, 95% CI

Random, 95% CI

88

100%

-0.16[-0.55,0.23]

Heterogeneity: Tau2=0.05; Chi2=3.42, df=2(P=0.18); I2=41.55%
Test for overall effect: Z=0.8(P=0.42)
Favours TCA

-2

-1

0

1

2

Favours other medication

Analysis 2.2. Comparison 2 Tricyclic antidepressants versus another medication, Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

2.2.1 Tricyclic antidepressants versus new-generation antidepressants (NaSSA, serotonin noradrenaline reuptake inhibitor (SNRI),
TeCA)
Eberhard 1988

13/40

5/30

Jiang 2005

0/32

0/36

74.15%

1.95[0.78,4.88]
Not estimable

Ju 2003

0/34

0/34

Not estimable

Kong 2004

0/15

0/45

Not estimable

Ouyang 2006

0/40

0/40

Not estimable

Xu 2004

0/35

0/35

Not estimable

Yang 2006

0/35

0/35

Ye 2006

2/35

3/35

25.85%

0.67[0.12,3.75]

Subtotal (95% CI)

266

290

100%

1.48[0.59,3.72]

Not estimable

Total events: 15 (Experimental), 8 (Control)
Heterogeneity: Tau2=0.08; Chi2=1.16, df=1(P=0.28); I2=13.84%
Test for overall effect: Z=0.83(P=0.41)
0.01

Favours TCA

0.1

1

10

100

Favours other medication

Analysis 2.3. Comparison 2 Tricyclic antidepressants versus another medication,
Outcome 3 Anxiety (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.3.1 Tricyclic antidepressants versus new-generation antidepressants
(NaSSA, SNRI, SSRI)
Kong 2004

15

5 (3)

45

3 (4.1)

23.66%

0.51[-0.08,1.11]

Yang 2006

35

10.5 (2.1)

35

8.2 (1.9)

25.32%

1.13[0.62,1.63]

Ye 2006

32

1.5 (0.5)

33

1.5 (0.5)

25.71%

0[-0.49,0.49]

Zhao 2006

30

1.6 (0.6)

30

1.7 (0.6)

25.31%

-0.14[-0.65,0.36]

100%

0.37[-0.21,0.95]

Subtotal ***

112

143

Heterogeneity: Tau2=0.28; Chi2=14.99, df=3(P=0); I2=79.99%
Test for overall effect: Z=1.25(P=0.21)
Favours TCA
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Analysis 2.4. Comparison 2 Tricyclic antidepressants versus another medication,
Outcome 4 Depression (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

2.4.1 Tricyclic antidepressants versus new-generation antidepressants
(NaSSA, SNRI, TeCA)
Eberhard 1988

27

23.4 (26.7)

25

31.4 (27.4)

14.09%

Ju 2003

34

5.9 (4.2)

34

4.8 (3.7)

17.16%

0.27[-0.2,0.75]

Ouyang 2006

40

6.9 (5.3)

40

7.2 (6.3)

19.28%

-0.05[-0.49,0.38]

Yang 2006

35

8.3 (2.4)

35

6.6 (3.2)

17.07%

0.6[0.12,1.08]

Ye 2006

32

1.5 (0.4)

33

1.4 (0.4)

16.64%

0.25[-0.24,0.74]

30

1.5 (0.6)

30

1.3 (0.6)

15.76%

0.19[-0.32,0.69]

100%

0.17[-0.07,0.4]

Zhao 2006
Subtotal ***

198

197

-0.29[-0.84,0.26]

Heterogeneity: Tau2=0.03; Chi2=7.09, df=5(P=0.21); I2=29.45%
Test for overall effect: Z=1.39(P=0.16)
Favours TCA

-2

-1

0

1

2

Favours other medication

Analysis 2.5. Comparison 2 Tricyclic antidepressants versus another medication, Outcome 5 Adverse effects.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

2.5.1 Tricyclic antidepressant versus new-generation antidepressants
(NaSSA, SNRI, TeCA)
Eberhard 1988

8/40

1/30

Jiang 2005

0/32

0/36

48.16%

Not estimable

6[0.79,45.42]

Ju 2003

0/34

0/34

Not estimable

Kong 2004

0/15

0/45

Not estimable

Ouyang 2006

0/40

0/40

Not estimable

Xu 2004

0/35

0/35

Not estimable

Yang 2006

0/35

0/35

Ye 2006

2/35

2/35

51.84%

1[0.15,6.71]

Subtotal (95% CI)

266

290

100%

2.37[0.39,14.28]

Not estimable

Total events: 10 (Experimental), 3 (Control)
Heterogeneity: Tau2=0.68; Chi2=1.67, df=1(P=0.2); I2=40.26%
Test for overall effect: Z=0.94(P=0.35)
Favours TCA

0.01

0.1

1

10

100

Favours other medication

Analysis 2.6. Comparison 2 Tricyclic antidepressants versus another medication, Outcome
6 Treatment response (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

2.6.1 Tricyclic antidepressant versus new-generation antidepressants
(NaSSA)
Ye 2006

18/35

22/35

35.59%

Zhao 2006

22/30

22/30

64.41%

1[0.74,1.36]

65

65

100%

0.93[0.73,1.19]

Subtotal (95% CI)

0.82[0.54,1.23]

Total events: 40 (Experimental), 44 (Control)
Heterogeneity: Tau2=0; Chi2=0.63, df=1(P=0.43); I2=0%
Favours other medication

0.5
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Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

Test for overall effect: Z=0.57(P=0.57)
Favours other medication

0.5

0.7

1

1.5

2

Favours TCA

Comparison 3. New-generation antidepressants (SARI, NaSSA, SSRI) versus another medication
Outcome or subgroup title

No. of
studies

1 Severity/intensity of medically unexplained physical symptoms (post-treatment score on self report scales)

4

1.1 New-generation antidepressants (noradrenergic and specific serotonergic antidepressant (NaSSA), selective serotonin
reuptake inhibitor (SSRI)) versus other new-generation antidepressants (noradrenaline reuptake inhibitor (NRI), serotonin
noradrenaline reuptake inhibitor (SNRI), SSRI)

4

2 Acceptability

4

2.1 New-generation antidepressants (NaSSA, SSRI) versus other
new-generation antidepressants (NRI, SNRI, SSRI)

4

3 Depression (post-treatment score on self report and clinician-rated scales)

4

3.1 New-generation antidepressants (NaSSA, SSRI) versus other
new-generation antidepressants (NRI, SNRI, SSRI)

3

3.2 New-generation antidepressant (serotonin antagonist and
reuptake inhibitors (SARI)) versus non-steroidal anti-inflammatory drugs

1

4 Adverse effects

4

4.1 New-generation antidepressants (NaSSA, SSRI) versus other
new-generation antidepressants (NRI, SNRI, SSRI)

4

No. of
participants

Statistical method

Effect
size

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals
only

Std. Mean Difference (IV,
Random, 95% CI)

-0.16
[-0.45,
0.14]

Risk Ratio (M-H, Random,
95% CI)

Subtotals
only

Risk Ratio (M-H, Random,
95% CI)

0.92 [0.60,
1.40]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals
only

169

Std. Mean Difference (IV,
Random, 95% CI)

0.41 [0.00,
0.82]

140

Std. Mean Difference (IV,
Random, 95% CI)

-3.87
[-4.44,
-3.31]

Risk Ratio (M-H, Random,
95% CI)

Subtotals
only

Risk Ratio (M-H, Random,
95% CI)

0.84 [0.35,
2.03]

182

196

196

Analysis 3.1. Comparison 3 New-generation antidepressants (SARI, NaSSA,
SSRI) versus another medication, Outcome 1 Severity/intensity of medically
unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

3.1.1 New-generation antidepressants (noradrenergic and specific serotonergic antidepressant (NaSSA), selective serotonin reuptake inhibitor (SSRI)) versus other new-generation antidepressants (noradrenaline reuptake inhibitor
(NRI), serotonin noradrenaline reuptake inhibitor (SNRI), SSRI)
Favours NGA
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Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

Aragona 2005

15

30 (19)

14

31.5 (16.2)

16.28%

-0.08[-0.81,0.65]

Han 2008a

50

16 (4.2)

45

16.8 (4.2)

53.07%

-0.19[-0.59,0.21]

Han 2008b

28

7.4 (5.1)

17

8.2 (3.6)

23.72%

-0.17[-0.77,0.43]

Sanada 2010

8

10.1 (8.3)

5

10.2 (4.4)

6.93%

-0.01[-1.13,1.1]

Subtotal ***

101

100%

-0.16[-0.45,0.14]

81

Heterogeneity: Tau2=0; Chi2=0.13, df=3(P=0.99); I2=0%
Test for overall effect: Z=1.03(P=0.3)
Favours NGA
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Favours other medication

Analysis 3.2. Comparison 3 New-generation antidepressants (SARI,
NaSSA, SSRI) versus another medication, Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

3.2.1 New-generation antidepressants (NaSSA, SSRI) versus other
new-generation antidepressants (NRI, SNRI, SSRI)
Aragona 2005

6/17

9/18

28.68%

0.71[0.32,1.56]

Han 2008a

13/45

11/50

37.31%

1.31[0.66,2.63]

Han 2008b

8/28

5/17

20.33%

0.97[0.38,2.49]

Sanada 2010

3/11

5/10

13.68%

0.55[0.17,1.72]

Subtotal (95% CI)

101

95

100%

0.92[0.6,1.4]

Total events: 30 (Experimental), 30 (Control)
Heterogeneity: Tau2=0; Chi2=2.26, df=3(P=0.52); I2=0%
Test for overall effect: Z=0.4(P=0.69)
Favours NGA

0.01

0.1

1

10

100

Favours other medication

Analysis 3.3. Comparison 3 New-generation antidepressants (SARI, NaSSA, SSRI) versus another
medication, Outcome 3 Depression (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

3.3.1 New-generation antidepressants (NaSSA, SSRI) versus other new-generation antidepressants (NRI, SNRI, SSRI)
Aragona 2005

15

42.9 (12.8)

14

38.9 (10.7)

23.01%

0.33[-0.4,1.06]

Han 2008a

50

19.2 (15.2)

45

9.8 (11.3)

46.62%

0.69[0.28,1.11]

Han 2008b

28

11.2 (13.7)

17

10.6 (10.6)

30.38%

0.05[-0.56,0.65]

Subtotal ***

93

100%

0.41[0,0.82]

76

Heterogeneity: Tau2=0.05; Chi2=3.13, df=2(P=0.21); I2=36.13%
Test for overall effect: Z=1.98(P=0.05)
3.3.2 New-generation antidepressant (serotonin antagonist and reuptake inhibitors (SARI)) versus non-steroidal anti-inflammatory drugs
Wang 2003

70

Subtotal ***

70

5.4 (2.1)

70

16.3 (3.4)

70

100%

-3.87[-4.44,-3.31]

100%

-3.87[-4.44,-3.31]

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%
Test for overall effect: Z=13.39(P<0.0001)
Favours NGA
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Analysis 3.4. Comparison 3 New-generation antidepressants (SARI,
NaSSA, SSRI) versus another medication, Outcome 4 Adverse effects.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

3.4.1 New-generation antidepressants (NaSSA, SSRI) versus other
new-generation antidepressants (NRI, SNRI, SSRI)
Aragona 2005

2/17

4/18

31.6%

Han 2008a

3/45

4/50

37.12%

0.53[0.11,2.53]

Han 2008b

0/28

0/17

Sanada 2010

3/11

2/10

31.27%

1.36[0.28,6.56]

Subtotal (95% CI)

101

95

100%

0.84[0.35,2.03]

0.83[0.2,3.52]
Not estimable

Total events: 8 (Experimental), 10 (Control)
Heterogeneity: Tau2=0; Chi2=0.7, df=2(P=0.7); I2=0%
Test for overall effect: Z=0.38(P=0.7)
Favours NGA
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0.1

1

10

100

Favours other medication

Comparison 4. Pharmacotherapy versus a combination of medications
Outcome or subgroup title

No. of
studies

1 Severity/intensity of medically unexplained physical
symptoms (post-treatment score on self report scales)

3

1.1 Tricyclic antidepressant versus tricyclic antidepressant + antipsychotic

1

1.2 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

2

2 Acceptability

2

2.1 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

2

3 Anxiety (post-treatment score on self report and clinician-rated scales)

2

3.1 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

2

4 Depression (post-treatment score on self report and
clinician-rated scales)

3

4.1 Tricyclic antidepressant versus tricyclic antidepressant + antipsychotic

1

4.2 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

2

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

No. of
participants

Statistical method

Effect size

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

34

Std. Mean Difference (IV, Random, 95% CI)

0.26 [-0.42,
0.94]

107

Std. Mean Difference (IV, Random, 95% CI)

0.77 [0.32,
1.22]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals
only

Risk Ratio (M-H, Random, 95%
CI)

0.80 [0.25,
2.52]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

Std. Mean Difference (IV, Random, 95% CI)

0.95 [-0.91,
2.82]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals
only

34

Std. Mean Difference (IV, Random, 95% CI)

0.79 [0.09,
1.49]

107

Std. Mean Difference (IV, Random, 95% CI)

0.58 [-0.33,
1.48]

118

107

113
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Outcome or subgroup title

No. of
studies

5 Adverse effects

2

5.1 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

2

6 Treatment response (post-treatment score on self report and clinician-rated scales)

1

6.1 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic

1

No. of
participants

118

60

Statistical method

Effect size

Risk Ratio (M-H, Random, 95%
CI)

Subtotals
only

Risk Ratio (M-H, Random, 95%
CI)

0.6 [0.16,
2.29]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals
only

Risk Ratio (M-H, Random, 95%
CI)

1.7 [0.94,
3.08]

Analysis 4.1. Comparison 4 Pharmacotherapy versus a combination of medications, Outcome 1 Severity/
intensity of medically unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

4.1.1 Tricyclic antidepressant versus tricyclic antidepressant + antipsychotic
Zitman 1991

18

Subtotal ***

18

3.6 (2.6)

16

3 (1.8)

16

100%

0.26[-0.42,0.94]

100%

0.26[-0.42,0.94]

Heterogeneity: Not applicable
Test for overall effect: Z=0.75(P=0.45)
4.1.2 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic
Huang 2012

27

16.9 (7.1)

24

11.1 (3.3)

46.5%

1.02[0.43,1.6]

Li 2006

26

2.5 (0.8)

30

2.1 (0.7)

53.5%

0.55[0.02,1.09]

Subtotal ***

53

100%

0.77[0.32,1.22]

54

Heterogeneity: Tau2=0.02; Chi2=1.3, df=1(P=0.26); I2=22.81%
Test for overall effect: Z=3.34(P=0)
Favours AD

-2

-1

0

1

2

Favours AD + AP

Analysis 4.2. Comparison 4 Pharmacotherapy versus a combination of medications, Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

4.2.1 Selective serotonin reuptake inhibitor versus selective serotonin
reuptake inhibitor + antipsychotic
Huang 2012

9/30

9/30

86.73%

1[0.46,2.17]

Li 2006

0/30

2/28

13.27%

0.19[0.01,3.73]

60

58

100%

0.8[0.25,2.52]

Subtotal (95% CI)
Total events: 9 (Experimental), 11 (Control)

Heterogeneity: Tau2=0.24; Chi2=1.19, df=1(P=0.28); I2=16.04%
Test for overall effect: Z=0.38(P=0.7)
Favours AD
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0.1
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Analysis 4.3. Comparison 4 Pharmacotherapy versus a combination of medications,
Outcome 3 Anxiety (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

4.3.1 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic
Huang 2012

27

11.9 (2.3)

24

7 (2.8)

49.37%

1.92[1.25,2.59]

Li 2006

26

2.1 (0.8)

30

2 (0.7)

50.63%

0.01[-0.51,0.54]

Subtotal ***

53

100%

0.95[-0.91,2.82]

54

Heterogeneity: Tau2=1.72; Chi2=19.18, df=1(P<0.0001); I2=94.79%
Test for overall effect: Z=1(P=0.32)
-2

Favours AD

-1

0

1

2

Favours AD + AP

Analysis 4.4. Comparison 4 Pharmacotherapy versus a combination of medications,
Outcome 4 Depression (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental
N

Mean(SD)

Control
N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

4.4.1 Tricyclic antidepressant versus tricyclic antidepressant + antipsychotic
Zitman 1991

18

Subtotal ***

18

40.4 (6.9)

16

34.5 (7.7)

16

100%

0.79[0.09,1.49]

100%

0.79[0.09,1.49]

1.05[0.46,1.64]

Heterogeneity: Not applicable
Test for overall effect: Z=2.21(P=0.03)
4.4.2 Selective serotonin reuptake inhibitor versus selective serotonin reuptake inhibitor + antipsychotic
Huang 2012

27

9.4 (2.8)

24

6.6 (2.5)

48.92%

Li 2006

26

2.2 (0.8)

30

2.1 (0.8)

51.08%

0.12[-0.4,0.65]

Subtotal ***

53

100%

0.58[-0.33,1.48]

54

Heterogeneity: Tau2=0.35; Chi2=5.28, df=1(P=0.02); I2=81.06%
Test for overall effect: Z=1.24(P=0.21)
-1

Favours AD

-0.5

0

0.5

1

Favours AD + AP

Analysis 4.5. Comparison 4 Pharmacotherapy versus a combination of medications, Outcome 5 Adverse effects.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

4.5.1 Selective serotonin reuptake inhibitor versus selective serotonin
reuptake inhibitor + antipsychotic
Huang 2012

3/30

5/30

Li 2006

0/30

0/28

60

58

Subtotal (95% CI)

100%

0.6[0.16,2.29]
Not estimable

100%

0.6[0.16,2.29]

Total events: 3 (Experimental), 5 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=0.75(P=0.45)
Favours AD
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Analysis 4.6. Comparison 4 Pharmacotherapy versus a combination of medications, Outcome
6 Treatment response (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

4.6.1 Selective serotonin reuptake inhibitor versus selective serotonin
reuptake inhibitor + antipsychotic
Huang 2012
Subtotal (95% CI)

17/30

10/30

100%

1.7[0.94,3.08]

30

30

100%

1.7[0.94,3.08]

Total events: 17 (Experimental), 10 (Control)
Heterogeneity: Not applicable
Test for overall effect: Z=1.75(P=0.08)
Favours AD

0.2

0.5

1

2

5

Favours AD + AP

Comparison 5. Subgroup analysis 1: Co-morbidity (based on the comparison pharmacotherapy versus placebo)
Outcome or subgroup title

No. of
studies

1 Severity/intensity of medically unexplained physical symptoms (posttreatment score on self report scales)

4

1.1 Co-morbid mental disorders

3

1.2 No co-morbid mental disorders

1

2 Acceptability

4

2.1 Co-morbid mental disorder

2

2.2 No co-morbid mental disorder

2

No. of
participants

Statistical method

Effect size

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

243

Std. Mean Difference (IV, Random, 95% CI)

-0.91 [-1.36, -0.46]

200

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.35, 0.21]

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

163

Risk Ratio (M-H, Random, 95% CI)

1.01 [0.64, 1.61]

390

Risk Ratio (M-H, Random, 95% CI)

1.05 [0.59, 1.89]

Analysis 5.1. Comparison 5 Subgroup analysis 1: Co-morbidity (based on the
comparison pharmacotherapy versus placebo), Outcome 1 Severity/intensity of
medically unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

5.1.1 Co-morbid mental disorders
Kroenke 2006

55

9.7 (3.4)

57

11.5 (3.2)

38.94%

-0.54[-0.92,-0.16]

Luo 2009

40

33.1 (18.8)

40

55.3 (25.4)

34.11%

-0.98[-1.45,-0.52]

Muller 2008

25

5.6 (5)

26

12.5 (5.1)

26.95%

-1.34[-1.96,-0.73]

Subtotal ***

120

100%

-0.91[-1.36,-0.46]

100%

-0.07[-0.35,0.21]

123

Heterogeneity: Tau2=0.1; Chi2=5.38, df=2(P=0.07); I2=62.82%
Test for overall effect: Z=3.95(P<0.0001)
5.1.2 No co-morbid mental disorders
Volz 2000

99

0.9 (0.8)

101

1 (0.7)

Favours pharmacotherapy
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Experimental
N

Subtotal ***

Control

Mean(SD)

N

99

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

101

100%

-0.07[-0.35,0.21]

Heterogeneity: Not applicable
Test for overall effect: Z=0.48(P=0.63)
Favours pharmacotherapy

-2

-1

0

1

2

Favours placebo

Analysis 5.2. Comparison 5 Subgroup analysis 1: Co-morbidity (based on
the comparison pharmacotherapy versus placebo), Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

5.2.1 Co-morbid mental disorder
Kroenke 2006
Muller 2008

21/55

22/57

97.83%

0.99[0.62,1.58]

1/25

0/26

2.17%

3.12[0.13,73.06]

80

83

100%

1.01[0.64,1.61]

1.01[0.36,2.82]

Subtotal (95% CI)
Total events: 22 (Experimental), 22 (Control)

Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.48); I2=0%
Test for overall effect: Z=0.06(P=0.95)
5.2.2 No co-morbid mental disorder
Melzer 2009

10/121

5/61

31.92%

Volz 2000

14/104

13/104

68.08%

1.08[0.53,2.18]

225

165

100%

1.05[0.59,1.89]

Subtotal (95% CI)
Total events: 24 (Experimental), 18 (Control)

Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%
Test for overall effect: Z=0.18(P=0.86)
Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%
Favours pharmacotherapy

0.01

0.1

1

10

100

Favours placebo

Comparison 6. Subgroup analysis 2: Source of funding (based on the comparison pharmacotherapy versus placebo)
Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

1 Severity/intensity of medically unexplained physical symptoms (post-treatment score on self report scales)

7

804

Std. Mean Difference (IV, Random, 95%
CI)

-0.66 [-0.97,
-0.36]

1.1 Funding by pharmaceutical industry

5

685

Std. Mean Difference (IV, Random, 95%
CI)

-0.64 [-1.02,
-0.27]

1.2 No funding by pharmaceutical industry

2

119

Std. Mean Difference (IV, Random, 95%
CI)

-0.75 [-1.29,
-0.21]

2 Acceptability

6

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

2.1 Funding by pharmaceutical industry

6

Risk Ratio (M-H, Random, 95% CI)

0.99 [0.70, 1.40]

877
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Analysis 6.1. Comparison 6 Subgroup analysis 2: Source of funding (based on the
comparison pharmacotherapy versus placebo), Outcome 1 Severity/intensity of
medically unexplained physical symptoms (post-treatment score on self report scales).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

6.1.1 Funding by pharmaceutical industry
Kroenke 2006

55

9.7 (3.4)

57

11.5 (3.2)

15.21%

-0.54[-0.92,-0.16]

Muller 2008

25

5.6 (5)

26

12.5 (5.1)

11.02%

-1.34[-1.96,-0.73]

Müller 2004

87

12.4 (8.6)

86

18.3 (9.4)

16.53%

-0.65[-0.96,-0.35]

Volz 2000

99

0.9 (0.8)

101

1 (0.7)

17.04%

-0.07[-0.35,0.21]

Volz 2002

75

6.8 (5.5)

74

12.5 (7.6)

15.99%

-0.85[-1.18,-0.51]

75.78%

-0.64[-1.02,-0.27]

-0.98[-1.45,-0.52]

Subtotal ***

341

344

Heterogeneity: Tau2=0.14; Chi2=21.49, df=4(P=0); I2=81.39%
Test for overall effect: Z=3.41(P=0)
6.1.2 No funding by pharmaceutical industry
Luo 2009

40

33.1 (18.8)

40

55.3 (25.4)

13.57%

Pilowsky 1990

20

58.2 (23.9)

19

68 (21.2)

10.65%

-0.43[-1.06,0.21]

Subtotal ***

60

59

24.22%

-0.75[-1.29,-0.21]

403

100%

-0.66[-0.97,-0.36]

Heterogeneity: Tau2=0.08; Chi2=1.94, df=1(P=0.16); I2=48.47%
Test for overall effect: Z=2.71(P=0.01)
Total ***

401

Heterogeneity: Tau2=0.12; Chi2=24.9, df=6(P=0); I2=75.9%
Test for overall effect: Z=4.27(P<0.0001)
Test for subgroup differences: Chi2=0.1, df=1 (P=0.76), I2=0%
Favours pharmacotherapy

-2

-1

0

1

2

Favours placebo

Analysis 6.2. Comparison 6 Subgroup analysis 2: Source of funding (based on
the comparison pharmacotherapy versus placebo), Outcome 2 Acceptability.
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

6.2.1 Funding by pharmaceutical industry
Kroenke 2006

21/55

22/57

53.6%

Melzer 2009

10/121

5/61

11.16%

1.01[0.36,2.82]

Muller 2008

1/25

0/26

1.19%

3.12[0.13,73.06]

Müller 2004

0.99[0.62,1.58]

5/87

6/88

8.94%

0.84[0.27,2.66]

Volz 2000

14/104

13/104

23.81%

1.08[0.53,2.18]

Volz 2002

0/75

2/74

1.3%

0.2[0.01,4.04]

Subtotal (95% CI)

467

410

100%

0.99[0.7,1.4]

Total events: 51 (Experimental), 48 (Control)
Heterogeneity: Tau2=0; Chi2=1.74, df=5(P=0.88); I2=0%
Test for overall effect: Z=0.06(P=0.95)
Favours pharmacotherapy
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Comparison 7. Subgroup analysis 3: Source outcome rating (based on the comparison pharmacotherapy versus
placebo)
Outcome or subgroup title

No. of
studies

No. of
participants

Statistical method

Effect size

1 Severity/intensity of medically unexplained physical symptoms (post-treatment score)

7

1377

Std. Mean Difference (IV, Random, 95%
CI)

-0.75 [-1.00, -0.49]

1.1 Self report scales

7

804

Std. Mean Difference (IV, Random, 95%
CI)

-0.66 [-0.97, -0.36]

1.2 Clinician-rated scales

4

573

Std. Mean Difference (IV, Random, 95%
CI)

-0.91 [-1.42, -0.40]

Analysis 7.1. Comparison 7 Subgroup analysis 3: Source outcome rating (based
on the comparison pharmacotherapy versus placebo), Outcome 1 Severity/
intensity of medically unexplained physical symptoms (post-treatment score).
Study or subgroup

Experimental
N

Control

Mean(SD)

N

Std. Mean Difference

Mean(SD)

Weight

Random, 95% CI

Std. Mean Difference
Random, 95% CI

7.1.1 Self report scales
Kroenke 2006

55

9.7 (3.4)

57

11.5 (3.2)

9.52%

-0.54[-0.92,-0.16]

Luo 2009

40

33.1 (18.8)

40

55.3 (25.4)

8.58%

-0.98[-1.45,-0.52]

Muller 2008

25

5.6 (5)

26

12.5 (5.1)

7.09%

-1.34[-1.96,-0.73]

Müller 2004

87

12.4 (8.6)

86

18.3 (9.4)

10.25%

-0.65[-0.96,-0.35]

Pilowsky 1990

20

58.2 (23.9)

19

68 (21.2)

6.88%

-0.43[-1.06,0.21]

Volz 2000

99

0.9 (0.8)

101

1 (0.7)

10.53%

-0.07[-0.35,0.21]

Volz 2002

75

6.8 (5.5)

74

12.5 (7.6)

9.95%

-0.85[-1.18,-0.51]

62.81%

-0.66[-0.97,-0.36]

Subtotal ***

401

403

Heterogeneity: Tau2=0.12; Chi2=24.9, df=6(P=0); I2=75.9%
Test for overall effect: Z=4.27(P<0.0001)
7.1.2 Clinician-rated scales
Muller 2008

25

4.2 (4.5)

26

13.1 (4.6)

6.54%

-1.93[-2.6,-1.25]

Müller 2004

87

5.8 (4.2)

86

8.4 (4.6)

10.27%

-0.59[-0.89,-0.28]

Volz 2000

99

7.3 (4.4)

101

9.1 (5.8)

10.51%

-0.35[-0.63,-0.07]

Volz 2002

75

6.6 (4.3)

74

12 (5.6)

9.87%

-1.06[-1.41,-0.72]

287

37.19%

-0.91[-1.42,-0.4]

690

100%

-0.75[-1,-0.49]

Subtotal ***

286

Heterogeneity: Tau2=0.23; Chi2=23.7, df=3(P<0.0001); I2=87.34%
Test for overall effect: Z=3.5(P=0)
Total ***

687

Heterogeneity: Tau2=0.14; Chi2=49.87, df=10(P<0.0001); I2=79.95%
Test for overall effect: Z=5.75(P<0.0001)
Test for subgroup differences: Chi2=0.66, df=1 (P=0.42), I2=0%
Favours pharmacotherapy
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Comparison 8. Best-case/worst-case analysis (based on comparison 'new-generation antidepressants versus
placebo')
Outcome or subgroup title

No. of
studies

1 Treatment response (post-treatment
score on self report and clinician-rated
scales)

2

1.1 Complete-case analysis

2

1.2 Best-case analysis
1.3 Worst-case analysis

No. of
participants

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

119

Risk Ratio (M-H, Random, 95% CI)

2.02 [0.82, 4.97]

2

163

Risk Ratio (M-H, Random, 95% CI)

2.59 [1.90, 3.53]

2

163

Risk Ratio (M-H, Random, 95% CI)

1.41 [0.30, 6.63]

Analysis 8.1. Comparison 8 Best-case/worst-case analysis (based on comparison 'new-generation antidepressants
versus placebo'), Outcome 1 Treatment response (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

8.1.1 Complete-case analysis
Kroenke 2006

28/34

21/35

54.99%

1.37[1,1.88]

Muller 2008

21/24

7/26

45.01%

3.25[1.69,6.23]

58

61

100%

2.02[0.82,4.97]

Subtotal (95% CI)
Total events: 49 (Experimental), 28 (Control)

Heterogeneity: Tau2=0.36; Chi2=6.27, df=1(P=0.01); I2=84.06%
Test for overall effect: Z=1.54(P=0.12)
8.1.2 Best-case analysis
Kroenke 2006

49/55

21/57

77.28%

2.42[1.7,3.44]

Muller 2008

22/25

7/26

22.72%

3.27[1.71,6.26]

80

83

100%

2.59[1.9,3.53]

Subtotal (95% CI)
Total events: 71 (Experimental), 28 (Control)

Heterogeneity: Tau2=0; Chi2=0.65, df=1(P=0.42); I2=0%
Test for overall effect: Z=6.02(P<0.0001)
8.1.3 Worst-case analysis
Kroenke 2006

28/55

43/57

51.78%

0.67[0.5,0.91]

Muller 2008

21/25

7/26

48.22%

3.12[1.62,6.01]

80

83

100%

1.41[0.3,6.63]

Subtotal (95% CI)
Total events: 49 (Experimental), 50 (Control)

Heterogeneity: Tau2=1.18; Chi2=18.45, df=1(P<0.0001); I2=94.58%
Test for overall effect: Z=0.44(P=0.66)
Favours placebo
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Comparison 9. Best-case/worst-case analysis (based on comparison 'natural products versus placebo')
Outcome or subgroup title

No. of
studies

1 Treatment response (post-treatment
score on self report and clinician-rated
scales)

2

1.1 Complete-case analysis

2

1.2 Best-case analysis
1.3 Worst-case analysis

No. of
participants

Statistical method

Effect size

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

311

Risk Ratio (M-H, Random, 95% CI)

1.75 [1.29, 2.36]

2

324

Risk Ratio (M-H, Random, 95% CI)

1.92 [1.26, 2.94]

2

324

Risk Ratio (M-H, Random, 95% CI)

1.57 [1.27, 1.93]

Analysis 9.1. Comparison 9 Best-case/worst-case analysis (based on comparison 'natural products versus
placebo'), Outcome 1 Treatment response (post-treatment score on self report and clinician-rated scales).
Study or subgroup

Experimental

Control

Risk Ratio

n/N

n/N

M-H, Random, 95% CI

Weight

Risk Ratio
M-H, Random, 95% CI

9.1.1 Complete-case analysis
Müller 2004

39/82

18/82

31.42%

Volz 2002

61/75

37/72

68.58%

1.58[1.23,2.03]

157

154

100%

1.75[1.29,2.36]

2.47[1.56,3.92]

Subtotal (95% CI)

2.17[1.36,3.46]

Total events: 100 (Experimental), 55 (Control)
Heterogeneity: Tau2=0.02; Chi2=1.5, df=1(P=0.22); I2=33.19%
Test for overall effect: Z=3.64(P=0)
9.1.2 Best-case analysis
Müller 2004

44/87

18/88

40.06%

Volz 2002

61/75

37/74

59.94%

1.63[1.26,2.09]

162

162

100%

1.92[1.26,2.94]

1.64[1.09,2.48]

Subtotal (95% CI)
Total events: 105 (Experimental), 55 (Control)

Heterogeneity: Tau2=0.06; Chi2=2.71, df=1(P=0.1); I2=63.14%
Test for overall effect: Z=3.02(P=0)
9.1.3 Worst-case analysis
Müller 2004

39/87

24/88

25.47%

Volz 2002

61/75

39/74

74.53%

1.54[1.21,1.96]

162

162

100%

1.57[1.27,1.93]

Subtotal (95% CI)
Total events: 100 (Experimental), 63 (Control)

Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.79); I2=0%
Test for overall effect: Z=4.23(P<0.0001)
Favours placebo

0.2

0.5

1

2

5

Favours pharmacotherapy
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Table 1. Diagnostic categories of somatoform disorders

(Continued)

DSM-IV

ICD-10

yes

no

Somatisation disorder (300.81)

Somatisation disorder (F45.0)

x

-

Undifferentiated somatoform disorder
(300.82)

Undifferentiated somatoform disorder (F45.1)

x

-

-

Somatoform autonomic dysfunction (F45.3)

x

-

Pain disorder (307.8)

Persistent somatoform pain disorder (F45.4)

x

-

Hypochondriasis (300.7)

Hypochondriacal disorder (F45.2)

-

x

-

Other somatoform disorders (F45.8)

-

x

Somatoform disorders, unspecified
(300.82)

Somatoform disorders, unspecified (F45.9)

-

x

Body dysmorphic disorder (300.7)

Body dysmorphic disorder (F45.2)

-

x

Conversion disorder (300.11)

Dissociative and conversion disorders (F44)*

-

x

DSM-IV: Diagnostic and Statistical Manual of Mental Disorders; ICD-10: International Classification of Diseases.
Note. *Conversion disorder is not classified as a somatoform disorder in ICD-10 but is a separate diagnostic category.

Table 2. Co-morbid mental disorders or exclusion of co-morbid mental conditions in trials comparing
pharmacotherapy versus placebo or other medication (see also subgroup analyses 'Pharmacotherapy versus
placebo (subgrouped by co-morbidity of participants)')
Trial ID

Experimental
treatment
group
- medication
class

Control
treatment
group
- medication
class

Comorbid
mental
disorders?
Yes/no/
ns

Detailed information
about co-morbid diagnoses in participants

Detailed information about the exclusion of participants with co-morbid diagnoses

Kroenke
2006

SNRI

-

Yes

Major depression, generalised anxiety disorder,
social anxiety disorder

People with current/past history of mania, bipolar disorder, schizophrenia, or other psychotic disorder; history of serious or clinically unstable psychiatric condition; known or suspected alcohol or drug abuse within
6 months of screening

Luo 2009

SSRI

-

Yes

38/80 participants had
depression (17 itemHDRS ≥ 17)

People with co-exist depressive symptoms occurred
prior to pain with HDRS - Total Score ≥ 17

Melzer
2009

NP

-

No

-

People with historically known or clinical indication of
a psychiatric disorder

Müller
2004

NP

-

ns

-

People with co-morbid depression, drug/alcohol
abuse, schizophrenia, or schizo-affective disorder

or exclusion of participants with co-morbid
diagnoses (for studies
that do not provide details about co-morbid
conditions)
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Table 2. Co-morbid mental disorders or exclusion of co-morbid mental conditions in trials comparing
pharmacotherapy versus placebo or other medication (see also subgroup analyses 'Pharmacotherapy versus
placebo (subgrouped by co-morbidity of participants)') (Continued)
Muller
2008

SSRI

-

Yes

Dysthymia (27.5%); major depressive episode
(2.0%); anxiety disorder
(panic disorder/agoraphobia/social anxiety
disorder/generalised
anxiety disorder) (52.9%)

People with somatic symptoms that were judged to be
secondary to a psychiatric disorder other than MDS;
current or past psychotic disorder; significant suicidal
risk

Pilowsky
1990

TCA

-

ns

-

People with psychotic illness (including MDS), organic
brain syndrome, or alcohol dependence

Volz
2000

TCA

-

No

-

People with other significant Axis I diagnoses (e.g.
panic disorder, major depressive disorder, substance
abuse)

Volz
2002

NP

-

ns

-

People with an additional diagnosis of depression,
schizophrenia, schizo-affective disorder, or dementia

Altamura 1991

AP

AP

Yes

Dysthymia (n = 27), anxiety disorder NOS (n = 6)

ns

Aragona
2005

SSRI

NRI

No

-

People with a diagnosis of another mental disorder

Eberhard
1988

TeCA

TCA

ns

-

People with major depressive disorder, abuse of drugs,
and other psychiatric illnesses

Han
2008b

SSRI

SSRI

ns

-

People with history of or current (or both) psychotic
disorders (such as schizophrenia, schizoaffective disorder, and bipolar disorder); current DSM Axis I disorders
that could possibly account for the somatic symptoms
(e.g. MDD, anxiety disorders, factitious disorder, malingering, or another somatoform disorder such as somatisation disorder); substance abuse of dependence in
the previous 12 months; effect of co-morbid psychiatric
disorders on the effects of the antidepressants cannot
be excluded because of the absence of a structured
clinical interview, although participants were rigorously evaluated according to DSM-IV criteria

Huang
2012

SSRI +
AP

SSRI

no

-

People with a diagnosis of another mental disorder
(e.g. panic disorder, MDD, or substance abuse)

Jiang
2005

SNRI

TCA

ns

-

People with drug dependence, severe psychosis, or
paranoia

Ju 2003

SNRI

TCA

ns

-

People with psychotic symptoms, severe brain injury,
or substance abuse

Kong
2004

SSRI

TCA

ns

-

ns

Li 2006

SSRI +
AP

SSRI

ns

-

ns
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Table 2. Co-morbid mental disorders or exclusion of co-morbid mental conditions in trials comparing
pharmacotherapy versus placebo or other medication (see also subgroup analyses 'Pharmacotherapy versus
placebo (subgrouped by co-morbidity of participants)') (Continued)
Ouyang
2006

NaSSA

TCA

Yes

38/80 participants had
depression (17 itemHDRS ≥ 17). No information about other co-morbidities in the sample
was provided

People whose pain was caused by depression, anxiety,
or schizophrenia

Sanada
2010

SSRI

SNRI

ns

-

ns

Wang
2003

SARI

NSAID

Yes

Based on diagnostic criteria in CCMD-3: depression (n = 46), dysthymia
(n = 50), hypochondriasis
(n = 20)

Severely depressed, suicidal people

Yang
2006

SNRI

TCA

ns

-

ns

Ye 2006

NaSSA

TCA

ns

ns

People with any type of drug dependence

Xu 2004

SNRI

TCA

ns

-

ns

Zhao
2006

NaSSA

TCA

no

-

People with other mental disorders

Zitman
1991

TCA + AP

TCA

yes

Atypical depression (n =
1), dysthymic disorder (n
= 1), panic disorder (n =
1), nicotine abuse (n = 1),
tea abuse (n = 1), benzodiazepine abuse (n = 1)

People with a serious psychiatric disease necessitating immediate treatment; or who were alcohol or illicit
drug dependent

Anxiety disorder NOS: anxiety disorder not otherwise specified; AP: antipsychotic; CCMD: Chinese Classification of Mental Disorders; SARI:
serotonin antagonist and reuptake inhibitor; DSM: Diagnostic and Statistical Manual of Mental Disorders; HDRS: Hamilton Depression
Rating Scale; ID: identification; ns: not specified; MDD: major depressive disorder; MDS: major depressive syndrome; n: number; NaSSA:
noradrenergic specific serotonergic antidepressant; NP: natural product; NRI: noradrenaline reuptake inhibitor; NSAID: non-steroidal
anti-inflammatory drug; SNRI: serotonin noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic
antidepressant; TeCA: tetracyclic antidepressant.

Table 3. Concomitant treatments or exclusion/permission of concomitant treatments in trials comparing
pharmacotherapy versus placebo or other medication
Trial ID

Experimental
treatment
group medication class

Control
treatment
group medication class

Detailed information about the exclusion of or permission of concomitant treatments

Detailed
information about
concomitant treatments

Kroenke
2006

SNRI

-

- Exclusion: use of triptans, psychoactive herbal medications, or any other
psychoactive drugs or having a positive urine drug test at screening

- Proportion of participants
who took
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Table 3. Concomitant treatments or exclusion/permission of concomitant treatments in trials comparing
pharmacotherapy versus placebo or other medication (Continued)
- Permitted: zaleplon, zopiclone (1 dose nightly) as needed for insomnia for
up to 6 nights during the 14 days immediately following randomisation and
short-term treatments for symptoms of allergies, colds, or influenza (without
psychotropic effects)

at least 1
concomitant medication in
venlafaxine
ER groups
vs. placebo
were 63.6%
vs. 63.3%;
for NSAIDs
10% vs.
13%; for
paracetamol (acetaminophen)
7% vs. 9%;
for COX-2
inhibitors
8% vs. 3%;
and for salicylates 4%
vs. 4%

Luo 2009

SSRI

-

- Exclusion: use of antidepressants for the treatment of pain or depression

-

Melzer
2009

NP

-

- Exclusion: psychotherapy, physiotherapy, acupuncture, or using psychoactive drugs including central stimulants and α-/β-blockers were excluded

-

- Permitted: in case of sleeping disorders, chloral hydrate was allowed up to 3
g/day
Müller
2004

NP

-

- Exclusion: use of psychotropic drugs 4 weeks before and during the study,
concomitant psychotherapy, and concomitant treatment with phenprocoumon or cyclosporin (or both)

-

Muller
2008

SSRI

-

- Exclusion: use of psychotropics or cognitive-behavioural therapy

-

Pilowsky
1990

TCA

-

-

-

Volz 2000

TCA

-

-

-

Volz 2002

NP

-

- Exclusion: concomitant treatment with psychopharmacological active compounds

-

Altamura
1991

AP

AP

-

-

Aragona
2005

SSRI

NRI

- Exclusion: psychotropic drugs endowed with an analgesic action (e.g.
amitriptyline)

-

- Permitted: benzodiazepines at low doses for people with sleep disturbances
- Because people with other mental disorders were excluded, participants
did not take any other type of psychotropic drugs
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Table 3. Concomitant treatments or exclusion/permission of concomitant treatments in trials comparing
pharmacotherapy versus placebo or other medication (Continued)
Eberhard
1988

TeCA

TCA

- Exclusion: other central nervous system-active drugs

-

Han 2008a

NaSSA

-

- Exclusion: other psychotropic medications; use of prescription analgesics,
muscle relaxants, and corticosteroids

- Mirtazapine group:
46% lorazepam,
10% alprazolam

- Permitted: hypnosedatives and benzodiazepines only for temporary control
of insomnia or anxiety; concomitant medications such as non-prescription
paracetamol were allowed only on an as-needed basis

- Venlafaxine group:
32% lorazepam,
29% alprazolam
Han
2008b

SSRI

SSRI

- Exclusion: other psychotropic medications; use of prescription analgesics,
muscle relaxants, and corticosteroids
- Permitted: hypnosedatives and benzodiazepines only for temporary control
of insomnia or anxiety; concomitant medications such as non-prescription
paracetamol were allowed only on an as-needed basis

- Fluoxetine group:
32.1% lorazepam,
7.1% alprazolam
- Sertraline group:
35.3% lorazepam,
17.6% alprazolam

Huang
2012

SSRI + AP

SSRI

- Exclusion: other psychotropic medications

-

Jiang
2005

SNRI

TCA

- Permitted: treatment of adverse effects insomnia/anxiety with benzodiazepines and nausea with vitamin B6

-

Ju 2003

SNRI

TCA

- Exclusion: antidepressant and AP medication

-

- Permitted: benzodiazepines for insomnia, only for temporary control of the
symptoms

- Permitted: sleep medication alprazolam (0.4-0.8 mg/day)
Kong 2004

SSRI

TCA

- Permitted: alprazolam of a maximum dose of 0.8 mg/day

-

Li 2006

SSRI + AP

SSRI

-

-

Ouyang
2006

NaSSA

TCA

- Exclusion: any other medication

-

Sanada
2010

SSRI

SNRI

-

-

Wang
2003

DAS

NSAID

- Exclusion: any other medication

-

- Permitted: exception of benzodiazepines for participants with sleep difficulties
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Table 3. Concomitant treatments or exclusion/permission of concomitant treatments in trials comparing
pharmacotherapy versus placebo or other medication (Continued)
Xu 2004

SNRI

TCA

-

-

Yang 2006

SNRI

TCA

- Permitted: alprazolam (0.4-0.8 mg/day) for participants with sleep difficulties

-

Ye 2006

NaSSA

TCA

- Permitted: zolpidem for participants with sleep difficulties

-

Zhao 2006

NaSSA

TCA

- Exclusion: use of MAOI or other antidepressants during the first 2 weeks of
treatment; use of other medication such as antidepressants, mood stabiliser, antipsychotic medication, or electroconvulsive therapy during the 8 treatment weeks

-

- Permitted: benzodiazepines were allowed for participants with insomnia.
Benzhexol was allowed for participants with extrapyramidal adverse effects
Zitman
1991

TCA + AP

TCA

- Permitted: benzodiazepines and non-narcotic analgesics could be continued during the trial, but the participants were asked to keep the dose as low
as possible

-

AP: antipsychotic; COX: cyclo-oxygenase; DAS: ; ER: extended release; ID: identification; MAOI: monoamine oxidase inhibitors; NaSSA:
noradrenergic specific serotonergic antidepressant; NP: natural product; NRI: noradrenaline reuptake inhibitor; NSAID: non-steroidal
anti-inflammatory drug; SNRI: serotonin noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic
antidepressant; TeCA: tetracyclic antidepressant.
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Experimental treatment

Placebo

Control treatment

Total

% attrition

Attrition

Total

% attrition

Med- Chemical agent
ication
class

Attrition

Total

% attrition

Pilowsky 1990

TCA

Amitriptyline

ns

26

25.0

ns

24

31.0

-

-

-

-

-

Kong 2004

TCA

Amitriptyline

0

15

0

-

-

-

SSRI

Paroxetinea

0

45

0

Jiang 2005

TCA

Amitriptyline

0

32

0

-

-

-

SNRI

Venlafaxine

0

36

0

Yang 2006

TCA

Amitriptyline

0

35

0

-

-

-

SNRI

Venlafaxine

0

35

0

Xu 2004

TCA

Amitriptyline

0

35

0

-

-

-

SNRI

Venlafaxine

0

35

0

Ouyang 2006

TCA

Amitriptyline

0

40

0

-

-

-

NaSSA Mirtazapine

0

40

0

Zhao 2006

TCA

Amitriptyline

ns

30

ne

-

-

-

NaSSA Mirtazapine

ns

30

ne

Zitman 1991

TCA

Amitriptyline

ns

ns

ne

-

-

-

TCA
+
AP

ns

ns

ne

Ye 2006

TCA

Clomipramine

2

35

5.7

-

-

-

NaSSA Mirtazapine

2

35

5.7

Eberhard 1988

TCA

Clomipramine

13

40

32.5

-

-

-

TeCA Maprotiline

5

30

16.7

Ju 2003

TCA

Doxepin

0

34

0

-

-

-

SNRI

Venlafaxine

0

34

0

Volz 2000

TCA

Opipramol

14

104

13.5

13

104

12.4

-

-

-

-

-

Zitman 1991

TCA
+
AP

Amitriptyline + flupentixol

ns

ns

ne

-

-

-

TCA

Amitriptyline

ns

ns

ne

Amitriptyline + flupentixol
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Table 4. Attrition rate (acceptability: proportion of participants who dropped out during the experimental as well as the comparator intervention,
calculated as a proportion of the total number of randomised participants)

0

45

0

-

-

-

TCA

Amitriptyline

0

15

0

Li 2006

SSRI

Paroxetine

0

30

0

-

-

-

SSRI
+
AP

Paroxetine + quetiapine

2

28

7.1

Sanada 2010

SSRI

Paroxetine

3

11

27.3

-

-

-

SNRI

Milnacipran

5

10

50.0

Luo 2009

SSRI

Fluoxetine

ns

40

ne

ns

40

ne

-

-

-

-

-

Han 2008b

SSRI

Fluoxetine

8

28

28.6

-

-

-

SSRI

Sertraline

5

17

29.4

Huang 2012

SSRI

Citalopram

9

30

30.0

-

-

-

SSRI
+
AP

Citalopram + paliperidone

9

30

30.0

Aragona 2005

SSRI

Citalopram

6

17

35.3

-

-

-

NRI

Reboxetine

9

18

50.0

Muller 2008

SSRI

Escitalopram

1

25

4.0

0

26

0

-

-

-

-

-

Han 2008b

SSRI

Sertraline

5

17

29.41

-

-

-

SSRI

Fluoxetine

8

28

28.6

Huang 2012

SSRI
+
AP

Citalopram + paliperidone

9

30

30.0

-

-

-

SSRI

Citalopram

9

30

30.00

Li 2006

SSRI
+
AP

Paroxetine + quetiapine

0

30

0

-

-

-

SSRI

Paroxetine

2

28

7.1

Kroenke 2006 b

SNRI

Venlafaxine (extended release)

21

55

38.2

22

57

38.6

-

-

-

-

-

Jiang 2005

SNRI

Venlafaxine

0

36

0

-

-

-

TCA

Amitriptyline

0

32

0

Yang 2006

SNRI

Venlafaxine

0

35

0

-

-

-

TCA

Amitriptyline

0

35

0

Xu 2004

SNRI

Venlafaxine

0

35

0

-

-

-

TCA

Amitriptyline

0

35

0
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Table 4. Attrition rate (acceptability: proportion of participants who dropped out during the experimental as well as the comparator intervention,
calculated as a proportion of the total number of randomised participants) (Continued)

Venlafaxine

0

34

0

-

-

-

TCA

Han 2008a

SNRI

Venlafaxine

13

45

28.9

-

-

-

Sanada 2010

SNRI

Milnacipran

5

10

50.0

-

-

Ouyang 2006

NaSSA Mirtazapine

0

40

0

-

Ye 2006

NaSSA Mirtazapine

2

35

5.7

Zhao 2006

NaSSA Mirtazapine

ns

30

Han 2008a

NaSSA Mirtazapine

11

Eberhard 1988

TeCA Maprotiline

Aragona 2005

NRI

Wang 2003

Doxepin

34

0

NaSSA Mirtazapine

11

50

22.0

-

SSRI

Paroxetine

3

11

27.3

-

-

TCA

Amitriptyline

0

40

0

-

-

-

TCA

Clomipramine

2

35

5.7

ne

-

-

-

TCA

Amitriptyline

ns

30

ne

50

22.0

-

-

-

SNRI

Venlafaxine

13

45

28.9

5

30

16.7

-

-

-

TCA

Clomipramine

13

40

32.5

Reboxetine

9

18

50.0

-

-

-

SSRI

Citalopram

6

17

35.29

SARI

Traxodone

0

70

0

-

-

-

NSAID Ibuprofen

0

70

0

Altamura 1991

AP

Levosulpride

2

15

13.3

-

-

-

AP

Racemic sulpiride

2

15

13.3

Altamura 1991

AP

Racemic sulpiride

2

15

13.3

-

-

-

AP

Levosulpride

2

15

13.3

Müller 2004

NP

St. John's wort LI 160

5

87

5.8

6

88

6.8

-

-

-

-

-

Volz 2002 d

NP

St. John's wort LI 160

0

75

0.0

2

74

2.7

-

-

-

-

-

Melzer 2009

NP

Ze 185 3-/4-combinationc

10

121

8.3

5

61

8.2

-

-

-

-

-

AP: antipsychotic; ID: identification; NaSSA: noradrenergic specific serotonergic antidepressant; ns: not specified; ne: not estimable; NP: natural product; NRI: noradrenaline
reuptake inhibitor, SARI: serotonin antagonist and reuptake inhibitor; SNRI: serotonin noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic
antidepressant; TeCA: tetracyclic antidepressant.
Total sample sizes and attrition rates refer to the total number of randomised participants.
a Trial included 3 arms: paroxetine, open paroxetine, and placebo; we combined the attrition rate of paroxetine and open paroxetine.
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Table 4. Attrition rate (acceptability: proportion of participants who dropped out during the experimental as well as the comparator intervention,
calculated as a proportion of the total number of randomised participants) (Continued)

Cochrane

intention-to-treat (ITT) population, they only included participants who had at least 1 post-baseline efficacy evaluation yielding in an ITT sample of 112. No information was
provided about how the 117 participants were distributed among treatment groups. Therefore, we calculated drop-out rate based on the 112 sample.
c Trial included 3 arms: Ze 185 4-combination, Ze 185 3-combination, and placebo; we combined the attrition rate of the Ze 185 3-combination and 4-combination.
d Originally 151 participants were randomised. No participants were excluded after the placebo run-in phase. However, study authors defined ITT population as a sample of all
randomised participants with at least 1 assessment under trial medication. 2 participants had to be excluded from the analysis due to missing values for the primary efficacy
variable after baseline. Therefore, the ITT sample included 149 participants. No information was provided how the original 151 participants were distributed among groups.
Therefore, we calculated drop-out rate based on the sample.
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APPENDICES
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
CENTRAL search terms (10 April 2014):
(somatization OR somatisation OR somatoform OR (pain NEXT disorder) OR MUPS OR medically unexplained OR unexplained symptoms)
AND (randomized)

Appendix 2. PsycINFO Ovid search strategy
Ovid PsycINFO search terms (2 May 2014):
[RCT Filter]
1. treatment effectiveness evaluation.sh.
2. clinical trials.sh.
3. mental health program evaluation.sh.
4. placebo.sh.
5. placebo*.ti,ab.
6. randomly.ab.
7. randomi#ed.ti,ab.
8. trial.ti,ab.
9. ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).mp.
10. (control* adj3 (trial* or study or studies or group*)).ti,ab.
11. factorial*.ti,ab.
12. allocat*.ti,ab.
13. assign*.ti,ab.
14. volunteer*.ti,ab.
15. (crossover* or cross over*).ti,ab.
16. "2000".md.
17. ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group or versus)).ab.
18. or/1-17
19. exp somatization/
20. hysteria/
21. (somatiz* or somatis* or hysteri* or briquet or polysymptom* or poly symptom* or multisomat* or multi somat*).mp.
22. (multiple and (medically unexplained or unexplained symptoms or physical symptoms or symptom diagnos*)).mp.
23. MUPS.ti,ab.
24. or/19-23
25. 18 and 24
26. exp Pharmacology/
27. exp Drugs/
28. exp Drug Therapy/
29. "3340".cc.
30. (drug* or pharma* or psychopharma* or psycho pharma* or psychotropic* or psycho tropic* or antipsychotic* or anti
psychotic* or antiepileptic* or anti epileptic* or neuroleptic* or anticonvuls* or anti conculs* or antiemetic* or anti emetic* or
hypnotic*).mp.
31. (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or
noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or reuptake))
or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or
heterocyclic*).mp.
32. (anxiolytic* or ((anti anxiety or antianxiety) adj1 (drug* or agent*)) or tranquili#er* or sedative*).mp.
33. exp "Medicinal Herbs and Plants"/
34. exp Dietary Supplements/
35. (nutraceutical* or herbal).mp.
36. or/26-35
37. 25 and 36
Key:
"2000".md. = Methodology: 'Treatment Outcome/Clinical Trial'
"3340".cc. = Concept Code: 'Clinical Psychopharmacology'

Appendix 3. PSYNDEX search
PSYNDEX search terms (23 March 2014):
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(somatisier* OR somatoform* OR schmerzstoerung OR medizinisch unerklaert* OR medizinisch ungeklaert* OR koerperbeschwerden OR
koerpersymptome) AND randomisiert*
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Preparation of the protocol:
Maria Kleinstäuber: developed and drafted the protocol.
Michael Witthöft, Andrés Steffanowski, Michael Lambert, Günter Meinhardt, Klaus Lieb, Wolfgang Hiller: supervised preparation of the
protocol and gave feedback on the draft version of the protocol.
Preparation of the review:
Maria Kleinstäuber and Michael Witthöft independently reviewed titles and abstracts in the first step and screened full-texts regarding
eligibility of studies for the review in the second step.
Maria Kleinstäuber and Michael Witthöft independently appraised the quality of the included studies.
Maria Kleinstäuber and a research assistant trained in the data extraction procedure independently extracted data of the included studies.
Andrés Steffanowski, Wolfgang Hiller, Harm van Marwijk, and Michael Lambert supervised the preparation of the review process and
arbitrated in the case of disagreements.
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
1) For literature search the following search terms were added: "somatoform disorder*", somatoform and "autonomic dysfunction",
"somatic symptom disorder*","pain disorder".
Rationale: the former search strategy did not include these important terms although they are part of the title of the review and the
inclusion criteria. Therefore, it was necessary to add them.
2) The syntax for the PsycINFO search was adapted.
Rationale: according to the changes in the search strategy (see the first difference between protocol and review), the syntax for the PsycINFO
search had to be adapted.
3) We made changes to the searches of electronic databases: instead of the search in PubMed and EMBASE, we conducted an additional
search in CENTRAL.
Rationale: we decided to run one search in CENTRAL because this database included all records from PubMed, indexed as publication
type=RCT as well as records from EMBASE, obtained from a Cochrane RCT screening project.
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4) In the section 'Types of interventions', we added the comparator intervention 'combination of medications'. Correspondingly, we added
the comparison 'medication versus a combination of medications' to the section 'Data extraction and management'.
Rationale: the literature search obtained three studies where the efficacy of a combination of medications was compared with a single
medication. In order to avoid excluding these studies and because they also fit the objectives of our review, we decided to add another
comparison.
5) In the section 'Types of participants' under 'Participants characteristics', we modified the age criterion. We added the following sentence:
"where a trial has defined adults to include those older than 65 years but most participants were under 65 years of age we included the
trial; however, we excluded any trial that focused on older adults or where the mean age of participants was greater than 65 years'.
Rationale: we modified the inclusion criteria of people regarding age in order to prevent the exclusion of good-quality studies only because
they slightly exceed our originally defined age range.
6) In the section 'Types of participants' under 'Diagnosis', we deleted the originally required structured clinical interview for making the
diagnoses.
Rationale: with screening the full texts of the potentially eligible studies for this review it became clear that requiring a structured clinical
interview was too strict and inappropriate a criterion. There were several studies where a unstructured psychiatric interview was conducted
in order to determine the diagnosis(es) of a participant.
7) In the section 'Types of participants' under 'Diagnosis', we added the DSM-5 diagnosis 'somatic symptom disorder' and the Chinese
Classification of Mental Disorders (CCMD-III).
Rationale: the DSM-5 was published in 2014 shortly after the protocol of this review had been published. In the protocol, we had already
announced that the diagnostic criteria would be adapted as soon as the DSM-5 was published. The criteria of somatoform disorders in the
CCMD-III correspond to the criteria of somatoform disorders in DSM-IV or -III and in ICD-10 or -9.
8) In the section 'Types of outcome measures', we made the following changes:
• under 'Primary outcomes', we noted that the acceptability rate was also presented as risk ratio.
Rationale: the calculation of the risk ratio gives the opportunity to compare the treatment and comparator group for the number of dropouts.
• under 'Secondary outcomes', we divided the originally combined outcome 'depression and anxiety' into two separate outcomes.
Rationale: during coding the characteristics and statistical values of the included studies we realised that in many studies qualitatively
equivalent measures of depression and anxiety were available (e.g. the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety
Rating Scale (HARS)). Therefore, it was impossible to decide which of these measures should be included. Furthermore, we decided against
excluding one or both outcomes from the review because anxiety as well as depressive symptoms are import co-morbid complaints in
people with somatoform disorders.
• under 'Secondary outcomes', we added that for the outcomes anxiety and depression the subscales of validated questionnaires
assessing general psychopathology and VAS were acceptable.
Rationale: subscales of validated questionnaires assessing general psychopathology or VAS were accepted measures for the 'severity/
intensity of MUPS'. We decided afterwards to accept them as eligible measures of depression and anxiety.
• under 'Secondary outcomes', we noted that the drop-out rate due to adverse effects was also presented as an RR.
Rationale: the calculation of the RR gives the opportunity to compare the treatment and comparator group for number of drop-outs due
to adverse effects.
11) In the section 'Types of outcome measures' under 'Secondary outcomes' we clarified that the treatment response referred to the
primary outcome 'severity of MUPS'.
Rationale: during the coding of the statistical values of the included studies it became clear that the section about treatment response as
outcome was not formulated clearly enough. Therefore, we tried to clarify this section.
12) In the section 'Subgroup analysis and investigation of heterogeneity', we changed the following aspects: Subgroup analyses were
conducted only for the primary outcomes
Rationale: subgroup analyses have to be treated with caution, as they are hypothesis-forming rather than hypothesis-testing and should
be reduced to a reasonable minimum.
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13) In the section 'Sensitivity analysis', we changed the following analysis:
• we changed exclusion of results based on mixed-effects models or on intention-to-treat approach (last observation carried forward
(LOCF)) into exclusion of results based on complete-case analyses
Rationale: we changed this sensitivity analysis because we realised that a large number of studies dealt with missing values by applying
the LOCF approach and only in a small number of trials conducted complete-case analyses.
We added further sensitivity analyses:
• exclusion of Chinese studies.
Rationale: the CCDANCTR retrieved many Chinese studies. While several of these were identified through routine searches of MEDLINE,
EMBASE, and PsycINFO (used to inform the register), the provenance of some of the other Chinese studies in the CCDANCTR was less
clear and probably dated back to an opportunistic search of Wang Fang Data (c/o The British Library) in 2007. Therefore, we decided to
add a sensitivity analysis of excluding studies that were conducted in China. Unfortunately, none of the comparisons had enough studies
available in order to conduct this sensitivity analysis.
We excluded the following sensitivity analyses that were originally proposed in the protocol from the review:
• exclusion of CRCTs;
• exclusion of CRCTs for which intracluster correlation coefficients were used;
• for dichotomous outcomes only: exclusion of results based on available/observed cases.
Rationale: we excluded these sensitivity analyses because no or insufficient studies were available.
• Sensitivity analyses were conducted only when at least 10 studies were available and only for the primary outcomes.
Rationale: results of sensitivity analyses with a very small number of studies are difficult to interpret. Furthermore, sensitivity analyses
have to be treated with caution, as they are hypothesis-forming rather than hypothesis-testing and should be reduced to a reasonable
minimum.
14) In the section 'Summary of findings tables', we deleted the sentence on reporting Summary of findings tables only for the medication
versus placebo comparisons.
Rationale: several peer reviewers suggested that a 'Summary of findings' table for the tricyclic antidepressants versus new-generation
antidepressants and antidepressants alone versus antidepressants plus antipsychotic comparison should be added.

INDEX TERMS
Medical Subject Headings (MeSH)
Antidepressive Agents, Second-Generation [*therapeutic use]; Antidepressive Agents, Tricyclic [*therapeutic use]; Antipsychotic Agents
[*therapeutic use]; Randomized Controlled Trials as Topic; Serotonin Uptake Inhibitors [*therapeutic use]; Somatoform Disorders
[*drug therapy]

MeSH check words
Adult; Humans; Middle Aged

Pharmacological interventions for somatoform disorders in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

